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1. Introduction 
Fungi are ubiquitous pathogens and represent a considerable health risk. A variety of 
different species are accountable for fungal diseases, allergies or have the ability of 
mycotoxin production. Mycotoxins are secondary metabolites, produced by diverse fungi. 
They are of diverse chemical structures and properties, which explains their various 
biological effects and toxicological endpoints.  
Alternaria spp. belong together with Penicillia, Fusaria and Aspergilla to the groups of fungi 
producing mycotoxins. Many species are known to infest organic matter, furnishings and 
above all, they are common postharvest pathogens of diverse foodstuffs and can cause 
spoilage in the field and during storage (Barkai-Golan & Paster, 2008). 
Especially mycotoxin contamination of agricultural commodities represents a serious 
problem. The “Food and Agriculture Organisation” (FAO) has recently pointed out that at 
least 25% of the world wide produced grain are infested with mycotoxins. Based on the 
ability of Alternaria to grow in tropic, subtropic and even temperate climate zones, they are 
most commonly involved in pathogenesis. Even more serious than economic loss due to 
infested foodstuffs, are diseases directly associated with mycotoxin contamination- the so 
called mycotoxicoses. In the 90-ies consumption of Alternaria contaminated grain has been 
associated with an increased incidence of oesophageal cancer in Linxian, China (Liu et al., 
1992). Furthermore, Alternaria extracts and single Alternaria toxins, like the main secondary 
metabolites alternariol (AOH) and alternariol monomethyl ether (AME) have shown 
considerable toxic potential (Pero et al., 1973; Liu et al., 1992).  
Several reviews on Alternaria toxins have been published over the last few decades. 
However, the European Food Safety Authority (EFSA) has recently pointed out that there 
does not exist any relevant toxicity data for Alternaria toxins for identification of reference 
points for different toxicological effects. The Threshold of Toxicological Concern (TTC) 
approach has been applied on the data published about Alternaria toxins (including AME, 
AOH, TeA, TEN) so far. The estimated chronic dietary exposure to AME and AOH exceeds 
the relevant TTC value, indicating a need for additional compound-specific toxicity data 
(EFSA, 2011)  
For a better risk assessment of xenobiotics such as mycotoxins, the metabolic pathway has 
to be elucidated. In the present thesis, the impact of AME and AOH with regard to the 
phase I enzyme cytochrome P450 CYP1A1 and the phase II enzyme glutathione-S-
transferase in human oesophagus and colon carcinoma cells have been investigated.  
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2. Theoretical Background 
2.1. Alternaria Toxins 
Mycotoxins are secondary metabolites of fungi that are produced during the growth or 
storage of plant products. The synthesis of these secondary metabolites takes away energy 
from the growing fungi. Thus formation of mycotoxins occurs only if required for the fungal 
organism. The function of mycotoxins in fungi may be the suppression of bacterial growth or 
of other competing moulds. On the other hand mycotoxins cause toxic effects in other 
eukaryotic cells (Wexler et al., 2005). 
Mycotoxins of the genus Alternaria have recently received increasing attention, both in 
research programmes as well as in risk assessment studies. An example is the 4 year 
project “Safe organic vegetables and vegetable products by reducing risk factors and 
sources of fungal contaminants throughout the production chain: the carrot- Alternaria model” 
established by the European Union from 2000 to 2004. The objective was to develop 
detection methods, identifying Alternaria mycotoxin risks in the production chain and 
developing preventive measures. Since the carrot is one of the most popular vegetables of 
European consumers, it was chosen as model system. Based on the results of the study, 
Alternaria mycotoxins in organic carrots do not represent a hazard for consumers 
(EuropeanComission, 2003; Solfrizzo et al., 2004). 
2.1.1. The Alternaria Species  
Alternaria is a genus of ascomycetes fungi and belongs to the class of Dothideomycetes. 
The genus of Alternaria was originally described in 1817 (Esenbeck & Daniel, 1817). 
According to a statement of the German Federal Institute of Risk Assessment (BfR) in 2003 
depending on the source of information, Alternaria spp. are ubiquitous pathogens and 
saprophytes. They are among the most common postharvest pathogens of fruits and 
vegetables and can cause spoilage in the field as well (Ostry, 2008). Decaying wood, wood 
pulp, wall paper and compost are other known substrates of Alternaria (Gravesen et al., 
1994).  
Alternaria alternata is regarded as the major mycotoxin producing species, although A. citri, 
A. solani, A. longipes, A. tenuissima, A. arborescens and A. infectoria are also able to 
produce characteristic Alternaria toxins (Barkai-Golan & Paster, 2008). A. alternata produces 
a variety of mycotoxins although the major compounds are alternariol, alternariol 
monomethyl ether, altenuene, tenuazonic acid and altertoxin I (Scott, 2001). 
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2.1.2. Morphology of Alternaria 
The colonies of Alternaria spp. are black to olive-black or greyish and are suede-like to 
floccose. Alternaria species have septate, dark hyphae. The conidia may be observed singly 
or in acropental branched chains and may produce gem tubes. The end of the conidium is 
round, while it tapers at the apex (Murray et al., 2007). 
 
Figure 1: Morphology of Alternaria alternata (http://www.schadstofffrei.de/schimmelpilz-allergie.htm, 
http://www.mycology.adelaide.edu.au)  
2.1.3. Significance of Alternaria Species & Alternaria Toxins as 
Pathogens of various Foodstuffs 
Alternaria spp. are capable to produce more than 120 potentially toxic secondary 
metabolites. Most of them are phytotoxins, which play an important role in the pathogenesis 
of plants. However among them there are some mycotoxins which can be harmful for 
humans and animals (Panigrahi, 1997; Ostry, 2008).  
The optimal growth conditions for Alternaria spp. are between 22 - 28°C, but they are also 
capable to grow at lower temperatures, with minimal temperatures as low as -3°C. Thus 
Alternaria species are involved in spoilage during refrigerated storage (Sommer, 1985). 
Alternaria alternata generally is not able to penetrate directly through the plant paring, lesions 
like injured tissue are required for infection. These injuries mostly happen during harvesting 
or handling. The initiation of infection often occurs at the stem scar of tomatoes (figure 2 A), 
peppers and eggplants. (Barkai-Golan, 2002). Cucumbers, squashes and melons are 
frequently infected after being weakened by sun-scald, chilling injury or over-ripeness 
(Snowdon, 1992). A. alternata is associated with the core rot in apples (figure 2 B). A recent 
study suggests that the major pathogen of Top Red apples in South Africa belongs to A. 
tenuissima (Serdani M., 2002). 
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A B 
   
Figure 2: Tomatoes (A) and apples (B) infected with Alternaria alternata 
(http://www.extension.umn.edu and http://postharvest.tfrec.wsu.edu/)  
 
The most important Alternaria toxins are alternariol (AOH), alternariol monomethyl ether 
(AME), altenuene (ALT), altertoxins I, II, III (ATX-I, -II, -III) and tenuazonic acid (TeA). They 
belong to three different classes of chemical structures, depictured in figure 3 (Ostry, 2008). 
• dibenzopyrone derivatives: AOH, AME, ALT 
• perylene derivatives:  ATX-I, -II, -III 
• tetramic acid derivatives: TeA 
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Figure 3: Chemical Structure of AOH, AME, ALT, TeA (upper row) and ATX-I, -II, -III (bottom row) 
(Ostry, 2008) 
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Scott (2011) reviewed the natural occurrence of Alternaria toxins in various fruits and 
vegetables visibly infected by Alternaria spp. High levels of AOH and TeA were found in 
apples, tomatoes, mandarins, peppers and olives, increased AME and ALT levels were 
detected in the latter two as well. The natural occurrence of Alternaria toxins in contaminated 
processed food is of even more interest for human health. TeA was found in tomato 
products, whereas AOH and AME were present in apple juice. Several other agricultural 
commodities, including grains, sunflower seeds, oilseed rape, sorghum and pecans were 
also found to be infested with various Alternaria toxins. 
The maximum concentrations of Alternaria toxins in marketed products were reported to be 
in the range of 1 - 103 µg/kg. Higher levels were only found in samples visibly infected with 
Alternaria spp. (Ostry, 2008). Ackermann et al. (2011) developed a comparative enzyme 
immunoassay method for the determination of low levels of AOH in apple and tomato 
products. With this analytical system a rapid and easy method is available for the 
identification of AOH in foods and feeds. Since AOH was found to be very stable in apple 
juice, even at temperatures up to 80 - 100°C (Scott PM, 2001), and since tomatoes are a 
most common substrate for Alternaria species (da Motta S., 2000), the development of a 
suitable screening method was highly important. In apple (67%) and tomato products (93%) 
the alternariol concentration was found with high frequency to be in the range of 1 - 13 µg/kg. 
Apple and tomato products represent a significant part of the vegetable and fruit 
consumption in Germany, thus the regular consumption of alternariol contaminated products 
results in a long-term, low-level daily exposure in the ng/kg bodyweight range (Ackermann et 
al., 2011).  
Siegel et al. (2010) investigated the stability of AOH, AME and ALT at the process of bread 
baking. The results indicated that wet baking barely leads to the degradation of Alternaria 
toxins. However significant degradation occurs at dry baking with stability decreasing in the 
order of AME > AOH > ALT (Siegel et al., 2010). 
2.1.4. Factors affecting the Formation of Alternaria Toxins  
Since mycotoxin production is influenced by several factors, the presence of fungi does not 
necessarily imply the presence of toxins. Conditions promoting fungal growth do not 
necessarily coincide with those responsible for mycotoxin production (Drusch & Ragab, 
2003). Alternaria alternata is reported as the most important mycotoxin-producing species 
(Scott, 2001).  
Alternaria spp. are flexible pathogens, capable of growing in both arid and humid areas. 
Factors known to affect production of mycotoxins in fruit include the fruit type, geographical 
location, climate, pre- and post-harvest treatment, method of harvest, presence of surface 
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injuries and storage conditions (Barkai-Golan & Paster, 2008). Nevertheless, the pre- and 
post-harvest key environmental determinants are water availability and temperature (Magan 
& Olsen, 2004).The water activity (aw) and temperature limits for A. alternata for germination 
are lower than those for production of ALT, AOH and AME. The absolute aw limit for 
germination is 0.86 aw and for growth and mycotoxin production about 0.88 - 0.89 aw. 
Conditions promoting the formation of all three mycotoxin moieties are at about 25°C and 
>0,97 aw (Magan N., 1985). 
2.1.5. Toxicity of Alternaria Toxins 
Acute Toxicity 
Alternaria Extracts 
In the 1980-ies a retrospective survey of cancer mortality in China indicated areas of high- 
incidence for oesophageal cancer in Linxian country. The occurrence of Alternaria alternata 
contaminated grain in the area of high incidence was noted and a relationship between fungi 
and oesophageal cancer was proposed (Dong et al., 1987; Liu et al., 1991). The toxicity of 
the crude extract of Alternaria spp. towards mice was investigated by Pero et al. (1973). At 
concentrations of 300 mg/kg body weight the crude extract caused acute toxic effects (Pero 
et al., 1973). Sauer et al. (1978) fed chicken and rats with corn-rice, containing cultures of 
four isolates of Alternaria alternata over a period of 21 days. Toxic symptoms and lethality 
are caused by culture media of Alternaria isolates synthesising TeA and ATX-I. Isolates 
producing AOH, AME and ALT in varying ratios did not show any deleterious effect (Sauer et 
al., 1978). 
Alternariol & Alternariol Monomethyl Ether 
AOH and AME were first isolated from the dried mycelium of A. tenius in 1953 and a total 
synthesis of these substances was performed in 2005 by Koch et al. (Raistrick et al., 1953; 
Koch et al., 2005). The acute toxicity of AME was investigated in several studies and is 
assessed as low compared with other Alternaria toxins (Pero et al., 1973; Sauer et al., 1978). 
Pero et al. (1973) showed that mice treated with either AME or AOH get sedated, display dull 
eyes, occasional stomach spasms and periodic panting. When treating brine shrimp larvae 
with AOH-containing medium the 50% lethal concentration was about 100 µg/ml. However, 
AME was not found to cause any mortality in brine shrimp larvae, although these findings 
can be due to its poor solubility in the used solvents (Griffin & Chu, 1983). 
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Altertoxins  
Altertoxin I, II and III were isolated the first time in 1973. ATX-I displayed toxic effects in rats, 
chicken and brine shrimp larvae (Sauer et al., 1978; Griffin & Chu, 1983). ATX-I, -II and -III 
were found to be mutagenic even without the need of metabolic activation in the Ames test 
using Salmonella typhimurium TA98, TA100, and TA1537. Altertoxin III appeared to be the 
most mutagenic towards TA98, followed by ATX-II and ATX-I (Stack & Prival, 1986). 
Cytotoxicity 
The effect of AOH on the proliferation of human endometrial adenocarcinoma Ishikawa cells 
and Chinese hamster lung fibroblast cells (V79) was assessed by flow-cytometry and 
electronic cell counting, respectively. The cell number of Ishikawa cells treated with 10 µM 
AOH for 48 h and 72 h was reduced more than 50%. AOH at a concentration of 25 and 
50 µM inhibited proliferation of V79 cells after 6 h of incubation but proliferation resumed 
when removing AOH (Lehmann et al., 2006). Fehr et al. (2010) investigated the cytotoxic 
effects of AME and AOH toward the vulva carcinoma cell line A431 using the 
sulforhodamine B (SRB) assay. Concentration-dependent growth inhibitory effects were 
observed after 24 h and 72 h treatment with AME and AOH, respectively. AOH was more 
potent than AME, although relatively high concentrations were required.  
The cytotoxic activity of AOH, AME, ALT, TeA, ATX-I and -II was investigated toward the 
human cervical adenocarcinoma cell line HeLa-S3 and Bacillus mycoides ATCC 6462. In 
HeLa-S3 cells ATX-II, AOH and AME were more toxic than in ATCC 6462 with ID50 values of 
0.5, 6 and 8 - 14 µg/ml, respectively. On the other hand TeA, AOH and ALT displayed higher 
bacterial toxicity. Although a 1:1 mixture of AME and AOH elicited the most potent action for 
Bacillus mycoides, any synergistic effect was observed in HeLa-S3 cells (Pero et al., 1973).  
Teratotoxicity 
Griffin & Chu (1983) investigated the teratogenic effects of AOH, AME, ALT and TeA using 
the chicken embryo assay. Yolk sac injection of Alternaria metabolites into 7-day old chicken 
embryos was performed. AOH, AME and ALT did not trigger any increase of mortality or 
malformation of hatched chicken, even at the maximum dose of 1 mg/egg. Although TeA 
displayed dose relevant mortality responses over the range of 0.15 - 1.5 mg/egg, the 
resulting 50% lethal dose calculated for this assay was 0.548 mg TeA/egg. The teratogenic 
effect of all tested substances was classified as low even at lethal or sublethal dose levels 
(Griffin & Chu, 1983). In another study Pero et al. (1973) indicated fetotoxic effects of AOH at 
100 mg/kg. Although AME did not show any effects at 50 mg/kg, a synergism between AOH 
and AME was suggested since the co-administration of each 25 mg/kg yielded significant 
responses.  
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Mutagenicity 
Statements concerning the mutagenicity of AME and AOH should be viewed critically, since 
controversial results were obtained with the Ames-test using different testing systems. AOH 
and AME presented mutagenic action independently of exogenous metabolic activation in 
the Bacillus subtilis rec assay and in the Escherichia coli ND160 revision test. AOH was 
found to be 4 - 8 times more potent than AME in both assays (Zhen et al., 1991). 
Mutagenicity of AME towards the E. strain ND160 was supported by An et al. (1989). In the 
Ames Salmonella test using strains TA98 and TA100 similar results were obtained by 
Schrader et al. (2001), however AME and AOH were only weakly mutagenic in TA100. In 
contrast, Davis & Stack (1994) did not observe any mutagenic effects in TA98, TA100, 
TA1537 and TA1538 independent of previous metabolic activation.  
On the other hand, the mutagenicity of AOH and AME was clearly confirmed in mammalian 
cells. AME treatment of hamster fibroblast cells (V79) induced persistent mutations, even 
without metabolic activation, indicating AME as a direct mutagen. Additionally, the mutagenic 
effect of AME was studied in vivo by injecting AME to sucking Wistar rats. The treatment 
increased the micronuclear rates of polychromatic erythrocytes of rat bone marrow (Liu et al., 
1992). AOH induced the hypoxanthine-guanine phosphoribosyltransferase (HPRT) gene 
locus in V79 cells and the thymidine kinase (TK) gene locus in mouse lymphoma 
L5178Y tk+/− cells in a concentration-dependent manner and in the lower micromolar range 
(Brugger et al., 2006).  
Dong et al. (1987) treated Chinese hamster lung fibroblast cells (V79) with an ether extract 
isolated from Alternaria alternata infested grain. The extract induced mutants, also in the 
absence of metabolic activation, indicating the presence of direct mutagens. Furthermore, 
treatment of mouse fibroblast cells (NIH/3T3) with the extract demonstrated its direct 
transforming activity. However, experiments with ether extracts isolated from A. alternata 
infested maize induced mutations in V79 cells only after metabolic activation, suggesting the 
existence of pre-mutagens, requiring previous metabolic activation (Liu et al., 1991). 
Genotoxicity 
Liu et al. (1992) investigated the genotoxic effects of AOH and AME in primary rat 
hepatocytes and human embryonic fibroblast 2BS cells. Both mycotoxins induce DNA single 
strand breaks in both cell lines, however the AOH-mediated effect is 8 - 10 times stronger 
compared to AME (Liu et al., 1992). Lehmann et al. (2006) investigated the genotoxic 
potential of AOH by using the induction of micronuclei, containing DNA fragments as 
indicator. A slight increase was observed in human Ishikawa cells and a pronounced 
increase in Chinese hamster cells (V79) (Lehmann et al., 2006).  
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The DNA strand breaking activity of AME and AOH in vitro was investigated by Pfeiffer et al. 
(2007a) in cultured Chinese hamster V79 cells, human liver HepG2 cells and human colon 
HT29 cells using the method of alkaline unwinding. Treatment with AOH and AME for 1 h 
induced strand breaks in all three cell lines, whereas treatment for 24 h induced a higher 
increase of strand breaks in HepG2 cells than in HT29 cells. Since HT29 cells exhibited a 
higher UDP-glucuronosyl transferase (UGT) activity towards AOH and AME, the smaller 
number of strand breaks after 24 h suggests the formation of less genotoxic metabolites 
upon glucuronidation (Pfeiffer et al., 2007a).  
Fehr et al. (2009) further investigated the genotoxic properties of AOH and AME in terms of 
the underlying mechanism of action in human colon carcinoma HT29 cells and vulva 
carcinoma A431 cells. The DNA strand breaking effect was already observed at 
concentrations ≥ 1 µM. AOH had a substantial affinity to the minor groove of the DNA, which 
might contribute to its DNA-damaging properties. AOH was identified as a topoisomerase I 
and II inhibitor, with preference for the IIα isoform at concentrations ≥ 25 µM. AME did not 
affect topoisomerase IIβ activity up to 200 µM but was found to be equipotent to AOH with 
respect to the inhibition of topoisomerase IIα. Additionally, AOH also acted as topoisomerase 
I and II poison, stabilising the cleavable complex. Since topoisomerase poisoning and DNA 
strand breakage occurred in the same concentration range, absence of these enzymes might 
inhibit the unknotting of DNA. However, DNA unwinding is a crucible prerequisite for 
replication, transcription, recombination and DNA-repair. A failure in this highly complex 
system consequentially leads to DNA double strand breaks (Fehr et al., 2009).  
Carcinogenicity 
Cultured human foetal oesophageal epithelium was exposed to AME and further cultivated 
for 7 days. The basal cells of oesophageal epithelium displayed papillary growth, disorderly 
arrangement and hyperplasia. The nuclei of the cells were larger, heavily stained and a 
nuclear karyokinetic phase was observed. Since the same effects were observed in groups 
treated with appropriate positive controls, AME was suggested to trigger human oesophageal 
cancer (Liu et al., 1991). Additionally, the binding of AME and AOH toward human 
oesophageal DNA is assumed to be of ionic type, which may play an important role for 
mutagenicity and carcinogenicity. Oesophageal tissue of human embryos treated with AOH 
for 24 h were inoculated subcutaneously into nude mice. In one of three animals the tissue 
developed squamous cell carcinoma (Liu et al., 1992). Furthermore, precancerous changes 
in mice oesophageal mucosa were observed after feeding the animals with 50 - 100 mg 
AME/kg body weight for 10 months. The oesophageal epithelium is inflamed and it is 
assumed that the generated cytokines and free-oxygen radicals might contribute to the 
observed dysplastic changes (Yekeler et al., 2001).  
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Estrogenic Effects 
Given that AOH is a diphenolic compound with a chemical structure similar to estrogen-
mimicking substances, an estrogenic effect was suggested. The receptor binding assay 
showed a 10,000-fold lower binding affinity of AOH towards the estrogen receptor (ER)α but 
only a 2,500-fold lower affinity towards ERβ in comparison with the endogenous hormone 
17β estradiol. Furthermore, AOH induced both, the alkaline phosphatase (ALP) activity and 
the corresponding ALP mRNA level. Thus, AOH acted as a pure ER agonist in the human 
endometrial adenocarcinoma Ishikawa cell line, with estrogenicity comparable to that of the 
phytoestrogen daidzein or the environmental estrogen bisphenol A (Lehmann et al., 2006). 
However, any estrogenic potential of AOH in porcine endometrial cells could be detected 
(Wollenhaupt et al., 2008).  
2.1.6. Metabolism of AOH & AME 
Pollock et al. (1982) administered 14C labelled AME to adult male Sprague-Dawley rats and 
detected the majority excreted unabsorbed in the faeces, while urine excretion accounted for 
less than 10%. Nevertheless, an extensive amount of metabolites was detected in urine and 
incubation of rat liver post-mitochondrial supernatant showed the formation of AOH and 
several polar metabolites (Pollock et al., 1982).  
Pfeiffer et al. (2007b) incubated microsomes from rat, human and porcine liver with AME and 
AOH and detected seven oxidative metabolites of AME and five of AOH. The most common 
four aromatic hydroxylation products of AME were 2-, 4-, 8- and 10-hydroxy-AME. Further 
metabolites were monohydroxylated at the C-1 methyl group or dihydroxylated and 
demethylated to AOH. AOH was hydroxylated at each conceivable position of the molecule. 
All aromatic hydroxylation products of AME and AOH were prone to cytochrome P450-
mediated hydroxylation at various positions, yielding either catechols or hydroquinones. The 
oxidative metabolism of AOH and AME is depicted in figure 4 and figure 5 (Pfeiffer et al., 
2007b). Since conjugation with glucuronic acid is a major pathway of detoxification and 
metabolic disposal, glucuronidation of AME and AOH was further investigated. Incubation of 
AOH with hepatic and intestinal microsomes of rat, pig and human in the presence of uridine 
diphosphate (UDP) glucuronic acid yielded equal amounts of AOH-3-O- and AOH-9-O-
glucuronide. Incubation with AME led predominately to the formation of AME-3-O- with only 
small amounts of AME-7-O-glucuronide (Pfeiffer et al., 2009). 
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Figure 4: Oxidative metabolism of AME (Pfeiffer et al., 2007b) 
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Figure 5: Oxidative metabolism of AOH (Pfeiffer et al., 2007b) 
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Further investigations addressing the metabolism of AOH and AME were performed with 
human epithelial colorectal adenocarcinoma Caco2 cells grown in the Millicell® system. Their 
apical and basolateral sides faced different compartments, thus allowing mimicking the 
behaviour of metabolites in the intestines. Given that Caco2 cells lack cytochrome P450 
activity, the formation of glucuronides and sulphates was studied. Based on the results of the 
experiment and the calculated permeability coefficients, AOH was expected to be rapidly 
absorbed from the intestinal lumen and reached the portal blood as aglycone, glucuronide 
and sulphate, whereas any AME aglycone was absorbed and only AME conjugates reached 
the portal blood (Burkhardt et al., 2009).  
To clarify whether hydroxylation of AOH and AME occured under in vivo-like conditions in the 
presence of conjugation reactions, the metabolism of these mycotoxins was studied in 
precision-cut rat liver slices of male Sprague Dawley rats. They were incubated with 50, 100 
and 200 µM AOH or AME for 24 h. The formed conjugates accounted for 86% of the AOH 
and 74% of the AME metabolites. Several hydroxylation metabolites and their O-methylation 
products were detected, indicating that aromatic hydroxylation was performed under in vivo- 
like conditions allowing conjugation reactions. To investigate the formation of oxidative AOH 
metabolites in vivo, bile duct-cannulated male Sprague Dawley rats received a single dose of 
AOH and the collected bile was analysed with regard to oxidative metabolites. The pattern of 
in vivo metabolites was comparable with the one of in vitro metabolites of AOH, clearly 
confirming the relevance of oxidative metabolism in vivo (Burkhardt et al., 2011).  
2.2. Xenobiotic Metabolism 
Xenobiotic metabolism consists of several metabolic pathways which are responsible for the 
modification of chemicals foreign to an organism´s biochemistry, for example drugs or 
poisons of anthropogenic or natural origin. During the biotransformation process xenobiotics 
are converted to more polar metabolites; their increased water solubility makes the excretion 
via urine or faeces easier (Klaassen & Watkins, 2003). The process relays on the action of 
drug metabolising enzymes, which belong to different enzyme families and catalyse phase I, 
II or III metabolising reactions (Xu et al., 2005). Biotransformation can either result in 
detoxification of toxic xenobiotics to inactive metabolites or in activation of relatively harmless 
substances to reactive intermediates, whereat the latter process is known as metabolic 
activation (Rushmore & Kong, 2002; Klaassen & Watkins, 2003).  
The metabolism of xenobiotics is divided in three phases: activation, conjugation and 
excretion. Phase I reactions, also known as activation reactions, introduce polar functional 
groups such as –OH, -SH, -NH2 or -COOH, slightly increasing the hydrophilicity of the formed 
product. Enzymes performing these types of reactions primary belong to the cytochrome 
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P450 superfamily, which can be found predominantly in the liver, gastrointestinal tract, lung 
and kidneys (Mansuy, 1998; Guengerich, 2003). Enzymatic reactions of phase II, also known 
as conjugation reactions, conjugate xenobiotics with water soluble, charged biomolecules, 
creating a substantially more hydrophilic conjugate. Typical phase II enzymes are 
sulphotransferases, UDP-glucuronosyltransferases, epoxide hydrolases, glutathione-S-
transferases and N-acetyltransferases (Rushmore & Kong, 2002). In the course of phase III 
reactions the formed metabolites are transported from the cell. Phase III transporters include 
P-glycoprotein (P-gp), multidrug resistance protein (MRP) and the organic anion transporting 
polypeptide 2 (OTAP2); all of them provide a barrier against drug penetration and are 
involved in drug absorption, distribution and excretion. P-gp and MRP belong to the family of 
ATP-binding cassette (ABC) transporters, utilising the energy required for the transport of the 
substrate through the cell membrane by hydrolysing ATP (Xu et al., 2005).  
2.3. The Aryl Hydrocarbon Receptor Pathway 
The aryl hydrocarbon receptor (AhR), also known as dioxin receptor, is a transcription factor 
known to mediate the biochemical and toxic effects of dioxins, polyaromatic hydrocarbons 
(PAHs) and related compounds (Abel & Haarmann-Stemmann). It controls the regulation of 
drug metabolizing enzymes, predominantly the expression of the cytochrome P450 family 
genes and some phase II enzymes. The AhR pathway is not only a regulator of drug 
metabolism, it can be activated by endogenous ligands and influence cell cycle control, 
immune response and cell differentiation (Stejskalova et al.).  
2.3.1. Gene Structure and Transcriptional Regulation of the AhR  
The aryl hydrocarbon receptor is constitutively expressed in many cell types and tissues. 
Basal AhR expression is found in human and mouse lung, liver, kidney, spleen and placenta 
as well as in various primary and tumour-derived cells and cell lines (Abel & Haarmann-
Stemmann). The chromosomal localisation of the human AhR gene is assigned to 
chromosome 7p15 with a length of about 50 kb, containing 11 exons. The overall intron/ 
exon structure of the human gene is homologous to the mouse gene, probably 20 kb longer 
(Bennett et al., 1996).  
Structure of the AhR & Arnt Protein 
The human AhR gene encodes for a protein of 848 amino acids with a calculated mass of 
96 kDa (Burbach et al., 1992). The ligand-activated aryl hydrocarbon receptor is a basic 
helix-loop-helix (bHLH) protein that heterodimerises with the bHLH protein Arnt (aryl 
hydrocarbon nuclear translocator) and is localised in the cytoplasm of different cells (Gu et 
al., 2000). The bHLH domain is required for protein dimerisation and DNA-binding. These 
processes are mediated by two sequences, the NLS (nuclear localisation signal) sequence is 
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important for AhR nuclear localisation and the NES (nuclear export signal) sequence 
contributes to the nuclear export. AhR and Arnt belong to two different classes of bHLH 
proteins. However, transcriptional activation of target genes by bHLH/PAS (further 
explanation concerning the PAS-domain see in the section below) factors requires 
association between a member of the AhR and the Arnt-class. The AhR-like component is 
responsible for interaction with gene promoters, whereas the Arnt-like component functions 
as a generic co-regulator. AhR and Arnt display different distribution patterns, suggesting 
diverse developmental roles (Wilson & Safe, 1998). The AhR PAS domain is involved in 
AhR/Arnt dimerisation (PAS A) and binding of AhR ligand and hsp90 (PAS B). These 
domains are designated as PAS because of their homology with the regulatory proteins 
known as Per, Arnt and Sim. The glutamine-rich transactivation domain is placed at the C-
terminal end of the AhR (Whitelaw et al., 1993). The domain structures of the AhR-protein 
are given in figure 6. 
 
Figure 6: Domain structure of the AhR (Denison et al., 2002), AhR: aryl hydrocarbon receptor, Arnt: 
aryl hydrocarbon nuclear translocator, bHLH: basic helix-loop-helix, DRE: dioxin 
responsive element, hsp90: heat shock protein (90k Da), NES: nuclear exposure signal, 
NLS: nuclear localisation signal, PAS: Per, Arnt, Sim 
2.3.2. Aryl Hydrocarbon Receptor-mediated Signal Transduction 
At least two different formations of AhR complexes are involved in the AhR-mediated signal 
transduction: the 9S and 6S form, which represent different sedimentation coefficients and 
also differ in their calculated molecular weight. In the absence of a ligand, the 9S aryl 
hydrocarbon receptor resides as a multi-protein complex in the cytosol (Rowlands & 
Gustafsson, 1997). It is associated with two molecules of hsp90, a heat shock protein of 
90 kDa which is responsible for maintaining the receptor in a latent non-DNA binding state 
and the correct folding of the ligand binding domain, respectively. In the repressed state the 
PAS domain of the AhR is bound to the hsp90 proteins. Additional members of the complex 
are the X-associated protein 2 (XAP2) and p23, a co-chaperone protein of 23 kDa. XAP2 
stabilises the whole complex and protects the AhR from ubiquitination and following 
proteosomal degradation. Ligand-binding induces a conformational change and a 
subsequent exposure of the nuclear localisation sequence (NLS). As a result of the exposed 
NLS the complex translocates into the nucleus, sheds hsp90, p23 and XAP2 and forms a 
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heterodimer with Arnt. Kazalauskas et al. (1999) report that Arnt is not needed for the 
nuclear translocation of the AhR, moreover it is assumed that hsp90 translocates with the 
ligand-bound receptor into the nucleus and dissociates as a result of the dimerisation with 
Arnt (figure 7) (Kazlauskas et al., 1999).  
 
Figure 7: AhR-Signalling Pathway (Denison & Nagy, 2003), AhR: aryl hydrocarbon receptor, Arnt: 
aryl hydrocarbon nuclear translocator, CYP1A1: cytochrome P-4501A1, DRE: dioxin 
responsive element, hsp90: heat shock protein (90k Da), XAP2: X-associated protein 2 
The molecular mass of the nuclear AhR/Arnt complex, also known as the 6S form, varies 
among species, strains and tissue types, ranging from 180 - 210 kDa. The 6S nuclear 
heterodimer is a transcription factor and binds to the core enhancer regulatory element 
known as xenobiotic or dioxin responsive element (XRE or DRE) which consists of the 
following sequence: 5´-T(C/T)GCGTG-3´. The AhR interacts with the 5´-half-site T(C/T)GC 
whereas the Arnt protein recognises the 3´-half-site (Wilson & Safe, 1998). Binding of the 
AhR/Arnt dimer leads to the recruitment of co-activators, which bind to the AhR/Arnt dimer 
and enhance transcription initiation. Furthermore, the binding of the AhR/Arnt dimer to the 
enhancer enables the binding of transcription factors to the promoter (Denison & Whitlock, 
1995). Finally the RNA polymerase II assembles at the promoter and the elongation phase 
starts (Hankinson, 2005).  
The AhR-signalling is quickly terminated upon elimination of the inducing xenobiotic. The 
exposure of the nuclear export signal (NES) sequence present in AhR by shedding of hsp90, 
p23 and XAP2, causes the activated aryl hydrocarbon receptor being transported from the 
nucleus into the cytoplasm. Since dimerisation with Arnt converts the AhR into its high affinity 
DNA-binding form, nuclear AhR complexes that fail to dimerise are shuttled into the 
cytoplasm. Subsequently the AhR is degraded via the 26S proteasome. The reasons for the 
degradation of AhR are wide ranging, in the first instance the process controls the duration 
and magnitude of the transcriptional activation by the AhR/Arnt dimer. The aryl hydrocarbon 
receptor-mediated signal transduction and termination process is shown in figure 7 
(Davarinos & Pollenz, 1999). 
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2.3.3. AhR-regulated Genes 
AhR-binding to dioxin response elements results in the increased transcription of several 
genes involved in xenobiotic metabolism, including phase I and phase II metabolising 
enzymes and several genes involved in proliferation, apoptosis, cell growth and 
differentiation. The most prominent example for phase I enzymes are monooxygenases of 
the CYP family. Several phase II enzymes, like glutathione-S-transferase A2 and NQO1 
(NAD(P)H quinone oxidoreductase 1) are also up-regulated by the AhR pathway (Bock & 
Kohle, 2006). An example for the dependence of apoptosis towards AhR-signalling is the 
regulation of Bcl-2 associated X protein (Bax) which promotes apoptosis. Exposure towards 
polyaromatic hydrocarbons like benzo(a)pyrene (BaP) can lead to the induction of apoptotic 
cell death in murine oocytes. An explanation for the premature initiation of the menopause for 
female smokers might be the destruction of oocytes triggered by the BaP-induced AhR 
pathway (Matikainen et al., 2001). Although numerous genes are regulated by the AhR 
pathway, the best studied is the induction of CYP1A1 which is also used as a model system 
to define the underlying gene regulation mechanism by AhR and other bHLH transcription 
factors (Denison & Whitlock, 1995).  
2.3.4. Ligands and Inducers 
Ligands of the aryl hydrocarbon receptor include a variety of structurally diverse chemicals, 
suggesting a promiscuous ligand-binding site. They can be separated into two major 
categories, anthropogenic-derived AhR ligands and naturally occurring ligands, formed in 
biological systems. HAHs (halogenated aromatic hydrocarbons) and PAHs belong to the first 
group, displaying a planar structure which accounts for the high AhR binding affinity. Both of 
them are usually referred as classical AhR ligands. The metabolically more stable HAHs are 
more potent than the PAHs, with binding affinities in the pM to nM range and nM to µM, 
respectively. Nevertheless, the most potent agonist known is 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD, figure 8), often used as a model substance to induce CYP1A1 gene 
expression. Structure-activity relationship analysis suggests that the AhR binding pocket can 
accept planar ligands with maximal dimensions of 14 x 12 x 5 Å (Poland & Knutson, 1982; 
Waller & McKinney, 1995).  
Cl
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Figure 8: Structure of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) 
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Recently a relatively large number of AhR ligands have been identified with completely 
diverse structural and physicochemical properties. Although the majority of these chemicals 
are relatively weak inducers, their identification as ligands supports a re-evaluation of the 
currently accepted view of AhR ligand structure. Within the naturally occurring ligands there 
are two subclasses: dietary and endogenous physiological AhR ligands (Denison et al., 
2002). 
Naturally occurring dietary AhR Ligands 
The greatest source of exposure for humans and animals to AhR ligands is the diet. Although 
they are very weak agonists, most of the natural occurring ligands can be found in food. 
Examples for dietary ligands are carotinoides, curcumin and indole-3-carbinol (I3C). It is 
reported that precursors with any or weak AhR binding activity can be converted to 
significantly more potent AhR ligands in the mammalian digestive tract, e.g. the conversion 
from I3C to indolo-(3,2,-b) carbazole (ICZ), which has perhaps the highest affinity of all 
naturally occurring agonists (Gillner et al., 1993).  
The largest group of dietary AhR ligands are flavonoids, including flavones, flavanols, 
flavanones and isoflavones. These chemicals are widely distributed in dietary plant products 
and the levels in human blood can reach the low µM range, concentration sufficient to 
interact with the AhR (Formica & Regelson, 1995). Flavanoids can exhibit agonistic and 
antagonistic effects, depending on their concentration, the investigated tissue or species 
(Denison et al., 2002). 
Synthetic AhR Ligands 
3´-Methoxy-4´-nitroflavone (MNF)  
The effect of 3´-methoxy-4´-nitroflavone (MNF, figure 9), a synthetic flavone, towards the 
expression of CYP1A1 mRNA, protein and enzyme activity was investigated in mouse 
hepatoma cells (Hepa.2DLuc.3A4-cells), using luciferase reporter gene assay and Western 
blot analysis. Cells treated with MNF displayed a dose-dependent induction of CYP1A1 
protein expression, suggesting an agonistic effect for this protein. Otherwise any reporter 
protein was expressed, which may be due to a differential activation of gene transcription. An 
antagonistic effect of MNF was observed for Hepa.2DLuc.3A4-cells, co-incubated with 
150 pM TCDD and increasing MNF concentrations. The TCDD-induced expression of the 
luciferase reporter and the CYP1A1 gene decreased in a MNF concentration-dependent 
manner. Further experiments addressed possible effects of posttranslational modulation of 
protein stability and regulation through diverse signal transduction pathways, but neither of 
them proved to be the explanation for the observed effects. The third possibility may be a 
primary mechanism accounting for the differential gene expression. Induction of CYP1A1 by 
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MNF depended on the CYP1A1 promoter sequence, which is a complex 2 kb spanning 
regulatory region, whereas p2DLuc has just a minimal promoter. Furthermore the obtained 
results suggested that MNF required a clustered DRE structure to enhance substantial gene 
transcription (Zhou & Gasiewicz, 2003). MNF acting as a low efficacy AhR ligand can act as 
an antagonist or agonist depending on its concentration as examined towards human breast 
cancer cells (MCF-7). MNF was reported to act as a pure antagonist in MCF-7 cells, 
suggesting species specific differences in AhRs, differences in the promoter regions between 
human and mouse CYP1A1 and thirdly, the species and tissue specific expression of co-
activator/ co-repressor proteins (Lu et al., 1995). 
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Figure 9: Structure of 3´-methoxy-4´-nitroflavone (MNF) 
Alternaria Toxins as AhR Ligands 
Alternaria toxins, like AME and AOH represent potential ligands of the AhR, naturally 
occurring and acting as agonists. The activation of the AhR pathway by appropriate agonists 
is followed by an induction of cytochrome P450 enzymes. The influence of AOH and AME 
towards the regulation of CYP1A1 in HepG2, KYSE510 and HT29 cells was investigated by 
M. Fehr (2008). He identified AME and AOH to induce CYP1A1 gene and protein expression 
in KYSE510 and HepG2 cells, whereas a greater response was detected in KYSE510 cells. 
Both mycotoxins did not trigger any CYP1A1 induction in HT29 cells (Fehr, 2008).  
Schreck et al. investigated AME- and AOH-mediated expression of CYP1A1 in murine 
hepatoma cells differing in their AhR-signalling using Western blot analysis. Pfeiffer et al. 
(2008) reported for AOH and AME the highest activity of the AhR-regulated enzyme 
CYP1A1. The dependence of the mycotoxin-mediated CYP1A1 induction on AhR and Arnt 
was shown by comparison of wild type Hepa-1c1c7, Arnt-deficient Hepa-1c1c4 and AhR-
deficient Hepa-1c1c12 cells. In AhR- and Arnt-expressing Hepa-1c1c7 cells, CYP1A1 
protein-levels were already induced after 5 h of incubation with 40 µM AME, whereas 40 µM 
AOH-induced CYP1A1 expression only after 24 h. AME was a better substrate for CYP1A1 
than AOH, suggesting it to be also a better AhR ligand. Any induction of CYP1A1 expression 
was detected after 24 h treatment with AOH or AME in AhR- and Arnt-deficient cells, 
supporting the hypothesis that the AhR-pathway is involved in AOH-/ AME-induced CYP1A1 
expression in murine hepatoma cells (Schreck et al., 2011). 
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Endogenous Ligands for the AhR 
The existence of endogenous physiological AhR ligands has been suggested in numerous 
studies where the AhR signalling pathway in the absence of exogenous ligands (Denison & 
Nagy, 2003). Sadek & Allen-Hoffmann (1994) investigated the effect of semi-solid 
methylcellulose suspensions with human keratinocytes and dermal fibroblasts towards 
CYP1A1 gene expression without addition of any xenobiotics. Increase of steady state 
CYP1A1 mRNA is observed for human keratinocytes, whereas dermal fibroblasts are 
nonresponsive. Moreover, induction is also observed in kerationocyte suspension with 
medium (Sadek & Allen-Hoffmann, 1994). 
The endogenous ligands are composed of a structurally diverse group of substances which 
are mainly relative weak agonists. They can be classified into different categories, 
comprising indoles, arachidonic acid metabolites, tetrapyroles and a variety of other ligands, 
whereby all of them are present in many species and tissues. Many of the toxic and 
biological effects of AhR ligands resulted from altered gene expression. The continuous and 
inappropriate expression of specific genes could be responsible for adverse effects of TCDD 
and other HAHs, which were usually observed after several days to weeks following 
exposure. This theory was consistent with endogenous ligands being relatively weak 
agonists and which could trigger only a transient activation of the AhR-signalling pathway 
(Denison & Nagy, 2003). Evidence for the AhR involved in normal development was 
described by Schmidt et al. (1996). They observed physiological changes and developmental 
defects in AhR-knockout mice like hypercellularity in liver tissue (Schmidt et al., 1996). 
2.3.5. Ligand-independent Activation of the AhR 
Recently the hypothesis of a ligand-independent AhR activation was developed, based on 
the existence of substances, which cause AhR-mediated effects without meeting the 
requirements for AhR ligands or display any binding in ligand-binding assays. Both 
arguments were given in the case of primaquine, a reported anti-malaria agent. CYP1A1 
gene expression and enzyme activity was induced in human hepatocytes and HepG2 cells. 
Furthermore, 8-methoxypsoralen (8-MP) and α-naphthoflavone (α-NF), both reported AhR 
antagonists, down regulate the primaquine-induced CYP1A1 induction. However, the 
absence of competitive binding of primaquine to the AhR suggests a probable not ligand-
activated pathway, supported by the not polycyclic aromatic structure of primaquine 
(Fontaine et al., 1999). Guigal et al. (2000) reported of 5- to 6-fold CYP1A1 mRNA increases 
after treatment of Caco2 cells with foetal or adult bovine and human serum. Furthermore, the 
induction observed with serum was suggested to be independent of the AhR pathway, 
because any reporter gene was expressed in serum-treated reporter gene transfected Caco2 
cells (Guigal et al., 2000). 
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2.4. The Cytochrome P450 System 
The cytochrome P450 (CYP, P-450) system consists of the ubiquitous monooxygenase 
family which is present in plants, animals and prokaryotes. The human genome encodes 57 
different CYPs, compared to more than 250 members of the plant Arabidopsis. The human 
P-450 genes are classified into 18 families and 42 subfamilies. Cytochrome P450s are 
hemoproteins and derive their name from the absorption maximum at a wavelength of 
450 nm, elicited by the carbon monoxide derivate of reduced cytochrome (Stryer, 2002; 
Philip Wexler, 2005). One of the most important functions of cytochrome P450s are their role 
in drug metabolism. Despite their general protective role, the action of the P-450 system is 
not always beneficial since the toxicity of several substrates can be enhanced by metabolic 
activation (Tompkins & Wallace, 2007). 
2.4.1. Enzyme Mechanism 
Cytochrome P450s catalyse regio- and stereospecific oxygen attack of hydrocarbons at 
physiological temperatures. Without a catalyst such a reaction would occur at high 
temperatures and would not be specific. The reactions catalysed by cytochrome P450 
enzymes generally are of following stoichiometry (Guengerich, 2003):  
Substrate + O2 + NADPH + H+  Product + H2O + NADP+   
The active catalytic centre of the enzyme is an iron-protoporphyrin IX (heme) with a thiolate 
group of a cysteine as fifth ligand. The sixth ligand of resting CYPs is a water molecule 
(Werck-Reichhart & Feyereisen, 2000). The catalytic mechanism of cytochrome P450 
monooxygenases consists of four steps (figure 10). The first step includes substrate-binding 
by displacing the sixth ligand, the water molecule. The second step is a one-electron 
reduction of the complex from Fe3+ to Fe2+. In the third step molecular oxygen binding results 
in the formation of a superoxide complex and the fourth step is a second reduction, leading 
to an activated oxygen species. Recent crystallographic analysis of the transiently activated 
oxygen species suggest the protonation of A- leading to the formation of B- and the formation 
of the oxoferryl species after cleavage of the O-O bond (Schlichting et al., 2000). The 
oxoferryl species is apparently most abundant and catalyses the hydroxylation reaction (O 
insertion). The iron-hydroperoxo form (B-) inserts OH+, producing protonated alcohols. The 
oxygen free forms of the enzyme catalyse isomerisation, reduction and dehydration. The 
existence of various forms of enzymes together with the variety of apo-proteins explains the 
diversity of reactions catalysed by the P450 system (Mansuy, 1998).  
 
31 
 
Figure 10: Catalytic mechanism of P-450 enzymes (Werck-Reichhart & Feyereisen, 2000) 
2.4.2. Human Cytochrome P450 Genes  
The organ expressing the highest levels of CYP enzymes is the liver, which plays a dominant 
role in the first-pass clearance of xenobiotics. Extrahepatic tissues also express xenobiotic 
metabolising CYPs, which can also influence the absorption of drugs and foreign chemicals. 
Since most therapeutic agents target extrahepatic tissues, the individual CYP profile may 
have a significant impact on the effectiveness of the treatment (Ding & Kaminsky, 2003). 
Table 1:  Human cytochrome P450 genes expressed in different tissues (Shimada et al., 1994; Ding 
& Kaminsky, 2003; Choudhary et al., 2005) 
organ expressed P-450 enzymes 
oesophagus 1A1, 1A2, 2A, 2E1, 2J2, 3A5 
small Intestine 1A1, 1B1, 2C9, 2C19, 2D6, 2E1, 2J2, 2S1, 3A4, 3A5 
colon 1A1, 1A2, 1B1, 2J2, 3A4, 3A5 
liver 1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1,3A 
Oesophagus 
Oesophageal cancer is the third common cancer of the gastrointestinal tract (GIT), reason 
enough to potentiate research concerning the underlying mechanism (Ding & Kaminsky, 
2003). Lechevrel et al. (1999) investigated oesophageal tissue with regard to the pattern of 
CYP expression. They identified CYP2E1, an enzyme known to activate N-nitrosamines to 
DNA-damaging metabolites. Since smoking and alcohol consumption induce CYP2E1, they 
suggested CYP2E1 to contribute to the development of oesophageal cancer (Lechevrel et 
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al., 1999). This hypothesis was supported by the findings of Bergheim et al. (2007) who 
identified higher levels of CYP2E1, 3A4 and 3A5 mRNA in oesophageal tissue of squamous 
cell carcinoma. Higher CYP1A1 protein levels were expressed in tumour tissue compared to 
normal tissue (Bergheim et al., 2007). M. Fehr (2008) reported a 500-fold CYP1A1 induction 
in KYSE510 cells treated with 1 µM AOH for 24 hours. 
Liver 
The liver plays a predominant role in xenobiotic metabolism mediated by cytochrome P450, 
resulting in an ubiquitous expression of these enzymes (Scripture et al., 2005). Shimada et 
al. (1994) showed that CYP1A2, 2A6, 2B6, 2C, 2D6, 2E1 and 3A account for 72% of total 
CYP protein. Drahushuk et al. (1998) demonstrated a very weak constitutive expression of 
CYP1A1 protein in human microsomal liver samples, which could also be due to background 
exposure of polychlorinated dibenzodioxins (PCDDs) and related compounds. However, 
CYP1A1 was shown to be highly inducible by TCDD, resulting in significantly increased 
CYP1A1 protein and activity levels.  
Colon 
Colon and rectum cancer are responsible for the most cancer-related deaths in western 
countries. Despite this, few studies have been reported and very little information is available 
on the in vivo regulation of colonic CYPs (Ding & Kaminsky, 2003). The most prominently 
expressed CYPs are CYP3A3, CYP1A1 and CYP1A2. Expression of CYP3A3 and CYP1A1 
was found to be site-specific, either higher in colon or rectum, whereas the mRNA levels of 
CYP1A2 were variable. Exposure to various xenobiotics and/ or genetic polymorphism may 
contribute to differential CYP expression (Mercurio et al., 1995). 
2.4.3. Human Cytochrome P450 Isoforms and Hydroxylation  
of AOH & AME 
The Alternaria toxins AOH and AME undergo oxidative metabolism by cytochrome P450 
enzymes, hence Pfeiffer et al. (2008) investigated the activities of twelve major human CYP 
isoforms for the hydroxylation of AME and AOH. CYP1A1 is the most active isoform in the 
hydroxylation of AOH, followed by CYP1A2, CYP2C8 and CYP3A5. The formed 
hydroxylation products in descending order are: 2-OH-AOH, 4-OH-AOH and small amounts 
8-OH-AOH. CYP1A1 has been reported to have also the highest activity for aromatic 
hydroxylation of AME. Since most CYP isoforms display higher activities for AME than for 
AOH, it appears to be a better substrate (Pfeiffer et al., 2008). 
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2.4.4. Regulation of CYP1A1 Expression 
The AhR is involved in the induction of CYP1A1 transcription. Structure-activity studies 
indicate a correlation between receptor binding affinity of ligands and their potency as 
inducer. The binding of the heterodimeric AhR/Arnt complex to XRE or DRE is necessary for 
the subsequent expression of CYP1A1 protein (Fujisawa-Sehara et al., 1987; Denison & 
Whitlock, 1995). However, Fujii-Kuriyama et al. (1992) reported an additional cis-acting DNA 
regulatory element to be responsible for the constitutive expression of the rat CYP1A1 gene. 
The element is known as basal transcription element and is located about -43 bp upstream of 
the TATA sequence (Yanagida et al., 1990). 
2.5. The Glutathione-S-Transferase Enzymes 
Glutathione-S-transferases (GSTs) catalyse nucleophilic attack by reduced glutathione 
(GSH) on nonpolar compounds containing an electrophilic carbon, nitrogen or sulphur atom. 
GSTs catalyse conjugation reactions in phase II drug metabolism, a mechanism providing 
protection against a diverse spectrum of xenobiotics (Hayes & Pulford, 1995). Furthermore 
GSTs are also involved in protection against reactive oxygen species and in the biosynthesis 
of leucotrienes, prostaglandins, testosterone and progesterone. They are important targets 
for anti-asthmatic and antitumor drugs. They metabolise cancer chemotherapeutics, 
insecticides, herbicides, cancerogens and by-products of oxidative stress (Hayes et al., 
2005).  
GST-Families 
There are three different families which exhibit glutathione-S-transferase activity: cytosolic, 
mitochondrial and microsomal GSTs; every known GST isoform belongs to one family. All 
three families contain members that catalyse the conjugation of GSH with 1-chloro-2,4-
dinitrobenzene (CDNB). Based on amino acid sequences, seven classes of GSTs are known 
in mammalians: GST α, GST μ, GST π, GST σ, GST θ, GST ω and GST ζ (Hayes & 
McLellan, 1999). The largest GSTs in humans are the cytosolic GSTs, consisting of 16 
subunits (Hayes & Pulford, 1995). Their overlapping substrate specificity makes the 
identification of isoforms solely based on their catalytic properties very difficult. Beside 
catalysing conjugation, reduction and isomerisation reactions, cytosolic GSTs also bind 
hydrophobic ligands, essential in intracellular transport and elimination of xenobiotics (Hayes 
et al., 2005). 
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Induction of GST 
The expression level of GSTs can be increased in many species by exposure to xenobiotics, 
suggesting an important role in the adaptive response to chemical stress (Pickett et al., 
1984). Inducing substances of GSTs are mostly GST substrates or are transformed by 
cytochrome P450 enzymes to become GST substrates (Prochaska & Talalay, 1988). GSTs 
also modulate the induction of other enzymes, like quinone reductase, UDP-glucuronyl 
transferase, γ-glutamyl transferase and γ-glutamylcysteine synthetase. The modulation of 
other drug metabolising enzymes by GSTs suggests, that GST polymorphism influences 
other chemical defence mechanisms (Hayes & Wolf, 1990). 
Substrates of GST 
Substrates of GSTs are extremely diverse, PAHs, phenolic antioxidants, flavonoids, 
thiocarbamates and indoles have been reported as GST inducers in rats and mice (Hayes & 
Pulford, 1995). Structurally they do not seem to have a single feature in common. However, 
a parallel between GST inducers and Michael reaction acceptors, e.g. alkenes conjugated 
with electron withdrawing groups, or substances which are metabolised to Michael acceptors 
have been suggested (Prochaska & Talalay, 1988; Talalay et al., 1988). 
2.6. RNA Interference  
RNA interference (RNAi) is a regulatory mechanism of many eukaryotic cells which can also 
be used for specific inhibition of gene expression. Posttranscriptional gene silencing (PTGS) 
was implemented in 1998 by Andrew Fire and Craig Mello, using double-stranded RNA 
molecules of the nematode Caenorhabditis elegans for specific gene silencing (Lottspeich, 
2006). RNA interfering pathways are guided by small RNAs, including small interfering RNAs 
and micro RNAs (de Fougerolles et al., 2007). 
siRNA-Pathway 
Long double-stranded RNA (dsRNA) is cleaved by RNase III endonuclease Dicer into small 
interfering RNAs (siRNA) in mammalian cells. siRNAs which have been synthesised 
previously by chemical methods, are used directly by Dicer. Dicer is complexed with RNA-
binding proteins and the Argonaute 2 (Ago-2) domain of the RNA-induced silencing complex 
(RISC) (Zhang et al., 2004, figure 11). The double-stranded siRNA is loaded into RISC, 
cleaved by Ago-2 and the sense, or passenger strand is released. The activated RISC 
contains a single-stranded anti-sense, or guide RNA molecule that recognizes 
complementary mRNA and performs intermolecular base pairing. The catalytic domain of 
Ago-2 cleaves the mRNA and exposes the cutting point without the protective poly(A) tail. 
Subsequently cellular RNases degrade the mRNA and inhibit its function as transcription 
template (Kim & Rossi, 2008). 
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In mammalian cells, double-stranded RNA with more than 30 nucleotides (nt) length 
activates interferons. The siRNA fragments used for gene silencing generally have a length 
of 21 - 23 nt (Lottspeich, 2006). The first nucleotide on the 5´-end is generally unpaired, 
followed by a 19 nt long base pair region (Elbashir et al., 2001).  
miRNA-Pathway 
Another important part of RNAi involves microRNAs (miRNA, figure 11). These complexes 
trigger translational suppression due to imperfect completion with target mRNA, in contrast to 
siRNA, which requires a perfect complement with the targeted mRNA (Kim & Rossi, 2008). 
miRNAs are endogenous substrates which are transcribed by RNA polymerase II into large 
primary miRNA (pri-miRNA) transcripts with poly(A) tail and 5´cap. They are processed by 
the microprocessor complex (containing Drosha and DGCR8) into pre-miRNA, consisting of 
60 - 70 nt hairpins. Pre-miRNAs are exported from the nucleus to the cytoplasm by 
Exportin 5 and are processed by the Dicer enzyme complex for loading onto the Ago-2- 
RISC (Shan, 2010). When the RNA duplex loaded onto the RISC has imperfect sequence 
complementation, the antisense (or passenger) strand is unwound and the mature miRNA 
activates RISC. The mature miRNA recognises the target mRNA in the 3´untranslated region 
(3´-UTR) leading to translational inhibition (de Fougerolles et al., 2007). 
 
Figure 11: Mechanism of RNA interference (de Fougerolles et al., 2007)
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3. Aims and Objectives 
Fungi of the genus Alternaria are ubiquitous pathogens. Many species are known to infest 
various food stuffs and produce diverse secondary metabolites- Alternaria mycotoxins. The 
consumption of Alternaria contaminated grain has been associated with an increased 
incidence of oesophageal cancer in Linxian, China (Liu et al., 1992). Furthermore Alternaria 
extracts as well as single toxins such as alternariol (AOH) and its monomethyl ether (AME) 
have been described to possess genotoxic and mutagenic properties, however, the 
underlying mechanisms of action have not fully been elucidated so far (Dong et al., 1987; Liu 
et al., 1991, 1992; Schrader et al., 2001, 2006; Lehmann et al., 2005; Brugger et al., 2006; 
Fehr et al., 2009; Nitiss et al., 2006; Jackson, 2002; Maynard et al., 2009).   
Even though several reviews on Alternaria toxins have been published over the last few 
decades, valid evidence is limited concerning their risk to health of man and animal. The 
EFSA has pointed out recently that there is an urgent need for further investigations on the 
toxicity of Alternaria toxins, because data published so far do not allow comprehensive risk 
assessment (EFSA, 2011).  
In the present thesis the question was addressed whether AME and/ or AOH elicit CYP1A1 
transcripts in human oesophageal carcinoma cells (KYSE510) and whether this dependents 
on AhR expression. The problem was approached in two different ways: firstly by 
posttranscriptional suppression of the Ah-receptor and secondly by using an AhR-specific 
inhibitor. The establishment of optimal transiently AhR-siRNA transfected KYSE510 cells, 
serving as test system for the investigations, represented a crucial part of the thesis. 
Benzo(a)pyrene (BaP) and aroclor (ARO), which is a mixture of polychlorinated biphenyls, 
are both known as potent CYP1A1 inducers. These compounds were used as a suitable 
positive control in oesophageal cells. 3´-Methoxy-4´-nitroflavone, a synthetic flavone and 
known AhR antagonist, was used for the specific blocking of the Ah-receptor in the second 
approach. Subsequent treatment with AOH or AME was expected to provide information 
about the AhR-dependence of CYP1A1 induction as well.   
According to recent publication, AME and AOH are hydroxylated by cytochrome P450 
monooxygenase CYP1A1 to catechols during phase I metabolism (Burkhardt et al., 2011). 
To clarify whether both mycotoxins are subjected to phase II metabolism, the activity of 
glutathione-S-transferases (GST) was investigated in colon adenocarcinoma cells (HT29). 
Activity of glutathione-S-transferases was determined by the GST assay according to Habig 
et al. (1974), whereupon the implementation of the assay as a routine method had to be 
performed. 
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4. Results and Discussion 
4.1. HPLC Purity of AOH and AME 
Alternaria toxins used in the present thesis were purchased from Sigma-Aldrich, whereas the 
compounds used by M. Fehr (2008) were synthesised by Dr. K.-H. Merz, University of 
Kaiserslautern, Germany. The different mycotoxins were analysed by High Performance 
Liquid Chromatography (HPLC) prior the beginning of the experiment to assure comparable 
purity and thus cell response.  
4.1.1. HPLC-Chromatogram of AME 
The chromatogram of AME, purchased from Sigma-Aldrich, was recorded by C. Schwarz 
showing one main peak at a retention time of 17,866 min (figure 12), also depicted in the 
isoabsorbance plot (figure 13). The existence of a single main peak confirmed the purity of 
> 98% which is specified by the company.  
In contrast the HPLC-chromatogram of the synthesised mycotoxin presented far more peaks 
for AME (figure 14). The strongest signal was observed at a retention time of 17.674 min and 
several smaller peaks at 12.727, 14.031, 18.963, 19.884, 20.424, 21.428 and 21.878 min 
were detected. The signal at 17.674 min was by far the most intense one. The retention time 
was closely related to the main peak of the Sigma-Aldrich product, thus it was identified as 
the AME-related signal. In addition, the isoabsorbance plot, a plot of retention time versus 
wavelength in figure 13, clearly showed the presence of impurities in the synthesised 
sample. The exclusive occurrence in the synthesised mycotoxin suspected them to be 
impurities or precursors potentially left from the process of synthesis.  
 
Figure 12: HPLC-Chromatogram of AME purchased from Sigma-Aldrich 
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Figure 13: Isoabsorbance Plot of AME purchased from Sigma-Aldrich 
 
Figure 14: HPLC-Chromatogram of AME synthesised by Dr. K.-H. Merz, University of Kaiserslautern, 
Germany 
 
Figure 15: Isoabsorbance Plot of AME synthesised by Dr. K.-H. Merz, University of Kaiserslautern, 
Germany 
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4.1.2. HPLC-Chromatogram of AOH 
Both HPLC-chromatograms of AOH, the product purchased from Sigma-Aldrich (figure 16) 
as well as the one of the synthesised compound (figure 17) were recorded by C. Tiessen. 
The retention times of the main peaks, which were annotated to be the AOH-related signals, 
differ slightly, 8.972 min were registered for the Sigma-Aldrich product and 9.154 min for the 
synthesised one. The chromatogram of the synthesised AOH showed several smaller peaks 
at 2.791, 3.334, 5.631, 11.083, 11.586, 12.273, 16.354 and 28.887 min. The impurity-derived 
peaks detected in synthesised AME (figure 14) are of stronger intensity, suggesting a higher 
purity of synthesised AOH. However, in both cases the identity of the impurities remained 
unknown. 
 
Figure 16: HPLC-Chromatogram of AOH purchased from Sigma-Aldrich  
 
Figure 17: HPLC-Chromatogram of AOH synthesised by Dr. K.-H. Merz, University of Kaiserslautern, 
Germany 
The experiments performed by M. Fehr (2008) addressed the mycotoxin-mediated 
modulation of CYP1A1 mRNA levels and activity as well as cytotoxicity in human 
oesophageal (KYSE510), liver (HepG2) and colon (HT29) carcinoma cells. The results, 
especially obtained for synthesised AME have to be viewed critically. The detected impurities 
potentially affected the metabolic activity of cells. Thus the results were expected not to be in 
compliance with those obtained with the Sigma-Aldrich products. 
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4.2. Cytotoxicity of AME and AOH 
Prior to investigating gene modulating effects fostered by AME and AOH, the concentration 
range for testing had to be identified and determined to be suitable for the planned 
experiments. This implies that cell growth was not altered by cytotoxicity or other growth 
inhibitory effects.  
The analysed parameter of the sulforhodamine B (SRB) assay is the total cellular protein, 
which is determined by binding of the dye sulforhodamine B. Shortly after removing 
excessive dye, the protein-bound fraction is dissolved under alkaline conditions and the 
concentration is determined spectrophotometrically at λ = 570 nm.  
Briefly, 800 KYSE510 cells were seeded per well of a 96-well plate and grown for 72 hours. 
The medium was replaced by 0.1, 1 and 10 µM AME dissolved in DMSO, the final DMSO 
concentration in the medium being 1%. A 24 h treatment period followed and then the SRB 
assay was performed as described in chapter 6.2 “Sulforhodamine B (SRB) Assay”. After 
24 h of incubation with 0.1, 1 and 10 µM AME no significant changes of protein amount were 
observed (figure 18). Even the highest concentration tested in the assay (10 µM AME) did 
not notably diminish cell growth.  
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Figure 18: Cytotoxicity of AME in KYSE510 cells determined with the sulforhodamine B (SRB) assay. 
KYSE510 cells were incubated for 24 h with AME. Growth inhibition was calculated as the 
percent survival of treated cells over control cells (treated with the solvent 1% DMSO) x 
100 (T/C %). The values given are the mean ± SD of at least three independent 
experiments. Calculation of the statistical significances are performed on the basis of 
underlying T/C [%] values. 
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M. Fehr (2008) already investigated the cytotoxicity of AME and AOH in KYSE510 cells, 
treating the cells for 24 h and 72 h with the mycotoxins. Both AME and AOH inhibited cell 
growth in a concentration-dependent manner. The IC50 could not be calculated for the 24 h 
incubation, as it exceeded 100 µM, the highest concentration used for the assay. Treatment 
for 72 h notably inhibited cell growth, yielding IC50 of 42 ±10 µM AOH and 48 ±3 µM AME, 
respectively. However, the SRB assay was performed with the toxins synthesised by Dr. 
Merz, hence the containing impurities and precursors might contribute to an altered 
cytotoxicity. AME used by M. Fehr did not inhibit cell growth up to a concentration of 10 µM, 
consequently the compound purchased from Sigma-Aldrich was also tested in the range of 
0.1 - 10 µM (figure 18). 
The cytotoxicity of AME and AOH purchased from Sigma-Aldrich was investigated by 
N. Kahle in 48 h pre-cultivated KYSE510 cells as well. Cells were treated with both 
mycotoxins in the concentration range of 0.01 - 60 µM for 24 h. AME in the concentration of 
0.01 µM slightly inhibited cell growth, which turned into a weak cell proliferative effect at 
0.1 µM AME. A significant cytotoxic effect was determined at concentrations ≥ 25 µM AME. 
Taken together, all the data concerning the cytotoxicity of AME, recorded in the course of the 
present thesis and by N. Kahle, suggested any significant cell growth inhibition in the 
concentration range of 0.1 - 10 µM AME and indicated the suitability for the planned gene 
modulation experiments (Kahle N., 2012).   
In contrast to the data obtained by M. Fehr for AOH-mediated cytotoxicity, N. Kahle could 
show significant growth inhibitory effects in 48 h pre-cultivated KYSE510 cells at 
concentrations ≥ 50 µM. However, these results were obtained when the practical part of the 
present thesis was already finished. At the beginning of the present thesis, the only available 
data was the cytotoxicity profile of synthesised AOH, recorded by M. Fehr (2008). Since both 
HPLC-chromatograms, the one of AOH synthesised by Dr. K.-H. Merz and of the product 
purchased from Sigma-Aldrich mainly matched each other, comparable purity seemed to be 
given. Consequently, the cytotoxic potential of the compounds was believed to be similar as 
well. M. Fehr reported AOH to be less potent compared to AME; concentrations up to 50 µM 
AOH did not show any significant growth inhibitory effects. Therefore, 50 µM AOH were used 
as maximum concentration in CYP1A1 gene expression experiments in the present work. 
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4.3. Impact of AME and AOH on CYP1A1 and AhR Gene 
Transcription in KYSE510 Cells 
CYPs are drug metabolising enzymes, catalysing the monooxygenation reaction during 
phase I metabolism. AME and AOH were identified as suitable substrates for human 
recombinant CYP enzymes, whereby CYP1A1 represented the most active isoform. Minor 
metabolic activities were described for CYP1A2, 2C19 and 3A4 (Pfeiffer et al., 2008). 
The question whether AOH and AME modulate gene transcription of CYP1A1 and AhR was 
investigated by M. Fehr in different human tumour cell lines of the gastrointestinal tract. The 
objective was, in case of an interference on transcription, to compare the results from 
KYSE510 (oesophagus), HepG2 (liver) and HT29 (colon) cells, to identify potential 
differences with respect to organ specificity. The induction of CYP1A1 mRNA transcripts was 
investigated using quantitative real time PCR (qRT-PCR) and CYP1A1 activity was 
determined by the ethoxyresorufin-O-deethylase (EROD) assay. A cell line-specific effect of 
AME and AOH was observed. The induction of CYP1A1 mRNA and CYP1A1 activity in 
KYSE510 cells was more potent compared to HepG2 cells, whilst any induction was 
observed in HT29 cells (Fehr, 2008). Thus the cell line KYSE510 was chosen for the 
comparative analysis of compounds synthesised and those purchased from Sigma-Aldrich. 
Additionally the impact of both mycotoxins on AhR transcription was investigated.  
In the following, AME- and AOH-mediated CYP1A1 induction in oesophageal carcinoma 
KYSE510 cells should be tested, whether it is AhR dependent. Therefore the mRNA 
encoding AhR should be suppressed by using siRNA technology. AhR-suppressed cells 
were treated with the designated mycotoxins and the CYP1A1 transcripts were determined 
by qRT-PCR. 
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4.3.1. Effect of AME and AOH on AhR and CYP1A1 mRNA levels in 
KYSE510 Cells 
To determine the effect of AME and AOH on CYP1A1 transcription, 3*104 KYSE510 cells 
were seeded per well of a 24-well plate and cultivated for 24 h and 48 h, before incubation 
with the mycotoxins for 6 h, 12 h and 24 h. Cells were incubated with AME (0.1, 1, 10 µM) 
and AOH (0.1, 1, 10, 50 µM) under serum-containing conditions, with a final concentration of 
1% DMSO. Benzo(a)pyrene (BaP) and aroclor (ARO), both potent inducers of CYP1-
isoenzymes were used as positive controls at a concentrations of 5 µM (Whitlock, 1999; 
Almahmeed et al., 2004). Total RNA was reverse transcribed with the QuantiTect® Reverse 
Transcription Kit from Qiagen®. The cDNA was amplified by qRT-PCR using gene-specific 
primers (QuantiTect® Primer Assay) and SybrGreen Master Mix from Qiagen®. Transcript 
levels of target genes were normalized by β-actin mRNA levels that served as endogenous 
control (see chapter 6.4 “Gene Expression Analysis of CYP1A1 and AhR using quantitative 
Real Time PCR”). 
Optimisation of Pre-cultivation and Incubation Time in KYSE510 Cells  
Cell pre-cultivated for 24 h 
Short Time Incubation (6 h and 12 h) with AME 
Treatment of 24 h pre-cultivated KYSE510 cells with 0.1 and 1 µM AME for 12 h fostered a 
marginal increase of CYP1A1, whereas a strong decline in CYP1A1 mRNA levels was 
observed at 10 µM AME (figure 19 A). 6 h of treatment with 1 µM and 10 µM AME induced a 
drop of CYP1A1 mRNA (figure 19 B). The positive controls strongly increased CYP1A1 
levels, a 23.8-fold induction was observed after 12 h with ARO and a 28-fold induction after 
6 h of incubation with BaP. The experiments with 12 h and 6 h of incubation were performed 
to screen for a significant CYP1A1 induction. Since no indication of such an effect was 
observed, the experiments were not repeated. 
In summary the effects of AOH and AME on CYP1A1 induction in KYSE510 cells were 
marginal leading to the assumption, that the CYP1A1 induction fostered by AME may be 
time-dependent and would peak later in time. A time dependent induction of rat hepatic 
CYP1A1 and CYP1A2 expression after administration of the anti-angiogenic agent TSU-68 
was described by Kitamura et al. (2008). Therefore further experiments with 24 hours of 
incubation were performed. 
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Figure 19: Effect of AME on the transcript level of CYP1A1 and AhR after 24 h pre-cultivation and 
subsequent treatment for 12 h (A) and 6 h (B). 5 µM ARO was used as positive control. 
CYP1A1 and AhR transcripts are normalised to β-actin and compared to respective 
DMSO (1%) treated control cells. The data are plotted as relative mRNA quantity (RQ) of 
a single experiment. 
Incubation with AOH and AME for 24 h 
After pre-cultivating KYSE510 cells for 24 h and subsequently incubating for 24 h with AME 
any increase of CYP1A1 transcripts at 0.1 µM and 1 µM was observed compared to the 
solvent control (figure 20).  
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Figure 20: Effect of AME on the transcript level of CYP1A1 and AhR after 24 h pre-cultivation and 
subsequent treatment for 24 h. 5 µM ARO and 5 µM BaP were used as positive controls. 
CYP1A1 and AhR transcripts are normalised to β-actin and compared to respective 
DMSO (1%) treated control cells. The data are plotted as relative mRNA quantity (RQ) ± 
SD of at least three independent experiments. Calculation of statistical significances are 
performed on the basis of underlying ΔCT-values (***=p<0.001). 
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At 10 µM AME the CYP1A1 transcript level significantly decreased 0.2-fold (± 0.02). The 
positive controls benzo(a)pyrene and aroclor raised the CYP1A1 level to 37.2 (± 8.8) - and 
5.7-fold (± 1.2), respectively and thus demonstrated the inducibility of CYP1A1 in KYSE510 
cells. The decreased CPY1A1 mRNA level at 10 µM AME potentially was not due to 
cytotoxic effects since 10 µM AME did not affect cell growth in the SRB assay (figure 18). 
10 µM AME was the highest concentration tested, therefore it remained unclear whether the 
suppressing effect on transcription would be observed at any higher mycotoxin 
concentrations. Any of the tested AME concentrations and ARO did significantly influence 
cellular levels of AhR transcripts. Benzo(a)pyrene raised the cellular mRNA level of AhR to 
1.4-fold (± 0.2), yet not significantly, however suggesting a potential impact of the compound 
on AhR mRNA levels. 
 
In an orienteering experiment treatment of 24 h pre-cultivated KYSE510 cells with AOH for 
24 h caused a 3.4- and 5.1-fold increase of CYP1A1 mRNA levels at 0.1 µM and 1 µM AOH, 
respectively (figure 21) whereas no substantial effect was observed when applying the same 
concentrations of AME (figure 20). 5 µM ARO induced CYP1A1 by about 16-fold, acting 
more potent compared to AME. However, the validity of the data was not supported by at 
least three independently performed experiments, thus any significant conclusion concerning 
the outcome could be drawn.  
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Figure 21: Effect of AOH on the transcript level of CYP1A1 and AhR after 24 h pre-cultivation and 
subsequent treatment for 24 h. 5 µM ARO was used as positive control. CYP1A1 and AhR 
transcripts are normalised to β-actin and compared to respective DMSO (1%) treated 
control cells. The data are plotted as relative mRNA quantity (RQ) of a single experiment. 
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Cells pre-cultivated for 48 h 
Given that the mycotoxins did not significantly induce CYP1A1 at any of the tested incubation 
periods, further experiments with prolonged pre-cultivation were performed. A longer 
cultivation period is discussed to influence the inducibility of CYP1A1. Cytochrome P450 
enzymes are an important part of the cell´s drug metabolising system, requiring fully 
developed cell morphology to ensure a well operating system. Thus the confluency of cells 
was to be considered. To ensure cell communication, which is required to trigger a 
homogenous and strong response toward xenobiotics, contact between neighbouring cells 
has to be established (Hamilton et al., 2001). A confluent layer of cells can be reached by 
seeding more cells or prolonging the time of pre-experimental cell culture. 
Figure 22 shows the morphology of KYSE510 cells after different times of cell culture.  
(A) 6 days after seeding, the cells already established their typical morphology whereas  
(B) after 24 h the cells are still round shaped and the contact between neighbouring cells is 
not given. In order to obtain the cell´s typical morphology at about 70 - 80% confluency more 
time for pre-cultivation and/ or increased numbers of cells appears to be of relevance. The 
pre-cultivation time for KYSE510 cells was therefore extended to 48 h and used in the 
following studies.  
 
A B 
  
Figure 22: Morphology of KYSE510 cells after a culture period of (A) 6 days (Fang et al., 2003) and 
(B) after 24 h (Wang et al., 2011) 
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Incubation with AME for 24 h 
A significant 2.3-fold (± 0.2) increase of CYP1A1 transcripts after 24 h of incubation with 
1 µM AME was observed in 48 h pre-cultivated KYSE510 cells (figure 23). Any induction was 
observed for 0.1 µM AME, identifying the concentration as the no effect level. A decreasing 
trend could be observed at 5 µM and 10 µM, causing 0.7 (± 0.05) - and 0.6-fold (± 0.08) 
drops compared to the solvent control. The suitability of the assay was proven by the very 
potent induction of BaP, raising the CYP1A1 level to 270-fold (± 18.9). The Ah-receptor 
transcripts did not experience great changes upon treatment with any AME concentration, 
whereas BaP raised the cellular AhR levels 1.8-fold (± 0.1). 
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Figure 23: Effect of AME on the transcript level of CYP1A1 and AhR after 48 h pre-cultivation and 
subsequent treatment for 24 h. 5 µM BaP was used as positive control. CYP1A1 and AhR 
transcripts are normalised to β-actin and compared to respective DMSO (1%) treated 
control cells. The data are plotted as relative mRNA quantity (RQ) ± SD of at least three 
independent experiments. Calculation of statistical significances are performed on the 
basis of underlying ΔCT-values (**=p<0.01; ***=p<0.001). 
Incubation with AOH for 24 h 
After 24 h of incubation, 1 µM AOH increased CYP1A1 levels in KYSE510 cells to 7.8-fold 
(± 0.4) (figure 24). AOH at a concentration of 10 µM fostered a nearly equal 7-fold (± 2.6) 
raise, whereas 0.1 µM AOH triggered a 1.9-fold (± 0.5) increase. This was in contrast to the 
experiment with AME, where any effects were observed at concentration as low as 0.1 µM. 
The pattern of AOH-triggered effects exhibited similarities compared to the AME effects. In 
both cases, at the highest AME (10 µM) and AOH (50 µM) concentration tested, CYP1A1 
transcripts decreased to a similar magnitude. The positive control BaP strongly raised 
CYP1A1 mRNA levels (277-fold ±31.6) accompanied by a significant 1.7-fold (± 0.1) increase 
of AhR mRNA.  
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Figure 24: Effect of AOH on the transcript level of CYP1A1 and AhR after 48 h pre-cultivation and 
subsequent treatment for 24 h. 5 µM BaP was used as positive control. CYP1A1 and AhR 
transcripts are normalised to β-actin and compared to respective DMSO (1%) treated 
control cells. The data are plotted as relative mRNA quantity (RQ) ± SD of at least three 
independent experiments. Calculation of statistical significances are performed on the 
basis of underlying ΔCT-values (**=p<0.01; ***=p<0.001). 
It is hypothesized that the transcriptional induction of CYP1A1 by AME and AOH is mediated 
by the Ah-receptor. The CYP1A1 encoding gene is not constitutively expressed and it has 
been shown that the gene is negatively regulated under normal conditions (Guigal et al., 
2000). However, CYP1A1 is strongly substrate-inducible (Whitlock, 1999) which would be in 
accordance with the increase of relative amount of transcripts fostered by AME and AOH in 
oesophageal cells. Altogether, stronger effects of both mycotoxins on cellular CYP1A1 levels 
were observed in KYSE510 cells cultured for 48 h. Both, a prolonged cultivation time and 
higher cell density are important for the inducibility of CYP1A1. The former is responsible for 
the development of the cell´s morphology, ensuring an efficiently working metabolising cell 
system whereas the latter is crucial for the communication between neighbouring cells 
(Hamilton et al., 2001). Several papers report of experiments on CYP1A1 induction 
performed with cells cultivated longer than 24 h. Dohr et al. (1995) treated nearly confluent 
MCF-7 and MDA-MB 231 human breast cancer cells with TCDD to observe a strong 
CYP1A1 mRNA induction. Hoivik et al. (1997) cultured MCF-7 and mouse hepatoma 
Hepa 1c1c7-cells for 48 h and 70 - 80% confluency were reported by El Gendy & El-Kadi for 
human hepatoma HepG2 cells. On the contrary, Jeong et al. (1995) cultured Hepa 1c1c7-
cells for 24 h prior incubation with TCDD and observed strong CYP1A1-responds. However, 
since most papers report of culture periods longer than 24 h, the development of the cell´s 
morphology seems to be substantial for a strong CYP1A1 response. Nevertheless, the 
necessity of a certain cell density should not be neglected, given that increases in CYP1A1 
mRNA were also observed at shorter cultivation periods.  
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4.3.2. Knockdown of AhR in KYSE510 Cells 
The question was addressed whether CYP1A1 induction by AME and AOH is AhR-mediated 
in KYSE510 cells. The Ah-receptor pathway is believed to be the main contributor to 
CYP1A1 induction (Guigal et al., 2000). However, Delescluse et al. (2000) pointed out, that 
some substances are potent CYP1A1 inducers without being agonists of the AhR. Their lack 
of structural requirements for ligand-binding can be compensated either by their metabolites 
being AhR ligands or by cross-talk with another pathway, for example the retinoic acid 
receptor, estrogen receptor, protein tyrosine kinases or a yet unknown signal transduction 
pathway. RNAi technology was used to investigate the role of the AhR in AOH- and AME-
mediated CYP1A1 induction. The expression of AhR in human oesophageal KYSE510 cells 
was transiently suppressed by transfection with AhR-siRNA. Subsequently the effect of AME 
and AOH on CYP1A1 expression was analysed in these cells.  
Prior working with AhR-suppressed cells, the conditions for transient siRNA transfection of 
KYSE510 cells had to be established, ensuring a maximum of knockdown of at least 70%. 
The development of optimal transfection conditions was an important part of the present 
thesis. The siRNA transfection was performed using HiPerFect Transfection Reagent from 
Qiagen®, two different siRNAs (siRNA 1 and siRNA 2), which encoded different AhR 
sequences, and a negative control siRNA (dsRNA). Both siRNAs and the dsRNA were kindly 
provided by Prof. C. Weiss from the Karlsruher Institute of Technology (KIT), Germany. The 
optimised transfection protocol for HepG2 cells, recommended by Prof. C. Weiss as well as 
the manufacturer’s recommendations in section “Fast-Forward Transfection of Adherent 
Cells with siRNA/miRNA in 24-well Plates” (Qiagen®) served as an orienting procedure for 
the siRNA transfection of KYSE510 cells.  
Transient siRNA Transfection 
Two siRNAs differing in their sequence were analysed in order to identify the one with the 
higher AhR suppressing potential. The scrambled control siRNA (in the following referred to 
as dsRNA) does not affect the level of AhR mRNA. The whole transfection procedure was 
performed with dsRNA to encompass any change affecting cell culture conditions, cell 
viability or metabolism that could affect siRNA-transfected cells. Therefore dsRNA-treated 
cells were a suitable calibrator for monitoring the AhR-suppression by siRNA.  
The potency of AhR suppression, indicative for transfection efficiency, was investigated using 
RT-PCR and Western blot analysis (see chapter 6.4 “Gene Expression Analysis of CYP1A1 
and AhR using quantitative Real Time PCR” and chapter 6.5 “Western Blot Analysis of the 
Aryl Hydrocarbon Receptor”). Effects on the AhR mRNA levels were investigated while β-
actin was co-amplified as endogenous control used for normalisation. The posttranscriptional 
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suppression of the Ah-receptor is given, when the level of AhR mRNA in transfected cells 
(siRNA 1 or siRNA 2) does not exceed a 0.3-fold level compared to cells transfected with 
control RNA (dsRNA). For Western blot analysis the total protein was extracted with RIPA 
buffer. The cell-lysates were disrupted, centrifuged and the supernatant as well as the cell 
pellet were dissolved in SDS-buffer. The samples were heated to 95°C assuring complete 
protein denaturation (see chapter 6.5 “Western Blot Analysis of the Aryl Hydrocarbon 
Receptor”.) Thereafter samples were stored at -20°C until performing electrophoresis. 
Transient siRNA Transfection of HepG2 Cells  
First the recommended transfection protocol of Prof. C. Weiss for HepG2 cells was 
performed to become familiar with the method and to prove reproducibility. The applied 
conditions are listed in table 2.  
Table 2: Transfection conditions for HepG2 cells with HiPerFect Transfection Reagent (Qíagen®) 
according to Prof. Weiss (KIT), Germany  
transfection conditions for HepG2 cells 
number of seeded HepG2 cells  3*106/well 
volume of HiPerFect Transfection Reagent  3 µl/well 
volume of siRNA (1 or 2), dsRNA 0.2 µl/well 
transfection time  48 h 
 
Figure 25 displays the membrane of the Western blot analysis for AhR, 48 h post-
transfection with siRNA 1 and siRNA 2. In comparison to dsRNA-treated HepG2 cells, less 
intense bands were detected for siRNA 1 and siRNA 2 transfected cells. The weaker signal 
in siRNA 1 transfected cells suggested a more potent suppression of AhR-protein expression 
by this sequence. 
A B 
  
dsRNA siRNA 2 siRNA 1   dsRNA siRNA 2 siRNA 1  
Figure 25: AhR expression in HepG2 cells 48 h post-transfection with two different siRNA sequences 
(siRNA 1 and siRNA 2) and the negative control (dsRNA) determined by Western blot 
analysis, performed with the (A) supernatant and (B) pellet of siRNA-transfected cells. 
Transfection conditions see table 2. 
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Since no endogenous control for sample loading was included, the diminished band 
intensities could be due to lower protein concentration as well. However, the loading of 
samples according to protein content was performed with great care for correctness, making 
the decreased band intensities solely due to a successful Ah-receptor suppression.   
Transient siRNA Transfection of KYSE510 Cells  
In general the confluency of cells should not exceed 60 - 70% at the time of transfection. 
Since the doubling time of KYSE510 cells with 30 hours is nearly one-half of HepG2 cells, 
which varies between 40 - 60 hours, the number of seeded KYSE510 cells was reduced from 
1*106 cells/well to 3*104 cells/well and the volume of HiPerFect Transfection Reagent was 
increased from 3 µl to 4.5 µl. The transfection conditions used for KYSE510 cells are listed in 
table 3. 
Table 3: Optimised siRNA-transfection protocol for KYSE510 cells (HiPerFect Transfection Reagent, 
Qíagen®) 
optimised transfection protocol 
number of seeded KYSE510 cells  3*104/well 
volume of HiPerFect Transfection Reagent  4.5 µl/well 
volume of siRNA (1 or 2), dsRNA 0.2 µl/well 
transfection time  48 h 
 
Following the optimised transfection protocol, AhR mRNA levels in siRNA-transfected 
KYSE510 cells were reduced by 80% in comparison to dsRNA-treated cells (figure 26). In 
contrast, the level of AhR transcripts in siRNA 1 transfected cells was reduced only by about 
20%. Thus transfection with siRNA 2 met the required at least 70% knockdown of Ah-
receptor. 
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Figure 26: AhR and CYP1A1 transcripts of KYSE510 cells 48 h post-transfection with two different 
siRNA sequences (siRNA 1 & siRNA 2) and the control (dsRNA). CYP1A1 and AhR 
transcripts are normalised to β-actin and are compared to the control (dsRNA). The data 
are plotted as relative mRNA quantity (RQ) ± SD of at least three independent 
experiments. Calculation of statistical significances are performed on the basis of 
underlying ΔCT-values (*=p<0.1; **=p<0.01; ***=p<0.001). 
To test sufficient suppression of AhR at the protein level, Western blot analysis was 
performed using an AhR-specific antibody. Figure 27 represents the membrane after 
detection with the anti-AhR-antibody. Samples were lysed in Laemmli-buffer instead of RIPA-
buffer to achieve complete protein degradation without labour intensive extraction. 
 
dsRNA siRNA 2 siRNA 1  
Figure 27: AhR expression in KYSE510 cells 48 h post-transfection with two different siRNA 
sequences (siRNA 1 and siRNA 2) and the negative control (dsRNA) determined by 
Western blot analysis with the whole cell lysate. Transfection conditions see table 3.  
 
The signal for AhR at 122 kDa either in siRNA 1- or siRNA 2-transfected cells was notably 
lower in comparison to the signal for dsRNA-treated cells. Due to the absence of a loading 
control the attenuated signal in siRNA-transfected cells could not be ascribed exclusively to 
diminished AhR protein based on knockdown. However, the results corroborated the reduced 
levels of AhR mRNA in qRT-PCR. 
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4.3.3. Effect of AME and AOH on AhR and CYP1A1 mRNA levels in AhR-
suppressed KYSE510 Cells 
KYSE510 cells were cultivated for 48 h post-transfection with siRNA 2 enabling a sufficient 
suppression of Ah-receptor expression. The effect of AME (0.1 µM, 1 µM, 5 µM, 10 µM) and 
AOH (0.1 µM, 1 µM, 10 µM, 50 µM) on CYP1A1 and AhR mRNA levels was investigated in 
non-transfected, Ah-receptor suppressed and dsRNA-transfected KYSE510 cells. After 24 h 
of incubation, total RNA was isolated and used for gene transcription analysis (see chapter 
6.4 “Gene Expression Analysis of CYP1A1 and AhR using quantitative Real Time PCR“). 
Appropriate controls were implemented to assure correct evaluation of the performed 
experiments. Differently pre-treated cells (dsRNA-, siRNA- and non-transfected) were 
incubated with 1% DMSO and served as a calibrator with the ∆CT-values set to 1. The 
reliability of the assay was monitored by using the positive control benzo(a)pyrene, applied at 
a concentration of 5 µM. To compare the effects of AOH and AME in siRNA-transfected cells 
with those in non-transfected and dsRNA-transfected KYSE510 cells, all three differently pre-
treated cells were incubated with the same AME or AOH concentration. The successful 
suppression of AhR mRNA was monitored by pre-treating KYSE510 cells with dsRNA 
instead of siRNA. 
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AhR mRNA levels in dsRNA- and non-transfected KYSE510 Cells 
A potential impact of AOH and AME on AhR transcript levels in non-transfected and dsRNA-
transfected KYSE510 cells was controlled by qRT-PCR. Cells were incubated for 24 h with 
varying concentrations of AME and AOH. As shown in figure 28, AhR mRNA levels of non-
transfected and dsRNA-treated cells were not altered by both mycotoxins. BaP fostered 
significant, yet marginal increases of AhR transcripts in non-transfected and dsRNA-
transfected cells. The magnitude of the observed up-regulation was in the range of 1.7- to 
1.9-fold. The results demonstrated that both mycotoxins as well as the transfection 
procedure, including the insertion of dsRNA into KYSE510 cells, did not affect the AhR 
transcript level.  
 
 
Figure 28: Effect of (A) AME and (B) AOH on the transcript level of AhR in non-transfected and 
negative control siRNA (dsRNA) transfected KYSE510 cells after treatment for 24 h. 5 µM 
BaP was used as positive control. AhR transcripts are normalised to β-actin and 
compared to respective DMSO (1%) treated control cells. The data are plotted as relative 
quantity of AhR transcripts (RQ) ± SD of at least three independent experiments. 
Calculation of statistical significances are performed on the basis of underlying ΔCT-values 
(**=p<0.01; ***=p<0.001). 
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Transient Suppression of the Ah-Receptor in KYSE510 Cells  
A sufficient and reproducible knockdown of AhR in KYSE510 cells is essential for correct 
analysis and proper interpretation of the results. Thus, AhR transcript levels were analysed in 
parallel to the CYP1A1 transcript levels, assuring a knockdown of at least 70%. Figure 29 
displays the AhR mRNA levels in siRNA 2 transfected KYSE510 cells compared to dsRNA-
treated cells 48 h post-transfection and subsequent 24 h of treatment with either (A) AME or 
(B) AOH. Cells dsRNA-transfected and treated with 1% DMSO were used as control.  
 
Figure 29: AhR transcripts in AhR-suppressed KYSE510 cells 48 h post-transfection and 
subsequent 24 h of treatment with (A) AME and (B) AOH. 5 µM BaP was used as positive 
control. AhR transcripts are normalised to β-actin and compared to negative control 
siRNA (dsRNA). The data are plotted as relative quantity of AhR transcripts (RQ) ± SD of 
at least three independent experiments. Calculation of statistical significances are 
performed on the basis of underlying ΔCT-values (***=p<0.001). 
The requirement of an at least 70% AhR-suppression was met for all siRNA-transfected 
KYSE510 cells, treated either with AME (figure 29 A) or AOH (figure 29 B). The AhR was 
even suppressed by about 80%. Thus, cells were analysed for CYP1A1 induction. The AhR 
transcript level was slightly less suppressed in cells incubated with 5 µM BaP for 24 h. 
Nevertheless, cellular AhR mRNA did not exceed the 0.3-fold level and the suppression was 
sufficient for the studies on CYP1A1 transcription. 
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Effect of AME on CYP1A1 mRNA levels in AhR-suppressed KYSE510 Cells  
The investigation of AME-mediated changes in CYP1A1 transcription in AhR-suppressed 
KYSE510 cells required the implementation of two different controls. Firstly, successful 
suppression of AhR mRNA was monitored by pre-treating KYSE510 cells with dsRNA 
instead of AhR-siRNA, a more detailed description is given in the previous chapter. The 
second control was the use of differently pre-treated cells (non-transfected, AhR-siRNA and 
dsRNA-transfected KYSE510 cells) incubated with 1% DMSO. The CYP1A1 mRNA level in 
those cells represented the endogenous or basal level, which was set to 1, when calculating 
the AME-elicited changes in CYP1A1 transcripts.  
A significant impact towards CYP1A1 transcripts was observed in non-transfected, dsRNA- 
and AhR-siRNA transfected KYSE510 cells after 24 h of incubation with ≥ 1 µM AME 
(figure 30). AME at a concentration of 0.1 µM did not affect CYP1A1 transcript levels in the 
tested cell types. A modest decrease was observed for dsRNA pre-treated cells in 
comparison to the respective DMSO (1%) control whereas CYP1A1 levels slightly increased 
in AhR-siRNA transfected cells. Yet the effects were not significant, thus 0.1 µM AME was 
referred as no effect concentration. 
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Figure 30: CYP1A1 mRNA levels in AhR-siRNA, negative siRNA control (dsRNA)-transfected and 
non-transfected KYSE510 cells 48 h post-transfection and subsequent 24 h of treatment 
with AME. 5 µM BaP was used as positive control. CYP1A1 transcripts are normalised to 
β-actin and compared to respective DMSO (1%) treated cells. The data are plotted as 
relative quantity of CYP1A1 transcripts (RQ) ± SD of at least three independent 
experiments. Calculation of statistical significances are performed on the basis of 
underlying ΔCT-values (*/a=p<0.1; **/b=p<0.01; ***/c=p<0.001). 
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The induction of CYP1A1 transcripts in cells expressing AhR peaked at 1 µM AME with a 
maximum of 2.3 (± 0.2) - and 2.4-fold (± 0.08), respectively. In contrast, CYP1A1 mRNA in 
AhR-suppressed oesophageal cells was just slightly affected in comparison to the DMSO 
control. Given that the Ah-receptor, which is believed to be the main regulator of CYP1A1 
transcription (Nebert et al., 2004) is sufficiently suppressed (figure 29 A), it was expected that 
AME should not be able to elicit any induction of CYP1A1 transcripts. However, it has to be 
pointed out that, albeit the induction was significant, it was still marginal with 1.2-fold (±0.2). 
The amount of CYP1A1 mRNA declined at 5 µM AME and the trend continued at 10 µM for 
all three different cell types. In AhR-suppressed cells CYP1A1 mRNA was diminished 
significantly to 0.4 (± 0.2) - and 0.07-fold (± 0.02). A minor, yet significant drop of CYP1A1 
transcripts in comparison to the DMSO control was observed at 10 µM AME in non-
transfected KYSE510 cells (figure 23). However, the decline in dsRNA-transfected KYSE510 
cells was not significant. CYP1A1 transcription in AhR-suppressed cells should not be 
influenced by any AhR agonist purely acting via the Ah-receptor pathway. However, 5 µM 
benzo(a)pyrene, a substance which is only known to act by binding to the AhR (Whitlock, 
1999; Almahmeed et al., 2004), triggered a 54.3-fold (± 3.8) increase of CYP1A1 transcripts 
in AhR-suppressed KYSE510 cells. The remaining 30% of AhR mRNA, which were not 
suppressed by transient siRNA transfection and the fact that BaP is a very strong AhR-
inducer, could account for the observed high CYP1A1 mRNA induction. The reduced levels 
of CYP1A1 at higher AME-concentrations are not accompanied by changes of AhR mRNA 
(figure 23), thus supporting the hypothesis of AhR playing a role in AME-mediated CYP1A1- 
induction.  
Cytotoxicity has to be considered as a reason for the drop in CYP1A1 levels at ≥ 5 µM AME 
concentrations. However, cell viability of non-transfected KYSE510 cells was not significantly 
diminished in the range of 0.1 - 10 µM AME as shown by the SRB assay (figure 18). Given 
that the expression of CYP1A1 is mainly mediated by the Ah-receptor (Nebert et al., 2004), 
its knockdown, as it is the case in AhR-suppressed KYSE510 cells, could potentially lead to 
a higher concentration of non-metabolised AME in the respective cells. This would make 
AhR-siRNA transfected oesophageal cells far more sensitive towards xenobiotic exposure. 
This argument is not supported by increased CT-values of β-actin in siRNA-transfected cells 
in comparison to non-transfected cells. Higher CT-values are obtained when the amount of 
template DNA at the beginning of the PCR-amplification process is low. It is reasonable to 
assume increased cytotoxicity would be accompanied by higher CT-values. Since no such 
effect was observed, the role of cytotoxicity was considered to be of minor extend. However, 
a cytotoxicity assay, such as the SRB or MTT assay, with AhR-suppressed cells is necessary 
to verify the hypothesis.  
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The involvement of Ah-receptor in cell growth and differentiation should not be neglected. 
AhR-defective mouse hepatoma cells exhibited a slowed growth rate (Ma & Whitlock, 1996). 
A diminished cell growth, just as cytotoxicity, could be accountable for decreased CYP1A1 
mRNA levels. Incubation with 10 µM AME decreased CYP1A1 transcripts by 0.6-fold (± 0.08) 
in non-transfected cells, a partial antagonistic effect of AME towards AhR at 10 µM would be 
a considerable explanation. However, any investigations addressing AME as partial Ah-
receptor agonist/ antagonist have been performed by now, implying the necessity of further 
investigations. 
Another explanation for plummeting CYP1A1 transcripts at ≥ 5 µM AME in AhR-suppressed 
KYSE510 cells might be the interference with another, yet unknown pathway. The induction 
of CYP1A1 by dioxin has already been shown to involve tyrosine kinases in human 
keratinocytes (Gradin et al., 1994). CYP1A1 expression, triggered by the anti-ulcer drug 
omeprazole was believed to involve crosstalk of the Ah-receptor with protein tyrosine kinases 
(Backlund et al., 1997). A suggested interfering pathway could be exclusively activated when 
signal transduction by the Ah-receptor was blocked, as it is the case in siRNA-suppressed 
Ah-receptor. However, CYP1A1 induction by a different pathway than the AhR would be of 
considerably weaker extend since transcripts decreased below the endogenous level. 
Additionally, concentrations of ≥ 5 µM AME were necessary for activation. Nevertheless, the 
existence of an interfering pathway was not proven and requires further investigations. 
Effect of AOH on CYP1A1 mRNA levels in AhR-suppressed KYSE510 Cells 
CYP1A1 transcripts in non-transfected, dsRNA- and AhR-siRNA transfected KYSE510 cells 
was determined after 24 h of incubation with AOH. AOH up to 10 µM fostered a 
concentration-dependent increase of CYP1A1 transcript levels in AhR-expressing cells 
(figure 31). Already 0.1 µM AOH triggered a considerable 2-fold (± 0.5) increase of CYP1A1 
mRNA, while any alterations were observed for AME at the same concentration (figure 30). 
AOH raised CYP1A1 levels of non-transfected and dsRNA-transfected KYSE510 cells up to 
7.8 (± 0.4) - and 7.4-fold (± 1.2), respectively at a concentration of 1 µM AOH. The effect on 
CYP1A1 was similar at 10 µM AOH and abolished when applying AOH concentrations of 
50 µM.  
The induction of CYP1A1 by 0.1 µM AOH in AhR-suppressed cells was still evident, albeit 
not significant. Even if classified as an all over weak induction, CYP1A1 mRNA exceeded the 
endogenous level. The very low, yet still present transcript level of AhR in knockdown cells 
might be sufficient to grant AhR-dependent CYP1A1 induction at low AOH concentrations 
(figure 31). In comparison to AhR-expressing cells, CYP1A1 induction was significantly 
diminished in AhR-suppressed cells at 1 µM and 10 µM AOH. However, the amount of 
CYP1A1 mRNA was still significantly increased at 1 µM AOH, yet to a minor extend  
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(4.1-fold ± 0.03), compared to AhR-expressing cells. The potent CYP1A1 induction at 10 µM 
AOH in non-transfected and dsRNA-transfected cells declined to a 0.6-fold (± 0.04) level in 
AhR-siRNA transfected cells, indicating the complete abolishment of AOH-mediated CYP1A1 
expression. Incubation with 50 µM AOH reduced CYP1A1 mRNA levels in non-transfected, 
dsRNA- and AhR-siRNA transfected cells, indicating potential cytotoxic effects.  
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Figure 31: CYP1A1 mRNA levels in AhR-siRNA, negative siRNA control (dsRNA)-transfected and 
non-transfected KYSE510 cells 48 h post-transfection and subsequent 24 h of treatment 
with AOH. 5 µM BaP was used as positive control. CYP1A1 transcripts are normalised to 
β-actin and compared to respective DMSO (1%) treated cells. The data are plotted as 
relative quantity of CYP1A1 transcripts (RQ) ± SD of at least three independent 
experiments. Calculation of statistical significances are performed on the basis of 
underlying ΔCT-values (*/a=p<0.1; **/b=p<0.01; ***/c=p<0.001). 
While cytotoxicity was believed to play a minor role in the AME-fostered decrease of 
CYP1A1 transcripts at 10 µM, it is of greater importance when accounting for the AOH-
mediated effects at 50 µM. The impurities in AOH used by M. Fehr were believed to be 
insignificant with respect to the quantity, hence the SRB assay was not performed with AOH 
purchased from Sigma-Aldrich. However, the cytotoxic effect of Sigma-Aldrich AOH in 
KYSE510 cells was analysed by N. Kahle post-finishing the experimental part of the present 
thesis. The data clearly showed the onset of cell growth inhibition at 50 µM AOH. Thus there 
was strong evidence, that decreased CYP1A1 transcript levels in all three different cell types 
were prone to cytotoxic activity. 
Furthermore, at a concentration of 10 µM AOH potential cytotoxic effects in AhR-siRNA 
transfected cells cannot be excluded completely. Given that in AhR-suppressed KYSE510 
cells less CYP1A1 mRNA is transcribed, the diminished amounts of CYP1A1 protein may not 
detoxify AOH to the same extend compared to AhR-expressing cells. This could lead to 
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similar accumulation effects as already postulated for AME. Again, the issue could only be 
addressed by performing a cytotoxicity-assay with AhR-suppressed KYE510 cells.  
It might also be speculated that the suppression of the Ah-receptor could lead to the 
activation of a non AhR-mediated pathway at ≥ 10 µM AOH, affecting CYP1A1 transcription. 
Given that CYP1A1 transcripts decreased below the basal level, CYP1A1 expression via a 
putative pathway appeared to be considerably weaker than signalling via the Ah-receptor. As 
in the case of AME, the existence of an additional interfering pathway was just hypothesised 
and not proven by further experiments.  
4.3.4. Ligand Inhibition of the AhR in KYSE510 Cells 
In addition to the knockdown by AhR-siRNA, suppression of AhR function was approached 
by inhibition of ligand-binding in KYSE510 cells, using 3´-methoxy-4´-nitroflavone (MNF). In 
the literature, the synthetic flavone is described as a potent Ah-receptor antagonist in various 
cell systems. Lu et al. (1995) identified MNF as a pure AhR antagonist in human breast 
cancer cells (MCF-7). An antagonistic effect was also observed in human keratinocytes 
HaCaT by Schäfer, 2006.  
In the present work, the modulation of CYP1A1 transcription by AME was investigated in 
AhR-inhibited KYKSE510 cells. Oesophageal cells were first incubated with MNF, 
subsequently with AME and then the amount of CYP1A1 mRNA was determined. Thus, 
additional information for a better understanding of the mode of action of AME-mediated 
CYP1A1 induction was expected. Briefly, 3*104 KYSE510 cells were seeded per well of a 24-
well plate and cultivated for 24 h. Then the cells were treated with 10 µM MNF for 15 
minutes, enabling the adsorption of the molecules at the Ah-receptor binding site. 
Subsequently the MNF-containing medium was removed and complete medium (RPMI 1640 
containing 10% FBS and 1% P/S) with varying concentrations of AME (0.1, 1, 5 and 10 µM) 
was added and left for 24 h. Additionally, appropriate controls were implemented: MNF pre-
treated cells were incubated with 1% DMSO for 24 h serving as control for the AME-
mediated effects. To investigate the purely MNF-elicited effects complete medium 
(RPMI 1640 containing 10% FBS and 1% P/S) was applied for 24 h onto 10 µM MNF pre-
treated cells. A third control, which consisted of cells, pre-treated with 1% DMSO and a 
following 24 h incubation period with complete medium, was used to study MNF- and AME-
mediated effects in KYSE510 cells only.  
A concentration-dependent effect of AME was observed in MNF pre-treated KYSE510 cells 
after 24 h of incubation (figure 32). Treatment with 10 µM MNF increased the CYP1A1 
transcript level about 11-fold (± 3.7) compared to 1% DMSO pre-treated control cells. 
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Figure 32: CYP1A1 mRNA levels in 15 minutes pre-treated KYSE510 cells (with 10 µM MNF or 1% 
DMSO) and subsequent 24 h treatment with AME, DMSO (1%) or medium. CYP1A1 
transcripts are normalised to β-actin and compared to respective DMSO (1%) treated 
control cells. The data are plotted as relative quantity of CYP1A1 transcripts ± SD of at 
least three independent experiments. Calculation of statistical significances are performed 
on the basis of underlying ΔCT-values (*=p<0.1; **=p<0.01; ***=p<0.001). 
MNF is a known AhR antagonist, however some authors report of concentration-dependent 
agonistic and antagonistic effects. The antagonistic effect of MNF on TCDD-elicited 
luciferase gene induction in stably transfected Hepa.2DLuc.3A4-cells was observed at 
0.1 µM and in the range of 1 - 10 µM a low level of reporter induction was observed (Zhou & 
Gasiewicz, 2003). Goergens (2009) showed a concentration-dependent MNF effect towards 
CYP1A1 transcription in the human promyelocytic leukaemia cell line HL-60. It acted as an 
antagonist in the concentration range of 1 - 10 µM by diminishing the curcumin-fostered 
CYP1A1 mRNA expression. An agonistic effect was observed for MNF concentrations 
smaller than 1 µM and higher than 10 µM (Goergens, 2009). Ah-receptor agonistic/ 
antagonistic effects of MNF seemed to be strongly concentration- and cell line-dependent. 
Since an 11-fold increased CYP1A1 mRNA level was observed when applying 10 µM MNF, 
either an agonistic effect on the AhR or other potential responsive signal pathways, 
modulating CYP1A1 at that concentration need to be considered. However, subsequent 
incubation of MNF pre-treated cells with 1% DMSO for 24 h caused a minor, only 5.9-fold 
(± 0.4) increase of CYP1A1 mRNA compared to medium-treated cells. CYP1A1 transcripts 
even further decreased when applying increasing concentrations of AME.   
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The drop of CYP1A1 mRNA levels when replacing pure medium with 1% DMSO could be 
due to a potential displacement of Ah-receptor bound MNF by DMSO molecules. The strong 
AME concentration-dependent reduction of MNF-induced CYP1A1 transcripts supported a 
scenario of potential competitive properties of AME towards MNF at the AhR, implying 
binding to the receptor. Based on these results, it might be speculated that AME-mediated 
CYP1A1 induction was impeded by Ah-receptor bound MNF. This would support the role of 
AhR in AME-mediated CYP1A1 induction. However, an Ah-receptor antagonist, which did 
not induce CYP1A1 mRNA at certain concentrations, should be used to obtain a cell system, 
comparable to AhR-siRNA suppressed KYSE510 cells. MNF applied at a concentration of 
10 µM clearly induced CYP1A1 transcripts, the addition of another inducer, like AME, would 
lead one to expect an additive effect. Instead, CPY1A1 mRNA levels declined concentration-
dependently. The speculation of a potential displacement of MNF from the AhR binding site 
by AME could not be verified by the experiment conducted. Further investigations regarding 
the binding affinities and agonistic/ antagonistic effects of both substances in KYSE510 cells 
have to be performed to fully understand the underlying mechanism of action. 
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4.4. Impact of AOH and AME on Glutathione-S-Transferase 
Activity in HT29 Cells 
Enzymes of the glutathione-S-transferase (GST) family are phase II drug-metabolising 
enzymes. They act by catalysing the reaction of glutathione with an acceptor molecule to 
form S-substituted glutathione (Hayes et al., 2005). Xenobiotics are often activated by 
monooxygenases like cytochrome P450 enzymes which is followed by a nucleophilic attack 
of the thiol group of the reduced glutathione (Prochaska & Talalay, 1988). GSH-conjugates 
are subsequently eliminated via active transport systems (Ebert et al., 2001). The 
photometrical determination of the change in absorbance occurring during the glutathione-S-
transferase (GST)-catalysed reaction of glutathione and 1-chloro-2,4-dinitrobenzene (CDNB) 
is used for analysing GST activity. Nearly all GST isoenzymes can use CDNB as substrate 
for conjugation with glutathione (Habig et al., 1974). GSTP1 is the predominant isoform in 
HT29 cells used in the present work (Ebert et al., 2003). 
Both Alternaria toxins tested in the present thesis, are prone to phase I drug metabolism 
(Pfeiffer et al., 2008). Their impact on phase II drug metabolising enzymes GST in human 
colon carcinoma HT29 cells presented a further part of the present thesis. The colon 
carcinoma model was chosen due to published data by Pfeiffer et al. (2009) and Burkhardt et 
al. (2009), using the same, or comparable cell model. They demonstrated the formation of 
AOH- and AME-glucuronides by hepatic and intestinal microsomes. Both mycotoxins were 
also found to be readily conjugated to sulphates as well as to glucuronides in HT29 cells 
after 24 h incubation. The high glucuronidation activity coincided with a diminished DNA-
strand breaking potential, indicating that the activity of a cell in forming AME- and AOH-
glucuronides played a critical role in this context. Since glucuronidation and sulphation are 
both important detoxification reactions, the contribution of GSTs in colon tumour cells to the 
detoxification process should be analysed. The GST assay was established according to 
Habig et al. (1974) (see chapter 6.6 “Glutathione-S-Transferase (GST) Enzyme Activity“). 
Briefly, 1.2*106 HT29 cells were seeded per Petri dish and cultivated for 48 h and 72 h, 
respectively. After 24 h of incubation with AME and AOH, cells were detached using trypsin/ 
EDTA solution. The results are plotted as test over control [%], whereas 1% or 0.1% DMSO- 
and 1% water-treated control cells, respectively were used. 
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4.4.1. GST Activity after 24 h of Incubation with AME and AOH 
After 24 h of incubation with AME, any significant changes in GST activity compared to 
DMSO (1%) treated control cells were observed (figure 33 A). Although 0.1 µM AME fostered 
a marginal increase in GST activity up to 109% (± 16%), yet the change was not significant.  
In figure 31 B a slight increase of GST activity was observed at higher AOH concentrations. 
AOH at a concentration of 0.1 - 10 µM elevated the activity to about 107 - 108%. However, 
the changes were too minor to differ significantly from 1% DMSO-treated control cells. 
Exclusively 50 µM AOH significantly increased GST activity to 113% (± 0.4%).  
 
 
Figure 33: GST activity in HT29 cells determined in the GST assay according to Habig et al. (1974). 
Cells were pre-cultivated for 48 h and subsequently treated with either (A) AME or (B) 
AOH for 24 h, respectively. GST activities are calculated as the percent GST activity of 
treated cells over control cells (treated with the solvent 1% DMSO) x 100 (T/C%). The 
values given are the mean ± SD of at least three independent experiments. Calculation of 
statistical significances are performed on the basis of underlying T/C [%] values (*=p<0.1). 
At the time GST activity experiments were performed, it was assumed, that based on the 
results of M. Fehr concerning cytotoxic effects of AOH in HT29 cells, no cytotoxic action at 
50 µM AOH existed after 24 h incubation. However, later in according to results obtained by 
C. Tiessen, AOH purchased from Sigma-Aldrich already showed cell growth inhibitory effects 
at ≥ 50 µM in HT29 cells. Considering these results, the marginal, yet significant increase in 
GST activity at 50 µM AOH should be viewed critically. 
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Menadione (MEN) and tert-butylhydroperoxide (tBHP), described as inducers of GST activity 
in the literature (Dierickx et al., 1999; Fehr, 2008), were tested in three independent 
experiments. Since tBHP was only available as aqueous solution, control cells were treated 
with 1% water-containing medium. However, any of the compounds fostered a significant 
increase of GST activity (figure 34 A, B). 
1%DMSO 20µM MEN 5µM BaP 2,5µM BaP
0
20
40
60
80
100
120
140
n=3n=3 n=1
G
S
T-
ac
tiv
ity
 T
/C
 [%
]
n=1
A
 
0,1%DMSO 10µM CGA 20µM MEN CGA+Tiri CGA+Tri+Kat
0
20
40
60
80
100
120
140
160
n=1 n=1 n=1n=2
G
ST
-a
ct
iv
ity
 T
/C
 [%
]
n=2
C
 
Figure 34: GST activity in HT29 cells determined in the GST assay according to Habig et al. (1974). 
Cells were pre-cultivated for 48 h and subsequently treated with MEN, BaP, tBHP, BSO, 
CGA, CGA+Tri and CGA+Tri+Kat for 24 h. HT29 cells were incubated with the designated 
substances dissolved in media, containing final DMSO-concentration of (A) 1% or (B) 
0.1% or (C) 1% H2O. GST activities are calculated as the percent GST activity of treated 
cells over control cells (treated with the solvent 0.1% and 1% DMSO and 1% H2O, 
respectively) x 100 (T/C%). The number of replicates n is denoted in the bars, the mean ± 
SD is given for samples n ≥ 2. 
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Further compounds and combination of substances, which were reported to either induce 
GST mRNA, GST protein or GST activity such as benzo(a)pyrene (BaP) (Robertson et al., 
1986), 10 µM chlorogenic acid (CGA), co-incubation with 0.5 µM chlorogenic acid and 
5.5 µM trigonelline (CGA+Tri), co-incubation with 0.5 µM chlorogenic acid, 5.5 µM trigonelline 
and 1000 U/ml catalase (CGA+Tri+Kat) (Volz, 2010) and buthionine sulfoximine (BSO), a 
reported suppressor of GST activity which acts by depleting the cell´s GSH pool (Dierickx et 
al., 1999), were included in the testing for induction or suppression of GST activity 
(figure 34 A-C). However, none of the tested compounds caused a reproducible increase or 
decrease in GST activity in HT29 cells. The most impressive increase in GST activity was 
observed in cells treated with menadione in the presence of 0.1% DMSO. However, 
replicates were lacking. Thus, due to the high variation in the response of HT29 cells to GST 
inducers, the marginal induction of enzyme activity observed at 50 µM AOH, should be 
viewed critically and should not be overestimated. 
4.4.2. Optimisation of Incubation Time for GST Activity  
Induction of GST activity is considered to be time-dependent; hence the incubation time was 
modulated to achieve optimal induction of GST activity. Since neither treatment with known 
GST inducers (figure 34) nor with different AME or AOH concentrations (figure 33 A and B) 
triggered a significant or trustworthy increase of GST activity, the incubation time was 
reduced to 1 h, 6 h, 9 h and 16 h.  
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Figure 35: GST activity in HT29 cells determined in the GST assay according to Habig et al. (1974). 
Cells were pre-cultivated for 48 h and subsequently treated with (A) MEN, BaP and (B) 
tBHQ, tBHP for 1 h. GST activities are calculated as the percent GST activity of treated 
cells over control cells (treated with the solvent 1% DMSO) x 100 (T/C%). The number of 
replicates n is denoted in the bars, the mean ± SD is given for samples n ≥ 2. 
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M. Fehr (2008) observed in HT29 cells a significant increase in GST activity after 1 h of 
incubation with 20 µM menadione. The results of various experiments with HT29 cells, 
treated with substances known for their GST-inducing effects, including 5 µM 
benzo(a)pyrene (BaP), 10, 20 and 200 µM tert-butylhydroquinone (tBHQ) and 50 µM tert-
butylhydroperoxide (tBHP) (Dierickx et al., 1999) are shown in figure 35. MEN and BaP were 
tested in three independently performed experiments, whereas tBHP and tBHQ were tested 
just once. However, no significant increase in GST activity was observed for any of the 
tested compounds 
 
Figure 36 shows the effect on GST activity after 6 h of incubation with various concentrations 
of AME, whereas 5 µM benzo(a)pyrene (BaP) and 200 µM tert-butylhydroquinone (tBHQ) 
(Jiang et al., 2003) were used as positive controls. However, neither the mycotoxins nor the 
positive controls fostered significantly increased GST activity levels. The absence of any 
strong GST induction led to the decision to stop further experiments with incubation times as 
short as 6 h. 
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Figure 36: GST activity determined in the GST assay according to Habig et al. (1974). HT29 cells 
were pre-cultivated for 48 h and subsequently treated with AME and 5 µM BaP or 200 µM 
tBHQ for 6 h. GST activities are calculated as the percent GST activity of treated cells 
over control cells (treated with the solvent 1% DMSO) x 100 (T/C%). The number of 
replicates n is denoted in the bars, the mean ± SD is given for samples n ≥ 2. 
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Further investigations regarding the time-dependence of GST activity were performed by 
changing the time of incubation to 9 h (figure 37 A) and 16 h (figure 37 B). The increase in 
GST activity after 9 h of incubation with 10 µM and 20 µM sulforaphane (SFN) (Jiang et al., 
2003) and 20 µM menadione and after 16 h of incubation with 15 µM SFN, 20 µM MEN, 
200 µM tBHQ and 5 µM BaP appeared too marginal, thus further investigations were 
stopped, particularly due to lack of time within the frame of the thesis.  
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Figure 37: GST activity in HT29 cells determined in the GST assay according to Habig et al. (1974). 
Cells were pre-cultivated for 48 h and subsequently treated with (A) 10 µM or 20 µM SFN, 
20 µM MEN for 9 h or with (B) 15 µM SFN, 200 µM tBHQ, 5 µM BaP, 20 µM MEN for 
16 h. GST activities are calculated as the percent GST activity of treated cells over control 
cells (treated with the solvent 1% DMSO) x 100 (T/C%) of a single experiment. 
In summary, the data on GST activity in HT29 cells obtained so far, did not show a significant 
induction of glutathione-S-transferases by known inducers, by AME and AOH with exception 
of a marginal, yet significant increase at 50 µM AOH. However, this concentration turned out 
to be already cytotoxic for HT29 cells, so the induced GST activity should be viewed 
critically.  
 
 
69 
4.4.3. Modulation of GSTA1,-A2,-T1 and P1 transcript levels in HT29 Cells 
The analysis of mRNA levels was accomplished by qRT-PCR, which is a far more sensitive 
method than the photometric GST assay and technically preferred for screening. However, 
modulation of mRNA levels has to be verified always at the protein level. Since the induction 
of GST activity with known inducers was disappointing, orienting experiments on transcript 
levels of the GST isoenzymes, including GSTA1, -A2, -T1 and -P2 were performed in HT29 
cells after incubation with GST inducers at different time points. It was expected to get more 
information why the response of HT29 cells at the protein level was so weak and unsteady. 
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Figure 38: Effect of 50 µM tBHP on the transcript level of GSTA1, -A2, -T1 and –P1 in HT29 cells 
after 48 h pre-cultivation and subsequent treatment for 1 h and 24 h, respectively. GSTA1, 
-A2, -T1 and –P1 transcripts are normalised to β-actin and compared to respective H2O 
(1%) treated control cells. The data are plotted as relative mRNA quantity (RQ) of a single 
orienting experiment. 
Figure 38 displays the effect of 50 µM tBHP on the transcript level of various GST-
isoenzymes in HT29 cells. Incubation for 1 h with tBHP did not affect GST transcript levels. 
After 24 h of incubation, GSTA1 mRNA was increased 2.1-fold, whereas the GSTA2,-T1 and 
-P1 transcript levels were not affected. Any increased GST activity was observed after 24 h 
of incubation with 50 µM tBHP (figure 34 B), indicating that the GSTA1 mRNA increase is too 
marginal to induce enhanced GST activities or the 2.1-fold increase may cause a too low 
induction of enzyme activity to be recorded by photometric determination in the GST enzyme 
assay.  
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Figure 39 displays the effect of 15 µM SFN, 20 µM MEN, 200 µM tBHQ and 5 µM BaP on 
GSTA1 and –A2 mRNA levels after 1 h of incubation. Among the tested substances, only 
20 µM menadione fostered a 1.5-fold increase in GSTA1 mRNA and 5 µM BaP a 1.3-fold 
increase in GSTA2 mRNA. A maximum 1.2-fold induction of GSTA1 and GSTA2 mRNA was 
observed after incubation with all other substances. 
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Figure 39: Effect of 15 µM SFN, 20 µM MEN, 200 µM tBHQ and 5 µM BaP on the transcript level of 
GSTA1 and -A2 in HT29 cells after 48 h pre-cultivation and subsequent treatment for 1 h. 
GSTA1 and -A2 transcripts are normalised to β-actin and compared to respective DMSO 
(1%) treated control cells. The data are plotted as relative mRNA quantity (RQ) of a single 
orienting experiment. 
 
4.4.4. Glutathione-S-Transferase Activity in HepG2 Cells 
Treatment of HT29 cells with various substances, described as inducers of GST activity in 
the literature at varying incubation times did not result in a significant induction. However, 
significant increases of GST activities in HT29 cells were reported previously by several 
authors (Ebert et al., 2003; Nam & Shon, 2009). Thus, to exclude any problems in the 
responsiveness of the used HT29 cell clone (will be discussed in more detail at the end of 
chapter 4.4.5 “GST Activity in HT29 Cells cultivated for 72 h”) and to verify proper 
performance of the method, the assay was established in human liver carcinoma cells 
HepG2, known to express GST enzyme activity. This cell type not only represents most 
cellular features of normal human hepatocytes (Bouma et al., 1989) but was also shown to 
retain many enzymes involved in xenobiotic metabolism (Roberts et al., 1990). 
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Briefly, 3*106 HepG2 cells were seeded per Petri dish and cultivated for 48 h and 72 h, 
respectively. An incubation period of 2 h with 40 µM quercetin (Que), a reported suppressor 
of GST activity (Wiegand et al., 2009) and 5 µM BaP followed, whereas 15 µM SFN was 
applied for 24 h. Cells were trypsinised and the GST assay according to Habig et al (1974) 
was performed. The results were expressed as test over control [%], with 1% DMSO-treated 
cells as control.  
Quercetin fostered a 50% decrease of GST activity independent of cultivation time 
(figure 40 A and B). However, any increase of GST activity was observed upon incubation 
with benzo(a)pyrene and sulforaphane. 
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Figure 40: GST activity in HepG2 cells determined in the GST assay according to Habig et al. (1974). 
Cells were pre-cultivated for (A) 48 h and subsequently treated with 40 M Que for 2 h and 
15 µM SFN for 24 h and (B) pre-cultivated for 72 h and subsequently treated with 5 µM 
BaP for 2 h and 40 µM Que for 2 h. GST activities are calculated as the percent GST 
activity of treated cells over control cells (treated with the solvent 1% DMSO) x 100 
(T/C%) of a single orienting experiment. 
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Figure 41 shows the GST mRNA levels in HepG2 cells after 2 h of incubation with 5 µM BaP 
and 40 µM Que. BaP increased GSTP1 mRNA 8.7-fold, GSTA1, -A2 and -T1 levels 
remained nearly unchanged. However, this increase is only observed on the transcript level, 
different times of incubation (1 h see figure 35, 6 h see figure 36, 16 h see figure 37 B, 24 h 
see figure 34 C) did not enhance GST activity. GSTP1 mRNA is increased 3.1-fold after 
incubation with 40 µM Que. The enhanced GST mRNA level after Que treatment did not 
coincide with the observed diminishment in GST activity after 2 h (figure 40 A and B). 
However, since mRNA and protein isolation were performed both after 2 h of incubation, the 
minimum of mRNA transcripts was believed to be earlier in time, followed by an up-regulation 
after 2 h.  
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Figure 41: Effect of 5 µM BaP and 40 µM Que on the transcript level of GSTA1, -A2, -T1 and –P1 in 
HepG2 cells after 72 h pre-cultivation and treatment for 2 h. GSTA1, -A2, -T1 and –P1 
transcripts are normalised to β-actin and compared to respective DMSO (1%) treated 
control cells. The data are plotted as relative mRNA quantity (RQ) of a single orienting 
experiment. 
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4.4.5. GST Activity in HT29 Cells cultivated for 72 h  
Significant AME- or AOH-mediated increases of CYP1A1 transcripts in KYSE510 cells were 
observed only in cells cultivated for at least 48 h prior incubation with the mycotoxins. These 
results initiated the question, whether HT29 cells grown for 48 h are optimally developed for 
the expression of GST enzymes. However, the doubling time of HT29 cells, which varies 
between 40 - 60 h, is nearly twice as much as the 30 h doubling time of KYSE510 cells. 
HT29 cells, 48 h post-seeding were examined under the microscope. Their morphology was 
considered to be still in the developmental phase. Figure 42 A displays fully developed HT29 
cells, which are clustered in complex groups and each cell is in tight contact with the 
neighbouring one. In contrast, freshly seeded cells are of spherical shape, mostly single 
individuals surrounded by wide areas of free space (figure 42 B). Since the morphology of 
HT29 cells after 48 h of culture corresponded more closely to the latter description, the time 
of cultivation was prolonged to 72 h.  
A B 
  
Figure 42: Morphology of HT29 cells which (A) already established their morphology 
[http://jcs.biologists.org/content/119/1/31/F1.expansion.html] and (B) HT29 cells seeded 
quite recently [http://www.cellprofiler.org/examples.shtml].  
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Even after increasing the time of pre-cultivation, any significant increase of GST activity by 
AME was apparent in HT29 cells (figure 43 A). The results were similar to the unchanged 
GST activity in cells cultivated for 48 h (figure 33 A).  
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Figure 43: GST activity in HT29 cells determined in the GST assay according to Habig et al. (1974). 
Cells were pre-cultivated for 72 h and subsequently treated with (A) AME, (B) AOH and 
(C) 20 µM MEN, 10 µM CGA or 0.5 µM CGA + 5.5 µM trigonelline, respectively for 24 h. 
GST activities are calculated as the percent GST activity of treated cells over control cells 
(treated with the solvent 1% DMSO) x 100 (T/C%). The values given are the mean ± SD 
of three independent experiments. Calculation of statistical significances are performed on 
the basis of underlying T/C [%] values (*=p<0.1). 
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AOH at a concentration of 10 µM caused a minor, yet significant increase of GST activity to 
112% (± 1.4%). Previous experiments with shorter cultivation periods (48 h) showed a 
significant increase of GST activity not before 50 µM AOH (figure 33 B). However, the 
observed induction at 50 µM AOH should be viewed critically, since the onset of cytotoxic 
effects was demonstrated. Any cell growth inhibition was observed at ≤ 10 µM AOH in 48 h 
pre-cultivated HT29 cells. So far any data for AOH elicited cytotoxicity in 72 h pre-cultivated 
cells had been available. Based on the results obtained with 48 h pre-cultivated HT29 cells, 
there would be just a minimal probability of cell growth inhibition by 10 µM AOH in 72 h pre-
cultivated cells. However, due to changed culture conditions, cytotoxicity could not be 
completely excluded. 
The positive controls 10 µM chlorogenic acid (CGA) and co-incubated 0.5 µM chlorogenic 
acid, 5.5 µM trigonelline and 1000 U/ml catalase (CGA+Tri+Kat) displayed any significant 
increase in GST activity (figure 43 C). The same result was obtained for 50 µM tBHP, which 
was tested just once. Since no induction was observed with the positive controls, the data for 
50 µM AOH still needed to be viewed critically.  
The use of appropriate concentrations of foetal bovine serum (FBS) and antibiotics is a 
required part of cell culture conditions. In retrospect, a fungal contamination of the used FBS 
was identified causing some trouble for cell cultivation and potentially also for cell response. 
The potential production of toxins by the contaminating fungi could influence the activity of 
drug metabolising enzymes in the different cell lines used. Thus it might be speculated that 
the basal cellular GST level for instance is up-regulated to a level allowing any further 
induction, resulting in already constantly increased GST activities in the cell. Thus the 
contaminating fungi might account for, or at least contribute to the problems in GST 
induction.  
Taken together, despite several different approaches GST activity was neither in HT29 nor in 
HepG2 cells significantly increased after treatment with a number of different compounds, 
described as enhancers of GST activity in the literature. Nevertheless, GST activity was 
significantly increased by AOH in HT29 cells, albeit fairly weak. Doostdar et al. (1988) 
investigated GST activities in HepG2 cells cultivated in different media. Depending on the 
chosen medium, the obtained results differed up to 124% (Doostdar et al., 1988). The results 
demonstrated, that a variety of different parameters despite contamination had a pivotal 
influence on GST activity and needed to be tested in detail prior any final conclusions.  
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5. Conclusion 
Alternaria toxins, such as alternariol (AOH) and alternariol monomethyl ether (AME) are on 
the list of mycotoxins with an urgent need for further investigations of toxicity, permitting a 
better risk assessment for man and animal.  
Based on the data reported by Fehr (2008) and Schreck et al. (2011) on the induction of 
CYP1A1 by Alternaria toxins, the role of the aryl hydrocarbon receptor (AhR) in AME- and 
AOH-mediated CYP1A1 expression was investigated in human tumour cells. The 
consumption of grain contaminated with Alternaria spp. has been associated with an 
increased incidence of oesophageal cancer in Linxian, China (Liu et al., 1992), thus human 
oesophageal carcinoma cells KYSE510 were chosen as cell model.  
Prior to the studies on CYP1A1 expression, the cytotoxic potential of alternariol monomethyl 
ether (AME) was investigated in KYSE510 cells. After 24 h of treatment with AME in the 
concentration range of 0.1 - 10 µM, no significant cytotoxic effects were observed in the SRB 
assay. Thus the tested concentration range seemed to be appropriate for studies on gene 
transcription. The cytotoxic potential of alternariol (AOH) based on available data, which 
suggested any cytotoxicity at 50 µM AOH. However, in retrospect growth inhibitory effects 
≥ 50 µM AOH were detected. Thus, results in the present thesis with 50 µM AOH have to be 
rated critically.  
Two approaches were used to investigate the question whether mycotoxin-induced CYP1A1 
is AhR-dependent in oesophageal cells. Firstly, oesophageal AhR knockdown cells were 
generated by RNAi technology and served as an adequate model for studying the impact of 
Alternaria toxins on CYP1A1. Secondly, KYSE510 cells, pre-treated with the known AhR 
antagonist 3´-methoxy-4´nitroflavone (MNF) were used as cells with a reduced or either 
complete loss of functioning AhR. Hence knockdown of the Ah-receptor by transient siRNA 
transfection represented a major focus of the present thesis. Optimisation experiments for 
transient siRNA transfection, granting ideal transfection efficiency and knockdown of AhR of 
at least ≥ 70%, were performed with human oesophageal carcinoma cells (KYSE510). The 
optimised conditions for transfection of KYSE510 cells were: fast-forward protocol according 
to the manufacturer´s recommendations “Fast-Forward Transfection of Adherent Cells with 
siRNA/miRNA in 24-well Plates” (Qiagen®), 3*104 KYSE510 cells/well, 0.2 µl AhR siRNA2, 
4.5 µl HiPerFect Transfection Reagent from Qiagen® and 48 h post-transfection incubation 
with the mycotoxins for 24 h. The suppression of AhR in transfected cells was checked by 
qRT-PCR and by Western blot assuring a suppression of ≥ 70% at the transcription level and 
no signal for AhR at the protein level. Later on, suppression of AhR was routinely checked by 
qRT-PCR in all experiments conducted with the mycotoxins.  
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After 24 h treatment of non-transfected and dsRNA-transfected (negative control) KYSE510 
cells with AME, CYP1A1 levels remained nearly unaltered at 0.1 µM and were induced at 
1 µM up to 2.5-fold. At higher AME concentrations (5 µM and 10 µM) the transcript level of 
CYP1A1 was significantly reduced to about 60 - 70%. In contrast, AOH elicited a more potent 
CYP1A1 induction in oesophageal cells than AME. At 0.1 µM AOH the CYP1A1 induction 
was already 1.9-fold (± 0.5), at 1 µM and 10 µM the induction reached a maximum with about 
8-fold. The results indicated, that non-transfected and dsRNA-transfected control cells 
respond similar to the mycotoxins. Thus the transfection procedure did not alter KYSE510 
cells in their properties towards AME and AOH. In AhR-suppressed (AhR-siRNA transfected) 
KYSE510 cells the induction of CYP1A1 by AME as well as by AOH was significantly 
reduced up to complete abolishment, supporting the hypothesis of AhR-dependent CYP1A1 
induction by both Alternaria toxins. However, CYP1A1 mRNA expression in AhR-deficient 
KYSE510 cells plummeted below the endogenous level, when applying high AME (≥ 5 µM) 
and AOH (≥ 10 µM) concentrations. The interference of another, yet unknown pathway had 
to be considered and required further experiments.  
The results with KYSE510 cells inhibited by MNF (2nd approach) along general lines also 
supported a role of the AhR in modulation of CYP1A1 mRNA levels by AME. However, the 
picture is more complex. KYSE510 control cells pre-treated with 10 µM MNF for 15 minutes 
followed by incubation with 1% DMSO for 24 h, exhibited a significant, about 6-fold increase 
in CYP1A1 transcripts in comparison to non-treated cells. Thus suspecting MNF, when 
applied at 10 µM, to act potentially as Ah-receptor agonist in KYSE510 cells. Nevertheless, 
subsequent incubation with AME led to a significant and concentration-dependent reduction 
of CYP1A1 mRNA levels. Based on these results it might be speculated, that AhR inhibition 
by MNF impedes CYP1A1 induction by AME, emphasising the role of AhR in AME-mediated 
CYP1A1 induction. On the other hand the potent induction of CYP1A1 by MNF is reduced in 
the presence of AME allowing the assumption of a potential displacement of MNF from the 
AhR binding site. However, this hypothesis needs to be verified by receptor binding studies 
with labelled MNF. 
Glutathione-S-transferases (GST) are important phase II drug metabolising enzymes, 
bearing a considerable role in the detoxification of xenobiotics by conjugation with a 
glutathione molecule. One aspects of the present thesis was the implementation of the GST 
assay according to Habig et al. (1973). The reliability of the assay was tested by a variety of 
positive control-substances reported in the literature. However, any of the tested substances 
reproducibly induced GST activity to an adequate extend. In this context, several potential 
parameters, impacting on GST activity, were investigated in orienting experiments. Despite 
the problem of identifying a proper positive control, human colon carcinoma HT29 cells were 
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treated with AME and AOH for 24 h in a concentration range of 0.01 - 50 µM. Previous 
studies in human colon carcinoma cells (HT29) and results obtained with hepatic and 
intestinal microsomes, demonstrated the formation of AOH- and AME-glucuronides and -
sulphates. Thus, HT29 cells were considered to be a suitable test system to investigate the 
contribution of GST in the phase II detoxification process. Neither AME nor low 
concentrations of AOH significantly increased the GST activity, with exception of AOH at 
10 µM and 50 µM. Since the induction was quite marginal and in the latter case cytotoxicity 
could be of not negligible influence, the involvement of GST in phase II detoxification and 
metabolic disposal was considered to be of minor extend.  
The results of the present thesis on CYP1A1 expression in human oesophageal tumour cells 
showed a significant AME- and AOH-mediated increase of CYP1A1 transcripts and strongly 
suggested an Ah-receptor mediated induction of CYP1A1. Based on the existing data of 
dietary exposure, the EFSA Panel on Contaminants in the Food Chain (CONTAM) used the 
threshold of toxicological concern (TTC) approach to assess the relative level of concern for 
dietary exposure of humans. They recently pointed out, that the estimated chronic dietary 
exposure to AME (0.8 - 4.7 ng/kg body weight per day) and AOH (1.9 - 39 ng/kg body weight 
per day) exceeded the relevant TTC value, indicating a need for additional compound-
specific data.  
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6. Materials and Methods 
6.1. Cell Culture 
Cell culture is a complex process by which cells are grown under controlled conditions. 
Culture conditions can vary widely depending on the type and origin of cells. The artificial 
environment in which the cells are cultivated contains the following: a medium that supplies 
the essential nutrients, growth factors, optimal grow conditions (37°C, 5% CO2 and 95% 
relative humidity) and a regulated chemical environment (pH).  
The supply of essential substances as well as the neutralisation of the degradation products 
by culture media is part of the in vitro conditions. To prevent bacterial growth in case of 
contamination, antibiotics (1% P/S) are added to the culture media (Lindl, 2000). Before use 
all media are warmed up to 37°C. Any handling with cells is performed under sterile 
conditions. 
6.1.1. Cell Lines 
KYSE510 
KYSE510 cells were derived from an oesophageal squamous cell carcinoma, restricted from 
a 67-year-old Japanese woman after treatment with cisplatin and radiation. The cells are 
described as carrying a p53 mutation and amplification of MYC, HST1, CYCLIN D1. 
Furthermore they induce well-differentiated tumours in nude mice. The cells display 
epitheloid character, growing as monolayer with multilayer foci. The doubling time is about 
30 hours and RPMI 1640 containing L-glutamine, 1% (v/v) penicillin (10000 units)/ 
streptomycin (10000 µg/ml) (P/S) and 10% (v/v) heat inactivated fetal bovine serum (FBS) is 
used as culture medium. Cells are grown in monolayers in tissue culture bottles at 37°C, 5% 
CO2 and 95% relative humidity (DSMZ, Braunschweig). 
HT29 
The human colon adenocaricnoma cell line HT29 was established from the primary tumour of 
a 44-year-old Caucasian woman in 1964. The tumour is described to be 
heterotransplantable, forming well differentiated grade I tumours. The epitheloid HT29 cells 
grow adherent as a monolayer in large colonies with a doubling time of 40 - 60 hours. The 
culture medium used in the experiments is Dulbeccos´s Modified Eagle Medium (DMEM, 
with 4500 mg/l glucose, pyridoxine HCl, without sodium pyruvat) containing 1% (v/v) P/S and 
10% (v/v) heat inactivated FBS. Cells are grown in monolayers in tissue culture bottles at 
37°C, 5% CO2 and 95% relative humidity (DSMZ, Braunschweig).  
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HepG2 
HepG2 cells are human hepatoma cancer cells which were established from the tumour of a 
15 year old Argentinean harbouring a hyperploid karyotype. They are adherent cells which 
grow in a monolayer with a doubling time of 40 - 60 h. The used culture medium is 
RPMI 1640, containing L-glutamine, 1% (v/v) penicillin/ streptomycin (P/S) and 10% (v/v) 
heat inactivated FBS. Cells are grown in monolayers in tissue culture bottles at 37°C, 5%CO2 
and 95% relative humidity (DSMZ, Braunschweig).  
6.1.2. Re-culturing of Cells 
Frozen cell stocks (stored at -80°C) are thawed quickly in a water bath at 37°C and 
transferred to 6 ml respective cell culture medium, containing 20% (v/v) heat inactivated FBS 
and antibiotics. The cell suspension is centrifuged at room temperature for 4 minutes at 
450 x g, resulting in the formation of a cell pellet. The supernatant is discarded. The cell 
pellet is carefully resuspended in 6 ml medium (see above) and transferred to 4 ml medium 
already pipetted in a small tissue culture flask (25 cm2) and the suspension is added. The 
cells are cultivated at the above mentioned conditions. Upon achieving 80% confluency, the 
cells are passaged into a medium size tissue culture flask (75 cm2) and thereafter into a 
175 cm2 tissue culture flaks. The cells are maintained for at least one week in culture and 
20% (v/v) FBS supplemented medium before attaining experimental competence.  
6.1.3. Storage of Cells 
Long term storage of cells takes place in the biofreezer at -80°C and as well as in liquid 
nitrogen. To prevent the formation of ice crystals and to counter act a partial dehydration of 
the samples, a defrosting agent like dimethyl sulphoxide (DMSO) is added. The protection by 
DMSO is due to the replacement of water (Lindl, 2000). 
The cells are detached from the surface of the cell culture flask by trypsination as described 
in 6.1.5 “Sub-culturing of Cells”. 1 ml of the cell suspension is added to 500 µl of a mixture of 
70% (v/v) heat inactivated FBS and 30% (v/v) DMSO in a cryo tube. The cell stocks are 
carefully stirred and stored at -20°C for 24 hours. The use of bubble wrap foil and storage in 
a styrofoam box should prevent too rapid cooling. For long term storage the cell stocks are 
transferred to the biofreezer at -80°C or to liquid nitrogen. 
6.1.4. Changing of Cell Culture Medium 
To ensure the growth of a uniform monolayer, the routinely change of medium is required. 
Due to metabolic processes, nutrient ingredients are degraded by the cells and eliminated 
metabolites accumulate in the cell culture media resulting in a change to more acidic pH, 
indicated by a change of the medium colour from red to yellow (Lindl, 2000). 
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The cell culture medium is aspirated and the cell monolayer is rinsed with 5 ml pre-warmed 
PBS (phosphate buffered saline) to remove dead cells. Subsequently the appropriate volume 
of pre-warmed cell culture medium (10 ml medium for 25 cm2 culture flasks, 20 ml for 75 cm2 
and 40 ml for 175 cm2 culture flask) is added and the flask is placed back into the incubator. 
6.1.5. Sub-culturing of Cells 
At a cell confluence of about 80 - 90% a proper monolayer growth is not granted anymore. 
Further cell growth is suppressed and the cell layer can detach from the bottom of the cell 
culture flask and thus the cells might die off. Therefore it is necessary to reduce the cell 
number by sub-culturing the cells (Lindl, 2000). 
The depleted cell culture medium is aspirated and the cells are rinsed with 5 ml PBS to 
remove dead cells and residual cell culture medium. 2.5 ml pre-warmed trypsin solution is 
added and the cells are incubated at 37°C for 2.5 minutes by placing back the culture flask 
into the incubator. The culture flask is clapped several times to detach the cells. To stop the 
trypsin reaction 7.5 ml serum supplemented cell culture medium is added. Subsequently the 
cells are re-suspended by carefully pipetting up and down. Depending on the experimental 
setup, a certain volume of the cell suspension is transferred to the culture flask, 40 ml 
medium is added and the cells are further cultivated. After using the same culture flask for 
two times, it is replaced by a new, sterile one.  
At high passage numbers during cell culture, the genotype of tumour cells can change 
potentially causing changes in their properties. To avoid this problem the cell line is replaced 
at a certain passage number (after about 30 passages) by a new, re-cultured cell stock.  
6.1.6. Cell Counting 
To ensure similar conditions for the experimental procedures, the same number of cells 
should be used. The cell number is determined by using a Neubauer counting chamber 
(haemocytometer). Shortly before the cells are detached from the bottom of the flask, the 
counting chamber is arranged as follows: the cover glass is breath-moistened and gently slid 
onto the counting chamber. A dilution of cell suspension with trypan blue is prepared in a test 
tube of 1.5 ml. The grid of the haemocytometer consists of nine squares, whereas each has 
an area of 1 mm2. The depth is 0.1 mm, resulting in a volume of 0.1 µl/square and the entire 
counting grid has a volume of 0.9 µl. The counting chamber is loaded with 10 µl of the cell 
dilution by placing the tip of the pipette at the juncture between cover glass and counting 
chamber. As a result of the capillary effect, the suspension is drawn in between the cover 
glass and the chamber. The number of cells in the four squares is determined by counting 
(figure 44) and subsequently the arithmetic mean is calculated. Multiplication with the dilution 
factor and the volume factor of the haemocytometer (104) yields the number of cells/ ml. The 
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dye trypan blue (trypan blue solution 0.4%, Sigma) is used to distinguish between dead and 
living cells. The dye diffuses through the membrane into the cells. Living cells appear white, 
due to the fact that they are able to export the dye, whereas dead cells are not, thus 
remaining blue (Lindl, 2000). 
 
Figure 44: Depiction of the Neubauer counting chamber/ haemocytometer (Lindl, 2000) 
Reagents 
RPRMI 1640 medium Gibco, Invitrogen 
 + L-glutamine 
DMEM medium Gibco, Invitrogen 
 + 4.5 g glucose  
 + L-glutamine  
 - pyruvate  
FBS (heat inactivated) Gibco, Invitrogen 
P/S (5000 units/ml penicillin, 5000 µg/ml streptomycin) Gibco, Invitrogen 
DMSO, for molecular biology (>99.5%) Roth 
trypan blue solution (0.4%) Sigma 
10x PBS (Phosphate Buffered Saline) 
1710 mM NaCl     Roth 
100 mM Na2HPO4    Roth 
34 mM KCl     Roth 
18 mM KH2PO4    Roth 
The buffer is adjusted to pH 7.4 with conc. HCl and filled up to 1 l with bidest. water. The 
1:10 diluted PBS (1x PBS) is autoclaved. 
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Trypsin Solution 
500 mg trypsin  bovine pancreas, 3.6 U/mg, Serva 
250 mg EDTA  Merck 
100 ml 10x PBS 
The solution is filled up to 1000 ml with bidest. water and stirred on ice over night. Thereafter 
the pH-value is adjusted to 7.0 - 7.4 and the solution is filtrated under sterile conditions (filter 
pore size: 0.2 µm), 5 ml aliquots are prepared and stored at -20°C. 
6.2. Sulforhodamine B (SRB) Assay 
The sulforhodamine B (SRB) assay is a test for cytotoxicity and was performed according to 
Skehan (1990). Living cells are fixed and stained with the anionic dye sulforhodamine B 
(figure 45), which binds to alkaline amino acids of cellular proteins at acidic conditions. 
Subsequently at alkaline conditions (pH 10) the dye is dissolved away from the affixed cells. 
The effect of the test substances on cell growth is evaluated by measuring the absorbance of 
the coloured solution photometrically at 570 nm, as the dye is only bound to living cells 
(Skehan, 1990). 
ON N
SO3Na
SO3
 
Figure 45: Structure of sulforhodamine B 
Procedure 
• 800 KYSE510 cells/200 µl complete RPMI 1640 medium are seeded per well of a 96-
well plate and grown for 72 hours at 37°C, 5% CO2 and 95% relative humidity.  
• The cells are incubated for 24 hours with the test substances (AME in the present 
study at 0.1, 1 and 10 µM, originally dissolved in DMSO). A 1:100 dilution step with 
cell culture medium (containing 10% (v/v) FBS and 1% (v/v) P/S) yield incubation 
solutions with 1% (v/v) final DMSO concentration.  
• At the end of substance incubation, cell monolayers are fixed by adding 20 µl 
trichloroacetic acid (50%) per well. The plate is stored at 4°C overnight.  
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• To remove cell- and medium-residues, the culture plate is rinsed carefully four times 
with bidest. water. Afterwards it is stored at room temperature until complete dryness.  
• The fixed cells are stained with 50 µl SRB-solution (0.4 % w/v) per well and incubated 
for 1 hour at room temperature in the dark. 
• The excess of dye solution is removed by rinsing the 96-well plate two times with 
bidest. water and two times with acetic acid (1% v/v). 
• The plate is dried completely at room temperature in the dark. Subsequently the 
protein-bound dye is dissolved in 50 µl 10 mM Tris base solution (pH 10) per well and 
the absorbance is measured at 570 nm.  
The absorbance values of treated cells are compared with the values of solvent control cells 
(1% DMSO) and presented as test over control [T/C] values, where the mean of the solvent 
control (1% DMSO) is set to 100%.  
Reagents 
• trichloroacetic acid (≥99%, Roth): 50% v/v solution in bidest. water  
• acetic acid (≥96%, Roth):  1% v/v solution in bidest. water 
• SRB-solution (Sigma-Aldrich):  0.4% w/v solution in 1% acetic acid 
• Tris base (≥99.9%, Roth):  2.42 g Tris (10mM) are dissolved in 2 l bidest. 
     water, pH 10  
Data representation  
The evaluation of the obtained spectrophotometrical data is demonstrated using the 
experiment performed on the 24/03/2011 with 1 µM AME. For the representation of the 
graphs eight absorbance values (ABS) are chosen (table 4, 2nd column). Due to unsteady 
growth of the cells at the edge of the 96 well-plate in comparison to the wells in the middle of 
the plate, the absorbance values obtained from the external wells are not used for further 
evaluation. The blank value is determined by measuring the absorbance of 50 µl 10 mM Tris 
base solution (pH 10) which is subsequently subtracted from the obtained absorbances 
(table 4, 3rd column). Then the arithmetic mean and the standard deviation of the obtained 
absorbance values are calculated according the following formulas:  
n
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Table 4: Determined absorbance values in the SRB assay and calculated T/C [%] for 1 µM AME 
(experimental data recorded on the 24/03/2011) 
Data point # ABS ABS-blank T/C [%] 
1 1.561 1.473 107.85 
2 0.182 0.094 - 
3 1.473 1.385 101.41 
4 1.561 1.473 107.81 
5 1.405 1.317 96.41 
6 1.354 1.265 92.63 
7 1.269 1.181 - 
8 1.551 1.463 107.11 
x  1.206  
σ  0.432  
 
ABS (blank)= 0.088 
 
In order to detect and subsequently reject outliers, the Nalimov outlier test is used. Assuming 
a Gaussian distribution of the measured values, outliers are identified as such, when the test 
statistic q exceeds the critical threshold qcrit. (q > qcrit → outlier, table 5).  
The test statistic q is calculated according the following formulas: 
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Table 5: Critical threshold qcrit values at a 95% confidence level 
number of 
measured values qcrit 
n = 3 1.409 
n = 4 1.645 
n = 5 1.757 
n = 6 1.814 
n = 7 1.848 
n = 8 1.870 
n = 9 1.885 
 
After rejecting the identified outliers, the test statistic q is calculated again by modifying n, x 
and σ to the correct value. After comparison with the respective qcrit, any existing outliers are 
rejected again. The Nalimov test is performed until at least three absorbance values are left. 
In the following experiment two outliers are identified and grey shaded in table 4. They are 
not used for further data evaluation.  
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Then the test over control (T/C) values are calculated according the following formula and 
are given in the 3rd column of table 4.  
100
)(
[%]/ ×=
DMSOABSx
ABSCT
 
The arithmetic mean and standard deviation (σ) of the T/C [%] values are calculated for the 
respective concentrations (0.1 µM, 1 µM, 10 µM AME), including all replicate experiments. 
Both values are represented in the graph.  
T/C [%] (DMSO): 100%  (σ = 8.045) 
T/C [%] (1µM AME) 96.33%(σ = 11.987) 
Significant differences between AME- and solvent control (1% DMSO) treated cells are 
identified by the two tailed t-test. At first the degrees of freedom (f) are determined: 
f = 2 x n -2= 8  n: number of independently performed experiments (n = 5) 
Then the variances of 1 µM AME- and 1% DMSO-treated cells are calculated and used for 
the determination of the weighted variance (s2). 
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If the t-value (t) exceeds the critical threshold tcrit (t > tcrit, table 6), the difference in arithmetic 
means is assigned to be significant. In the performed experiment, arithmetic means of all 
tested AME-concentrations (0.1 µM, 1 µM, 10 µM) do not significantly differ from DMSO-
treated control cells.  
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Table 6: Critical threshold tcrit values at 95%, 99% and 99.9% confidence levels 
confidence level tcrit 
95% 2.306 
99% 3.355 
99.9% 4.501 
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6.3. Gene Silencing by using siRNA 
The expression of single genes can be suppressed by using siRNA technology. The 
introduction of short interfering RNA (siRNA) into the cell is a crucial requirement for the 
specific suppression of mRNA. siRNA is a short piece of double-stranded RNA, which is 
pried apart by the RNA-induced silencing complex (RISC), whereupon the antisense strand 
of RNA is responsible for the inactivation of mRNA and by extension the according gene. 
The whole process is known as RNA interference (RNAi) and an important part of the 
posttranscriptional gene silencing (PTGS) (Shan). In the present work the transfection 
reagent HiPerFect (Qiagen®) is used for siRNA transfection experiments. The aim was the 
suppression of AhR function in human oesophageal tumour cells (KYSE510). 
AhR siRNA 
Two siRNAs (siRNA 1 & siRNA 2) of different aryl hydrocarbon receptor (AhR) sequences 
were used. The exact sequences are not denoted by the supplier. Both siRNAs, a kind gift of 
Prof. C. Weiss (Karlsruher Institute of Technology, KIT Germany) are delivered as solutions 
in siRNA buffer with a concentration of 100 pmol/µl each. 
Negative Control siRNA 
The RNA used as negative control (dsRNA) has no homology to any known mammal gene. 
The dsRNA, also a kind gift of Prof. C. Weiss, is dissolved in siRNA buffer at a concentration 
of 20 pmol/µl. The sequence of the dsRNA is not specified by the supplier.  
HiPerFect Transfection Reagent  
HiPerFect Transfection Reagent (Qiagen®) consists of cationic liposomes. The liposomes 
bind siRNA and form complexes with high affinity toward cell membranes. The major 
mechanism involves endocytosis of the complexes, followed by disruption of the endosomal 
membrane. The optimal volume of transfection reagent and siRNA concentration depends on 
siRNA potency, cell type and the target gene (Qiagen, 2010). 
6.3.1. Establishment of transient siRNA Transfection in KYSE510 Cells 
The transient transfection of the KYSE510 cells is performed according to the manufacturers 
recommendations: “Fast-Forward Transfection of Adherent Cells with siRNA/miRNA in 24-
well Plates”. The volumes of required transfection reagent and of AhR1-/ AhR2-siRNA in the 
optimised protocol are calculated for one well of a 24-well plate (Qiagen, 2010). 
 
88 
According to the manufacturer (Qiagen®) several factors have to be considered to meet 
optimal siRNA transfection: 
• amount of siRNA 
• ratio of HiPerFect Transfection Reagent to siRNA 
• cell density at transfection 
• choice of transfection protocol 
• post-transfectional time of incubation 
The used fast-forward protocol implies cell plating and transfection to be performed on the 
same day. Furthermore, it is recommended that the transfection master mix is added drop- 
wise onto the cells and not vice versa, since optimal mixing of cells and transfection 
complexes is desirable.  
Post-transfection the gene silencing is verified by using quantitative real time PCR  
(qRT-PCR) and Western Blot analysis (see chapter 6.4 “Gene Expression Analysis of 
CYP1A1 and AhR using quantitative Real Time PCR” and chapter 6.5 “Western Blot Analysis 
of the Aryl Hydrocarbon Receptor”). The establishment of optimal siRNA-transfection 
conditions, including the number of seeded cells, volume of HiPerFect Transfection Reagent 
and siRNA is described in chapter 4.3.2 “Knockdown of AhR in KYSE510 Cells” and briefly 
summarised in table 7. The experimental setup for the transfection of KYSE510 cells in 24-
well-plate format is displayed in table 8. 
Procedure 
Transfection experiments with AhR1- and AhR2-siRNA showed that a better suppression 
with the latter siRNA, thus all the following experiments are performed with AhR2-siRNA. 
More detailed information about the conducted experiments is given in the chapter "Transient 
siRNA Transfection of KYSE510 Cells". 
• According to the optimised transfection protocol 3*104 KYSE510 cells are seeded per 
well of a 24-well plate in 0.5 ml RPMI 1640 culture medium, containing 10% (v/v) heat 
inactivated FBS and 1% P/S. 
• Subsequently cells are kept under normal growth conditions (37°C, 5% CO2, 95% 
relative humidity). 
• 0.2 µl of siRNA 2 and dsRNA, respectively are diluted in 50 µl serum free RMPI 1640 
cell culture medium, containing 1% P/S. 4.5 µl HiPerFect Transfection Reagent are 
diluted in another volume of 50 µl serum free RPMI 1640 cell culture medium.  
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• The transfection solution is added to the AhR2-siRNA solution and mixed by 
vortexing. Then the mixture is incubated for 10 minutes at room temperature to allow 
the formation of transfection complexes.  
• Afterwards the solution is added drop-wise onto the cells and gently swirling of the 
plate ensures uniform distribution of the transfection complexes. The cells are 
incubated under normal growth conditions for 48 h. 
 
Table 7: Optimised transfection conditions for KYSE510 cells with HiPerFect Transfection Reagent 
(Qíagen®) 
optimised transfection conditions 
number of seeded KYSE510 cells  3*104/well 
volume of HiPerFect Transfection Reagent  4.5 µl/well 
volume of siRNA (1 or 2), dsRNA 0.2 µl/well 
transfection time  48 h 
 
Table 8: Experimental setup for the transfection of KYSE510 cells with HiPerFect Transfection 
Reagent (Qiagen®) 24-well plate format 
 A B C D E F 
1       
2 dsRNA dsRNA dsRNA dsRNA dsRNA dsRNA 
3 siRNA2 siRNA2 siRNA2 siRNA2 siRNA2 siRNA2 
4       
6.4. Gene Expression Analysis of CYP1A1 and AhR using 
quantitative Real Time PCR (qRT-PCR) 
The quantitative real time PCR (qRT-PCR) is a polymerase chain reaction technique which is 
commonly used in gene expression analysis to amplify and simultaneously quantify target 
DNA. Usually DNA templates are amplified by PCR; yet if RNA is the target of interest, it hast 
to be transcribed first into DNA with the help of a reverse transcriptase enzyme. This method 
is known as reverse transcription PCR. Quantification of amplicons using conventional end-
point PCR is subjected to high deviations, thus real time PCR in which amplicons are 
monitored after each cycle is preferred. For quantification the fluorescent dye SYBR® Green 
is used. The compound intercalates with double-stranded DNA, allowing the determination of 
fluorescence correlating with the amount of amplicons and thus, with the amount of 
messenger RNA of a respective gene (Roche, 2008). 
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6.4.1. Incubation of Cells  
3*104 KYSE 510 cells/0.5 ml RPMI 1640 medium, supplemented with 10% (v/v) heat 
inactivated FBS and 1% (v/v) P/S, are seeded into each well of a 24-well plate. The cells are 
grown for 24 h and 48 h respectively at 37°C, 5% CO2 and 95% relative humidity. The 
experimental setup for incubation-experiments with transiently transfected cells is displayed 
in table 9 and table 10. The procedure for transient siRNA transfection in KYSE510 cells is 
described in chapter 6.3.1 “Establishment of transient siRNA Transfection in KYSE510 
Cells”. 
The test substances (AOH, AME, BaP, ARO) are dissolved in DMSO. Dilutions of 1:100 with 
cell culture medium, containing 10% (v/v) FBS and 1% (v/v) P/S, yield solutions with 1% 
DMSO as final concentration. The depleted cell culture medium is aspirated and the cells are 
rinsed with 500 µl pre-warmed PBS. Subsequently the cells are incubated with 500 µl of the 
respective chemicals in the appropriate concentration for 24 h. A solution containing 1% 
DMSO is used as solvent control. Due to unsteady growth of the cells at the edge of the 24 
well-plate in comparison to the wells in the middle of the plate, these wells are avoided for 
incubation experiments. 
Reagents 
• AME from Alternaria alternata (tenius) Sigma-Aldrich 
• AOH from Alternaria spp. (~96%)  Sigma-Aldrich 
• ARO      kindly provided by Dr. Metzler, Karlsruher 
      Institute of Technology (KIT), Germany 
• BaP (≥96%)     Sigma-Aldrich  
Table 9: Experimental setup for the incubation of non-transfected, dsRNA- and siRNA 2-transfected 
KYSE510-cells with AME in 24-well plate format 
 A B C D E F 
 non-transfected KYSE510 cells 
1 1% DMSO 0.1 µM AME 1 µM AME 5 µM AME 10 µM AME 5 µM BaP 
 dsRNA-transfected KYSE510 cells 
2 dsRNA 1% DMSO 
dsRNA 
0.1 µM AME 
dsRNA 
1 µM AME 
dsRNA 
5 µM AME 
dsRNA 
10 µM AME 
dsRNA 
5 µM BaP 
 siRNA 2-transfected KYSE510 cells 
3 siRNA 1% DMSO 
siRNA 
0.1 µM AME 
siRNA 
1 µM AME 
siRNA 
5 µM AME 
siRNA 
10 µM AME 
siRNA 
5 µM BaP 
4       
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Table 10: Experimental setup for the incubation of non-transfected, dsRNA- and siRNA 2-transfected 
KYSE510-cells with AOH in 24-well plate format 
 A B C D E F 
 non-transfected KYSE510 cells 
1 1% DMSO 0.1 µM AOH 1 µM AOH 10 µM AOH 50 µM AOH 5 µM BaP 
 dsRNA-transfected KYSE510 cells 
2 dsRNA 1% DMSO 
dsRNA 
0.1 µM AOH 
dsRNA 
1 µM AOH 
dsRNA 
10 µM AOH 
dsRNA 
50 µM AOH 
dsRNA 
5 µM BaP 
 siRNA 2-transfected KYSE510 cells 
3 siRNA 1% DMSO 
siRNA 
0.1 µM AOH 
siRNA 
1 µM AOH 
siRNA 
10 µM AOH 
siRNA 
50 µM AOH 
siRNA 
5 µM BaP 
4       
6.4.2. RNA Isolation 
The RNA isolation is performed using the RNeasy® Mini Kit (Qiagen®) according to the 
RNeasy® Mini Handbook-Protocol: Purification of Total RNA from Animal Cells using Spin 
Technology.  
The isolation of total RNA is performed according to the single step method as described in 
the manufacturer´s protocol (Qiagen®). The cells are first lysed and homogenised in the 
presence of a denaturating guanidine thiocyanate containing buffer, which immediately 
inactivates RNases assuring intact RNA. The addition of ethanol provides appropriate 
binding conditions to the silica membrane. Total RNA is obtained using solid phase 
extraction. Silica membranes are used, which allow the binding of RNA sequences longer 
than 200 nucleotides (nt). The procedure provides enrichment for mRNAs since most RNAs 
smaller than 200 nt (such as rRNA and tRNA) are selectively excluded (Qiagen, 2006). 
Procedure 
• The cell culture medium is aspirated and each well is rinsed twice with 500 µl ice-cold 
PBS. 
• The cells are lysed directly by adding 300 µl Buffer RLT per well. Shortly before use 
1% β-mercaptoethanol is added to the RLT-Buffer. 
• The cell lysate is collected with a 1000 µl Eppendorf pipette and transferred into a 
1.5 ml RNase-free test tube. 
• Subsequently the lysate is homogenised by passing it five times through a blunt 20-
gauge needle (0.9 mm diameter), fitted to a 1 ml RNase free syringe.  
• 300 µl 70% ethanol is added to the lysate and mixed well by pipetting.  
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• The whole sample is transferred onto a RNeasy spin column placed in a 2 ml 
collection tube. The lid is closed, the sample centrifuged at 9600 x g for 60 seconds 
and the flow through discarded.  
• 700 µl Buffer RW 1 is added to the RNeasy spin column and the centrifugation step is 
repeated as described above and the flow through discarded.  
• Then the membrane of the spin column is washed twice with 500 µl Buffer RPE. The 
first time it is centrifuged for 60 seconds, the second time for 120 seconds at 
9600 x g. After each centrifugation step the flow through is discarded.  
• Thereafter the RNeasy spin column is placed into a new 2 ml collection tube. It is 
centrifuged at full speed (21500 x g) for 60 seconds and then the collection tube is 
discarded. 
• The column is placed in a new 1.5 ml collection tube and 30 µl RNase-free water is 
added directly onto the membrane of the spin column. The sample is centrifuged at 
9600 x g for 60 seconds.  
• The obtained RNA is stored on ice and aliquots of 12 µl are prepared. Long term 
storage of RNA is performed in the biofreezer at -80°C. 
Reagents 
• PBS:    see chapter 6.1.6 “Cell Counting”  
• β-mercaptoethanol (99%): Roth 
• lysis buffer:   Buffer RLT with 1% β-mercaptoethanol 
• washing buffer A:  Buffer RW 1 
• washing buffer B:  Buffer RPE with 4 volumes of ethanol (96%, Roth) 
• eluent:    RNase-free water 
6.4.3. Concentration and Purity of RNA 
The concentration and purity of the isolated RNA is determined photometrically at λ = 260 nm 
using the NanoDrop 2000c Spectrophotometer (PeqLab). An absorbance of 1 unit at 260 nm 
corresponds to 44 µg of RNA per ml (A260 = 1  44 µg/ml). The ratio between the 
absorbance values at 260 and 280 nm gives an estimate RNA purity with respect to protein 
contaminants, which have an absorption maximum at λ = 280 nm. Pure RNA has an A260/A280 
ratio of 1.9 - 2.1. 
Procedure 
• The NanoDrop program is started and a new workbook is created.  
• Prior the measurement the NanoDrop-System is initialised by pipetting RNase free 
water onto the pedestal of the device. RNase free water (1.5 µl) is also used as blank. 
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The arm of the device is closed and the blank button in the software program is 
pressed.  
• Subsequently 1.5 µl of sample are transferred for measurement, using the measure 
button.  
• After the measurement the liquid is removed with a clean tissue wipe and the next 
sample is loaded. 
• After the measurement the workbook is saved and the pedestal of the device is 
cleaned with 1.5 µl RNase-free water.  
6.4.4. Reverse Transcription 
As the Taq-DNA polymerase used in PCR is not able to use RNA as template, it is necessary 
to transcribe the obtained RNA into complementary DNA (cDNA). Therefore an enzyme 
known as reverse transcriptase, usually obtained from RNA-containing retroviruses, is used. 
Reverse transcriptase is a multifunctional enzyme with three distinct enzymatic activities: a 
RNA-dependent DNA-polymerase, a hybrid-dependent exoribonuclease (RNase H), and a 
DNA-dependent DNA polymerase.  
Oligo(dT)-primer, consisting of 12 - 18 nucleotides, specifically bind to the poly(A) tail at the 
3´-end of eukaryotic messenger RNA (mRNA). The complementary DNA-strand is 
synthesised by the reverse transcriptase in 5´ 3´direction. Additional short random primers 
with different sequences bind statistically to the template mRNA and yield a pool of cDNA 
with different lengths. After the synthesis of the first cDNA strand, the RNase H activity of 
reverse transcriptase degrades the RNA in RNA:DNA hybrids and replaces it with a second 
cDNA strand (Qiagen, 2009a). A schematic depiction of the reverse transcription process is 
given in figure 46. 
 
Figure 46: Schematic depiction of reverse transcriptase (QuantiTect® Reverse Transcriptase 
Handbook) 
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The reverse transcription is performed using the QuantiTect® Reverse Transcription Kit 
(Qiagen) according the QuantiTect® Reverse Transcription Handbook-Protocol: “Reverse 
Transcription with Elimination of Genomic DNA for Quantitative, Real-Time PCR”. 
Procedure 
• Total RNA, gDNA Wipeout Buffer, Quantiscript Reverse Transcriptase, Quantiscript 
RT Buffer, RT Primer Mix and RNase-free water are thawed on ice. Each solution is 
mixed by flicking the tube and briefly centrifuged to collect residual liquid from the 
sides and lid of the tubes. 
• The genomic DNA elimination reaction mix is prepared on ice. For this purpose 
500 ng of the isolated RNA are diluted with RNase-free water up to a volume of 6 µl 
and 1 µl gDNA Wipeout Buffer is added.  
• The samples are incubated at 42°C for 2 minutes and put on ice immediately. 
• 3 µl Master Mix are added, consisting of 2 µl 5x Quantiscript RT Buffer, 0.5 µl 
Quantiscript Reverse Transcriptase and 0.5 µl RT Primer Mix. Prior addition the 
Master Mix is stored on ice.  
• Then the samples are incubated for 15 minutes at 42°C, followed by 3 minutes at 
95°C to inactivate the Quantiscript Reverse Transcriptase. 
• The obtained cDNA is stored on ice, respectively at -20°C or -80°C for long term 
storage.  
Reagents 
• 7x gDNA Wipeout Buffer 
• Quantiscript Reverse Transcriptase 
• 5x Quantiscript RT Buffer 
• RT-Primer Mix 
6.4.5. Real Time PCR 
The polymerase chain reaction (PCR) is used to amplify gene specific DNA. The enzyme 
performing this reaction is the Taq polymerase, originally isolated from the bacteria Thermus 
aquaticus. The PCR is performed using the QuantiTect® SYBR Green PCR Kit, consisting of 
2x QuantiTect SYBR Green PCR Master Mix, the respective cDNA templates and gene 
specific primers (QuantiTect Primer Assays) (Qiagen, 2009b). 
A typical PCR-run is a cyclic process consisting of three different temperature steps which 
are repeated about 40 times. The reaction is started with a temperature increase to 92 - 98°C 
for about 5 - 10 minutes. As a consequence of this, the double-stranded DNA is denatured 
into single strands (figure 47 A), a requirement for the annealing of gene-specific primers. As 
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the DNA-polymerase is only able to amplify double-stranded DNA with a free 3´OH-end, the 
addition of DNA-fragments of about 20 nucleotides (known as primers) is required. This step 
is known as primer annealing (figure 47 B), achieved by cooling down the reaction to a 
temperature defined by the melting temperature of the primers. The oligonucleotides or 
primers bind to the single-stranded DNA. Thereafter the temperature is increased to 72°C, 
creating optimal conditions for the Taq-DNA-polymerase activity. The extension of the 
primers is now performed, yielding double-stranded DNA which is used as template for the 
next PCR-cycle (figure 47 C). After the extension step the newly formed DNA is denatured 
into two single strands at 92 - 95°C and a new PCR-cycle is started (Lottspeich, 2006; 
Mülhardt, 2009). 
 
Figure 47: Mechanism of the polymerase chain reaction (PCR) (http://www.fsbio-hannover.de) 
Procedure 
• The template cDNA, 2x QuantiTect SYBR Green PCR Master Mix and the primers 
are thawed on ice and the individual solutions are mixed by vortexing.  
• Then the reaction mix is prepared according to table 11. 
• The reaction mix for one PCR determination is multiplied by the number of replicates, 
whereas the final reaction mix contains at least three reaction volumes in excess. 
Two excess reaction volumes are required for the no template controls and one to 
compensate the loss of volume due to pipetting.  
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Table 11: Reaction setup for the qRT-PCR 
component volume [µl] 
2x QuantiTect SYBR Green PCR Master Mix 10 
QuantiTect Primer Assay  2 
RNase free water 7 
total reaction volume 19 
 
• The primer assays used for the PCR are CYP1A1 (QuantiTect® Primer Assay, 
HS_CYP1A1_1_SG) and AhR (QuantiTect® Primer Assay, HS_AHR_2_SG) as target 
genes and ß-actin (QuantiTect® Primer Assay, HS_ACTB_1_SG) as reference or 
endogenous control gene. 
• The cDNA is diluted 1:2 by adding 10 µl RNase free water to 10 µl of the template 
solution. The concentration of the cDNA is estimated with 500 ng/10 µl, assuming that 
the efficiency of reverse transcription is 100%. Consequently the cDNA content of the 
diluted solution is estimated with 25 ng/µl. 
• To each well of a 96-well PCR plate (MicroAmp® Optical 96-well Reaction Plate, 
Applied Biosystems) 19 µl of the reaction mix are dispensed and 1 µl of the diluted 
cDNA (~ 25 ng cDNA) is added. The determination of mRNA amount for each gene 
per sample is performed in duplicates respectively triplicates. Then the PCR plate is 
sealed with foil (MicroAmp® 96-well Optical Adhesive Film, Applied Biosystems). To 
remove any air bubbles the plate is centrifuged at 1000 x g for 5 minutes at room 
temperature.  
• The PCR is performed with the StepOne PlusTM Instrument (96 wells, Applied 
Biosystems). Fluorescence is detected and quantified using the StepOneTM Software 
(version 2.1, © 2009 Applied Biosystems). Prior the PCR-run, the plate setup and run 
method are programmed (table 12). 
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Table 12: Real time PCR conditions of the QuantiTect SybrGreen protocol 
QuantiTect SybrGreen 
Experiment 
Properties StepOne Plus™ Instrument (96 wells) 
 Quantitation- Comparative CT (∆∆CT) 
 SYBR® Green Reagents 
 Standard (~ 2 h to complete a run) 
Run Method Holding Stage Step 1: 100% 95°C 15:00 
 Cycling Stage Step 1: 100% 94°C 00:15 
  Step 2: 100% 55°C 00:30 
  Step 3: 100% 72°C 00:30 
 Melt Curve Stage Step 1: 100% 95°C 00:15 
  Step 2: 100% 60°C 01:00 
    Step 3: +0,5°C 94°C 00:15 
 Numbers of cycles 40  
 Reaction volume [µl] 20  
Plate Setup Endogenous Control ß-Actin  
 Dye as Passive Reference ROX  
Quantification using the ∆∆CT-method 
The amount of amplicons is detected at the end of each PCR-cycle by measuring the 
fluorescence in the sample, enabled by the fluorescent dye SYBR Green I, which binds to all 
double-stranded DNA molecules present in the PCR reaction mix. The excitation and 
emission maxima of SYBR Green I are at 494 nm and 521 nm, respectively. At the end of the 
PCR-amplification melting curve analysis is performed to verify the specificity and identity of 
PCR-products. One peak is normally recorded for each analysed gene. The appearance of 
two or more peaks indicates the formation of either primer dimers and/ or other nonspecific 
contaminating products, hampering a correct quantification of PCR-products (Qiagen, 
2009b). 
The real time amplification curves displays an exponential increase in fluorescence signal, 
necessary for the definition of a threshold for a constant fluorescence signal. For every 
amplification curve a threshold cycle (CT-value) is assigned, which indicates the number of 
PCR-cycles necessary to reach this constant fluorescence signal (Pfaffl, 2004). The relative 
quantification of the formed transcripts is performed according the ΔΔCT-method. Relative 
quantification is based on the expression levels of a target gene versus one or more 
reference genes. For the ΔΔCT calculation to be valid, the amplification efficiencies of the 
target and reference must be approximately equal (Livak & Schmittgen, 2001).  
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For relative quantification the amount for transcripts of the target gene is normalised with the 
amount of a non-regulated housekeeping gene such as β-actin, which is also used in the 
present work (A). An advantage of this method is the diminishment of variability in the 
expression results, due to tissue and matrix effects, different RNA isolation efficiencies and 
disturbances during the reverse transcription affecting the target as well as the housekeeping 
gene. Furthermore the relative transcription of a target gene in a sample, treated with the test 
compound, is related to an untreated control sample (B). The ratio for transcription is 
calculated according to C: 
A. ΔCT = CT (target gene) - CT (housekeeping gene) 
B. ΔΔCT = ΔCT (treated sample) – ΔCT (control sample) 
C. Ratio = 2 –ΔΔCT 
Data representation  
The arithmetic mean and the standard deviation of CYP1A1 and AhR relative quantities (RQ) 
are calculated using the values of all replicate experiments. For the identification and 
rejection of outliers the Nalimov test is applied. The procedure and used formulas are 
explained previously in chapter 6.2 "Sulforhodamine B (SRB) Assay".  
To assign significant differences between AME- and AOH- as well as solvent (1% DMSO) 
treated cells, the Student´s t-test is applied. Instead of using relative quantities, ΔCT-values 
are used for the calculation. The respective ΔCT-values of CYP1A1 and AhR relative 
quantities, already identified as outliers, are not used for the t-test. The calculation of the 
student´s t-test is performed using the function "TTEST" in Microsoft Excel 2007®. ΔCT-
values of 1% DMSO-treated cells are used as reference point and denoted as matrix 1, cells 
incubated with varying concentrations of the test substances as matrix 2.  
=TTEST(Matrix1;Matrix2;2;2) 
If the result of the t-test is smaller than the p-level, a significant difference is given. The 
smaller the p-level, the lower the probability of a coincidentally determined difference. The 
number of stars or small letters depicted in the graph, expresses the significance level 
(table 13).  
Table 13: Depiction of significance levels in the graphs 
p-level assignment 
p<0.001 *** c 
p<0.01 ** b 
p<0.1 * a 
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Reagents 
2x QuanitTect SYBR Green PCR Master Mix 
HotStar Taq DNA-Polymerase, QuantiTect SYBR Green PCR Buffer, SYBR Green I, ROX 
passive reference dye 
10x QuantiTect Primer Assay 
For reconstitution the vial is briefly centrifuged, 1.1 ml TE-buffer, pH 8.0 (10 mM Tris, pH 8.0 
with conc. HCl, 1 mM EDTA) are added and mixed by vortexing. The reconstituted assay is 
frozen in aliquots of 100 µl at -20°C until use. 
• CYP1A1 Primer Assay: QuantiTect® Primer Assay, HS_CYP1A1_1_SG, Qiagen, 
Lot no: 99640626 
• AhR Primer Assay: QuantiTect® Primer Assay, HS_AHR_2_SG, Qiagen, 
Lot no: 99640627 
• β-Actin Primer Assay: QuantiTect® Primer Assay, HS_ACTB_1_SG, Qiagen, 
Lot no: 97338266 
Additional materials 
• template cDNA 
• RNase free water 
6.5. Western Blot Analysis of the Aryl Hydrocarbon Receptor 
Western Blot analysis consists of two major steps: first, the proteins are separated in an 
acrylamide gel by electrophoresis and second, thereafter they are transferred onto a 
membrane and detected by immune-detection. Electrophoresis is defined as the migration of 
charged particles in a uniformly charged electric field. In the electric field an accelerating 
force is applied on to charged particles, also known as field strength. The molecule moves to 
the opposite charged electrode, the resulting friction has a decelerating effect. This means, 
that the velocity of charged molecules is directly proportional to the field strength and their 
own charge, but inversely proportional to their radius and the viscosity of the surrounding 
medium. The separation occurs due to their different sizes and charges (Lottspeich, 2006). 
SDS-PAGE  
The purpose of SDS-PAGE (sodium dodecly sulphate polyacrylamide gel electrophoresis) is 
to separate proteins according to their size, and no other physical feature. In most proteins 
the binding of SDS to the polypeptide chains imparts an even distribution of charge per unit 
mass. The anionic detergent SDS (figure 48) covers the individual charge of single amino 
acids of a protein, thus creating a uniformly negative charged protein.  
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The addition of ß-mercaptoethanol causes the cleavage of disulfide bonds. Heating a protein 
together with SDS and ß-mercaptoethanol disintegrates its secondary and tertiary structure, 
yielding a mix of negatively charged polypeptide chains with a charge directly proportional to 
the size of the molecule (Lottspeich, 2006). 
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Figure 48: Structure of sodium dodecyl sulphate (SDS) 
Disc (Discontinuous) Zone Electrophoresis  
Discontinuous zone electrophoresis is the standard technique employed nowadays for the 
analysis of proteins. This technique permits a focusing of proteins in sharp bands, 
simultaneously counteracting the stacking of proteins and providing higher resolution than 
conventional electrophoresis. To implement the mentioned advantages, two different types of 
gels are used: a small mashed resolving gel and a highly porous stacking gel, both gels differ 
in their pH-value. Disc electrophoresis is also marked by the use of different types of charge 
carriers: the amino acid glycin as the main charge carrier in the electrophoresis buffer, and 
the chloride ions, that are prevalent in sample and gel. The chloride ions (fast and leading 
electrolyte) move with a high velocity creating an anion gradient in the gel. When glycine ions 
migrate into the stacking gel, their velocity is very low because the pH of 6.8 is close to the 
isoelectric point (IEP) of glycine (terminating electrolyte). The protein molecules align 
themselves between the fast chloride ions and the slow glycine ions, leading to the formation 
of stacks of proteins at the boundary of the stacking and resolving gel. As soon as the 
proteins enter the smaller mashed resolving gel at pH of 8.8, the glycine ions dissociate 
completely and move faster. They overtake the proteins, which are now the charge carriers, 
and get separated according to their size (Lottspeich, 2006). 
Blotting 
Immune-detection is a sensitive technique, which relies on the specificity of antibodies (Ab) 
to bind to single protein spots. In order to make the proteins accessible to antibody detection, 
they are transferred from within the acrylamide gel onto a nitrocellulose membrane. The 
membrane is placed between the gel and the anode and a stack of filter papers is placed on 
top of that. The entire stack is placed in a buffer solution and due to hydrophobic interactions 
the proteins get bound to the membrane. Specific antibodies are used to identify the proteins. 
To avoid non-specific binding of antibodies to the membrane, the binding sites are blocked 
with blocking reagent containing a dilute solution of protein, usually bovine serum albumin or 
non-fat dry milk. After incubation of the membrane with the primary antibody (1°Ab) the 
membrane is exposed to a secondary antibody (2°Ab), directed against a species specific 
 
101 
portion of the primary antibody. An enzyme, such as horse radish peroxidase (HRP) is linked 
to the secondary antibody, catalyzing the reaction of the respective substrate LumiGlo. The 
product formed is able to generate luminescence in correlation to the amount of protein 
(figure 49).  
 
Figure 49: Schematic depiction of immune-blotting (http://www.cellsignal.com) 
Procedure 
Preparation of Protein Samples 
• The cell culture medium of siRNA-transfected KYSE510 cells is aspirated and the 
cells are rinsed with 500 µl pre-warmed PBS per well. The previous transfection 
procedure is described in chapter 6.3 "Gene Silencing by using siRNA".  
• The protein isolation is performed on ice. To each well 70 µl Laemmli buffer or RIPA-
buffer, respectively are added and the cells are scraped of the plate-surface with the 
tip of the pipette. Then the cell lysate is transferred into a 1.5 ml reaction tube.  
• Subsequently the protein samples are denatured at 95°C for 6 minutes in a heating 
block and sonificated for 1 minute.  
• The obtained protein samples are stored at -20°C until required for electrophoresis. 
Before use all protein samples are heated for 6 minutes at 95°C.  
Preparation of the Resolving and Stacking Gel  
• The glass plates are degreased using 70% (v/v) ethanol and the gel caster is built up. 
• At first the resolving gel is prepared first in a 15 ml tube according to table 14. The 
addition of APS (ammonium peroxide sulphate) as radical initiator and TEMED 
(N,N,N´,N´- tetramethylethylendiamine) as cross linking reagent is done shortly before 
filling the solution between two glass plates, separated by two spacers.  
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• Then the resolving gel is covered with a layer of n-butanol, causing the top of the gel 
to form a smooth surface. The gel polymerises at room temperature for about 
30 minutes. 
• Next, the n-butanol is removed precisely and the prepared stacking gel (table 14) is 
poured onto the resolving gel. A comb is placed into the stacking gel to create 
pockets for loading the samples. After the stacking gel is polymerised (about 
30 minutes), the comb is removed and the gel is ready for electrophoresis. 
Table 14: Preparation of the resolving and stacking gel (the volumes are calculated for two gels with 
10 cm x 8 cm) 
resolving gel (10%) stacking gel 
component volume component volume 
bidest. water 2.05 ml bidest. water. 1.2 ml 
1.5 M Tris (pH 8.8) 1.23 ml 0.5 M Tris (pH 6.8) 0.5 ml 
acrylamide (30%) 1.64 ml acrylamide (30%) 0.25 ml 
SDS (10%) 49.2 µl SDS (10%) 20 µl 
APS (10%) 24.6 µl APS (10%) 20 µl 
TEMED 2.46 µL TEMED 2 µl 
Electrophoresis 
• First the acrylamide gel is fitted into the gel chamber and filled up with 1x 
electrophoresis buffer.  
• The protein samples are heated at 95°C and centrifuged at 10,080 x g for 6 minutes.  
• Then 20 µl of each sample are filled into the gel pockets (figure 50). Each sample is 
loaded in duplicates onto the gel, whereas the exact position of each one is noted. 
Additionally 5 µl of the “SeeBlue® Plus2 Pre-Stained Standard” marker is applied to 
one of the middle gel pockets. The exterior pockets are filled with 20 µl SDS-buffer 
(1x), as due to the smile effect at the border of the SDS gels the identification of the 
correct protein size would be problematical.  
 
Figure 50: Loading the samples onto the gel  
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The electrophoresis apparatus is connected to the power supply, the voltage and current are 
set to 160 V, 1000 mA respectively and the run is performed for 1 h. 
 
Figure 51: Separation of the proteins during electrophoresis 
Protein Blotting 
• Two pieces of Whatman-paper and one nitrocellulose membrane are cut in the size of 
the acrylamide gel and equilibrated in 1x blotting buffer for 30 minutes.  
• Afterwards, a so called gel sandwich is prepared, which is shown in figure 52. The 
first piece of Whatman-paper is covered with a foam material pad and placed on the 
gray side of the cassette, which is the cathode of the transfer chamber. After the 
SDS-PAGE is completed, the gel is removed from the glass plate and transferred 
onto the pre-wet Whatman-paper. The gel is covered with the nitrocellulose 
membrane, another piece of Whatman-paper and a foam material pad. To avoid any 
air bubbles, a small cylinder is used to roll them out. The cassette is closed and 
locked with the white latch on the side. 
 
Figure 52: Schematic representation of a “wet blot” [Mini Trans Blot®- Electrophoretic Transfer Cell 
Instruction manual; BioRad] 
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• The cassette and the cooling loop are placed in the transfer tank, which is filled up to 
the mark with 1x blotting buffer. The hoses of the cooling unit are put in a beaker filled 
with ice water.  
• Then the lid is attached to the tank, the cables and the pump of the cooling unit are 
connected and the blotting is performed at 1000 mA for 1 h 15 min.  
• Upon completion of the transfer, the blotting unit is disconnected from the power 
supply, the blotting sandwich is disassembled and the membrane is removed for 
development with specific antibodies.  
Detection with Specific Antibodies 
• To block non-specific binding sites the membrane is shaken in a 5% (w/v) non-fat dry 
milk blocking reagent for 1 h at room temperature.  
• Then the membrane is cut in the middle into two pieces. Since every sample is 
applied in duplicates, every sample is present on each piece. The primary antibodies 
(AhR, which was a kind gift of Prof. C. Weiss from the Karlsruher Institute of 
Technology, KIT Germany and α-tubulin, mouse monoclonal, Santa Cruz) are diluted 
1:1000 with blocking reagent. The membrane is shrink-wrapped into a pocket filled 
with 1 ml of the diluted antibody solution and incubated over night at 4°C with 
agitation.  
• Then the membrane is washed twice with washing buffer for 10 minutes on a shaker.  
• The horse radish peroxidase (HRP) coupled secondary antibodies are diluted 1:5000 
with blocking reagent. Goat anti-rabbit IgG-HRP antibody is used for the membrane 
previously incubated with AhR-antibody and goat anti-mouse IgG-HRP is used for the 
α-tubulin incubated membrane. Then the membranes are incubated for 1 h at room 
temperature on a shaking device.  
• Then the membranes are rinsed two times with washing buffer for 10 minutes.  
• To prepare the LumiGlo® solution 2 ml Enhanced Luminol Reagent and 2 ml 
Oxidizing Reagent are mixed and each membrane is incubated for exactly 1 minute 
under agitation. A luminescence signal is emitted due to the reaction of luminol with 
hydrogen peroxide, catalysed by the horse radish peroxidase enzyme (figure 53).
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Each membrane is placed onto a tray and the detection is performed using the LAS-4000 
Image Reader (Fujifilm).  
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Figure 53: Reaction of LumiGlo® and HRP 
 
Antibodies 
• α-tubulin (B-7): mouse monoclonal, IgG2a, Santa Cruz, sc-5286, Lot no: D1808 
• goat anti-mouse: HRP-conjugated, IgG-HRP, Santa Cruz, sc-2005, Lot no: J2910 
• Anti-AhR (Aryl hydrocarbon receptor): rabbit polyclonal antibody, Enzo Life Science, 
Cat no: BML-SA210-0100 
• goat anti-rabbit, HRP-conjugated, IgG-HRP, Santa Cruz 
Reagents 
1.5 M Tris buffer 
36.4 g Tris(hydroxymethyl)-aminomethan (Tris) is dissolved in 200 ml bidest. water and the 
pH is set to 8.8. 
0.5 M Tris buffer 
12.1 g Tris (Roche) is dissolved in 200 ml bidest. water and the pH is set to 6.8. 
6x SDS buffer 
25 ml 0.5 M Tris buffer (pH 6.8) 
20 ml glycerol   Sigma-Aldrich 
620 mg SDS    Roth 
80 mg bromophenol blue  Roth 
The reagents are mixed together and dissolved in 50 ml bidest. water. Aliquots of 1 ml are 
prepared and stored at 4°C. Before use 52.6 µl ß-mercaptoethanol is added. 
10x electrophoresis buffer 
300 g glycin (2 M)  Sigma-Aldrich 
60.57 g Tris (250mM)  Roche 
1% SDS (20 g)  Roth 
The reagents are dissolved in 2 l bidest. water and the pH is set to 8.3.   
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40x blotting buffer 
234 g glycin    Sigma-Aldrich 
466 g Tris   Roche 
29.6 g SDS   Roth 
The reagents are dissolved in 2 l bidest. water. 
2x blotting buffer 
2.9 l bidest. water and 2 l methanol (Sigma-Aldrich) are filled into a 5 l volumetric flask. 
250 ml 40x blotting buffer are added and filled up with bidest. water. 
10x Tris buffered saline with Tween-20 (10x TBST) 
48.5 g Tris (200 mM)  Roche 
160.1 g NaCl (1.37 M) Roth 
Both reagents are dissolved and the pH is set to 7.5. 20 ml Tween-20 (1%(v/v), Sigma-
Aldrich) is added and filled up to 2 l with bidest. water. 
Blocking reagent 
5 g non-fat dry milk (5% (v/v), Roth) is dissolved in 1x TBST. 
20x Tris buffered saline (20x TBS buffer) 
96.6 g Tris (400 mM)  Roche 
303.9 g NaCl (2.6 M)  Roth 
The substances are dissolved in bidest. water, the pH of the solution is set to 7.6 and filled 
up to 2 l. 
Washing buffer 
250 ml 20x TBS buffer 
15 ml Tween-20 (0.3%) Sigma-Aldrich 
The reagents are mixed together and filled up to 5 l with bidest.water. 
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6.6. Glutathione-S-Transferase (GST) Enzyme Activity 
The enzyme family of glutathione-S-transferases plays an important role in the detoxification 
of xenobiotics. GST enzymes catalyse the transfer of the thiol group of reduced glutathione 
to electrophilic molecules. In the course of this process, a lot of substances are converted to 
more hydrophilic metabolites, encompassing a better excretion (Volz, 2010). 
The detection of GST enzyme activity is based on the GST-catalysed reaction of reduced 
glutathione (GSH) with 1-chloro-2,4-dinitrobenzene (CDNB) (figure 54). The formation of the 
corresponding thiolether conjugate is proportional to the enzyme activity. The formed product 
is determined photometrically at an absorption maximum of 340 nm. With this method the 
enzyme activity of all GST isoforms in the cytosol is detected (Immun Diagnostic, 2007). 
Cl
NO2
NO2
SG
NO2
NO2
+ GSH
GST
+ HCl
CDNB 2,4-Dinitrobenzyl-GSH  
Figure 54: Reaction of 1-chloro-2,4-dinitrobenzene (CDNB) with glutathione (GSH), catalysed by 
glutathione-S-transferase enzymes (GST) 
6.6.1. Procedure 
Seeding Cells and Incubation of Cells 
1.2*106 HT29 or 3*106 HepG2 cells are seeded per Petri dish (d = 10 cm) using 10 ml DMEM 
medium and RPMI 1640 medium, respectively supplemented with 10% (v/v) heat inactivated 
FBS and 1% (v/v) P/S. The cells are grown for 48 h and 72 h, respectively at 37°C, 5% CO2 
and 95% relative humidity in the incubator. 
The test substances are dissolved in DMSO and bidest. water, respectively; dilutions of 
1:100 with cell culture medium (containing 10% (v/v) FBS and 1% (v/v) P/S) yield incubation 
solutions with a final concentration of 1% DMSO and 1% bidest. water. The depleted cell 
culture medium is aspirated and each dish is rinsed with 5 ml pre-warmed PBS. After 
removing the washing solution the cells are treated with 5 ml of the designated chemicals in 
the appropriate concentration for 24 h, 16 h, 9 h and 1 h. An incubation solution, containing 
1% DMSO or 1% bidest. water, are used as solvent controls.  
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Sample Preparation 
• After 24 h incubation time the cell culture medium is removed and the dish is rinsed 
with pre-warmed PBS. 
• To each dish 1 ml trypsin solution is added and incubated for 2.5 minutes in the 
incubator. Then the cells are detached by slightly clapping the dish at the edge of a 
desk and the trypsin reaction is inhibited by adding 1 ml cell culture medium 
(containing 10% (v/v) FBS and 1% (v/v) P/S). 
• The cells are rinsed carefully from the surface and the suspension is transferred into 
a 15 ml test tube. Additionally the dish is rinsed with 1 ml cell culture medium.  
• 2 ml of the cell suspension is transferred into a 2 ml test tube and centrifuged at 
500 x g at 4°C for 10 minutes.  
• The cell culture medium is discarded, 1 ml PBS is added, the cell pellet is re-
suspended and the test tube is centrifuged at 500 x g at 4°C for additional 
10 minutes. 
• The PBS is removed and the cell pellet is lysed in the biofreezer at -80°C overnight.  
• Before starting with the GST assay, the cell pellet is thawed on ice and re-suspended 
in 500 µl potassium phosphate buffer. For proper cell disruption the lysate is passed 
15 times through a blunt 20-gauge needle (0.9 mm diameter), fitted to a 1 ml RNase 
free syringe. The lysate is centrifuged for 10 minutes at 1000 x g and 4°C. The 
supernatant is transferred into a new 1.5 ml test tube and used for the GST assay.  
Substrate Conversion 
• 700 µl potassium phosphate buffer, 40 µl GSH-solution and 40 µl supernatant are 
incubated at 37°C for 5 minutes under shaking (300 rpm).  
• 20 µl CDNB-solution is added, mixed by vortexing and 3 x 200 µl of the solution are 
pipetted into the wells of a 96-well plate. This step is accomplished in the dark, as the 
CDNB-solution is extremely light sensitive.  
• The plate is transferred into the VICTOR3V 1420 plate reader (Multilabel counter, 
Perkin Elmer) and the Wallac 1420 (version 3.0, revision 4) software is started. The 
absorption is monitored at 340 nm for 8 minutes, whereas a measurement is 
performed every 20 seconds.  
• The volume of supernatant used for the assay depends on the absorbance values 
obtained. Absorbance values higher than 2.0 at the end of the reaction time are 
avoided, because the linearity according to Beer-Lambert´s law is not granted any 
more. Using less supernatant means, that the volume of potassium phosphate buffer 
has to be adjusted, so that after the addition of CDNB-solution the total volume of the 
reaction mixture yields 800 µl.  
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• To determine the absorbance of the blank, 740 µl potassium phosphate buffer and 
40 µl GSH-solution are incubated at 37°C for 5 minutes under shaking (300 rpm). The 
increase of absorbance is measured after the addition of 20 µl CDNB-solution. 
• After measuring the GST activity, the protein concentration of the supernatant is 
determined according the Bradford assay (see chapter 6.6.2 “Determination of 
Protein Concentration by Bradford)”.  
Reagents 
• 1 x PBS  see chapter 6.1.6 “Cell Counting”  
• trypsin solution  see chapter 6.1.6 “Cell Counting”  
Potassium Phosphate Buffer 
50 ml 100 mM K2HPO4 (Roth) solution is prepared and the pH is adjusted to 7.4 by addition 
of 100 mM KH2PO4 (Roth) solution. 
GSH-solution 
20 mM reduced glutathione (GSH, Sigma-Aldrich) is dissolved in potassium phosphate 
buffer. For each analysis a fresh solution is prepared and stored on ice.  
CDNB-solution 
40 mM CDNB (Sigma-Aldrich) is dissolved in ethanol (96% v/v, Roth). Each time a fresh 
solution is prepared and due to the limited solubility of CDNB it is sonicated briefly. The light 
sensitive solution is stored in a black 1.5 ml test tube at room temperature.  
Calculating GST activity 
The calculation of the GST activity is demonstrated using the experiment performed on the 
17/09/2011 with 1 µM AME. For calculating GST enzyme activity the measured absorbance 
is plotted against the time (table 15). The obtained absorbance values in the interval between 
the 1st and the 5th minute are used for calculating the slope, because linearity is granted in 
that range. 
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Table 15: Determined absorbance vs. time for 1 µM AME (recorded on the 17/09/2011) 
time [min] ABS 
0.38 0.931 
0.65 0.987 
0.92 1.043 
1.19 1.096 
1.46 1.149 
1.72 1.197 
1.99 1.247 
2.26 1.295 
2.53 1.340 
2.80 1.385 
3.07 1.428 
3.34 1.470 
3.61 1.514 
3.88 1.552 
4.15 1.594 
 
time [min] ABS 
4.42 1.630 
4.68 1.668 
4.95 1.701 
5.22 1.743 
5.49 1.781 
5.76 1.814 
6.03 1.848 
6.30 1.875 
6.57 1.914 
6.84 1.951 
7.11 1.979 
7.38 2.013 
7.64 2.026 
7.91 2.071 
8.18 2.108 
The absorbance values used for the calculation of the slope [ΔA340/min] are grey shaded in 
table 15. The plot of the recorded absorbance versus time confirms the linearity in the range 
which is used for further calculations (figure 55). 
 
 
Figure 55: (A ) Plot of absorbance vs. time of the 1 µM AME-sample, measurement recorded on the 
17/09/2011, (B) the linear range between the 1st and the 5th minute is used for the 
calculation of the slope  
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Each absorbance determination is performed in triplicates, hence the slopes are determined 
independently three times and the arithmetic mean value is calculated. 
• [ΔA340/min]1 = 0.1589 
• [ΔA340/min]2 = 0.1586 
• [ΔA340/min]3 = 0.1588 
1588.0
3
1588.01586.01589.0min]/[
3
1)(
3
1
340 =
++
=∆=− ∑
=i
AactivityGSTmeanArithmetic  
The background absorbance elicited by the solvent, is determined by measuring a blank 
solution. The slope obtained for the blank is subtracted from the arithmetic mean value of the 
sample slope and the result is used for further calculations. 
• [ΔA340/min]blank = 0.0530 
1058.00530.01588.0min]/[min]/[ 340340 =−=∆−∆ blankSample AA  
The GST activity is calculated by applying Beer-Lambert´s law.  
Following parameters are used for the calculation: 
• absorption coefficient of the GST-CDNB-conjugate at λ = 340 nm: ε = 9,6 mM-1cm-1 
• path length in the Victor V3 plate reader for the 96-well plate: d = 0,45 cm 
The dilution factor (df) is the ratio of total sample volume and the used volume of the cytosol: 
• V (sample) = 800 µl 
• V (cytosol) = 20 µl 
40
20
800
===
V
V
Cytosole
Sampledf  
11
340
min**9799,040*
45,0*6,9
1058,0
*
*
min]/[
−−==
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mlµmolactivityGST
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d
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The activity of glutathione-S-transferases depends on the protein amount used for the 
analysis. Therefore GST activity is related to the protein concentration. The factor of 1000 is 
used for the conversion of µmol to nmol. 
• protein concentration = 3.74 mg/ml 
1
Pr
1 **01.2621000*
74.3
9799.0 −−== oteinmgmlnmolactivityGST  
Double determination of the absorbance values is performed with every sample, hence 
arithmetic mean values of both measurements are calculated. 
1
Pr
1
2
1
**97.273
2
94.28501.262.)(
2
1)1( −−
=
=
+
=−= ∑ otein
i
mgmlnmolactGSTAMEµMactivityGST
Since GST activity expressed in [nmol x ml-1 x mgprotein-1] represents absolute values, 
comparison of individual measurements is subjected to high variations. Furthermore, 
fluctuating absorbance background values due to individual lamp and spectrophotometer 
performances, are not taken into account. Therefore, the expression of test over control 
values (T/C) [%] is considered to be the better option.  
%32.99100*
68.271
82.269100*
)]%1.([.
)%1()%1(/ ===
DMSOactGSTmeanarith
DMSOactivityGSTDMSOCT  
Calculated GST activity of samples is compared with solvent control-treated cells (1%, 0.1% 
DMSO and 1% bidest. water, respectively), facilitating following correlation:   
%84.100100*
68.271
97.273100*
)]%1.([.
)1()1(/ ===
DMSOactGSTmeanarith
AMEµMactivityGSTAMEµMCT
 
 
Student´s t-test is applied to assign significant differences between sample and solvent 
control-treated cells. The application of the "TTEST" function in Microsoft Excel 2007® is 
already described in chapter 6.4.5 "Real Time PCR". Solvent control cells are again used as 
reference point and designated as "Matrix 1", whereas cells incubated with diverse test 
substances are used as "Matrix 2". 
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6.6.2. Determination of Protein Concentration by Bradford 
The method according to Bradford (1976) allows the detection of protein amounts as low as 
0.5 µg. The dye Coomassie Brilliant Blue G-250 binds to basic amino acids under acidic 
conditions. Due to the formation of complexes, the absorbance maximum is shifted from 
465 nm to 595 nm. A standard curve is necessary for the determination of the protein 
concentration. The protein used for the calibration should exhibit the same amount of basic 
amino acids as the unknown protein (Lottspeich, 2006). 
Bovine serum albumin (BSA standard solution, 2 mg/ml) is used for calibration in the range 
of 0.2 - 1.6 mg/ml. A standard curve is obtained after plotting the standard concentration 
versus the corresponding absorption values. The protein concentration is determined after 
subtraction of the blank value (potassium phosphate buffer) using the linear regression 
standard curve.   
Procedure 
10 µl of the BSA standard solution, potassium phosphate buffer or diluted supernatant are 
added to 1 ml Bradford reagent and mixed by vortexing. The appropriate dilution factor of the 
supernatant is a consequence of the obtained absorption values, which should be in the 
middle range of the standard curve. Thus a reliable protein concentration is assured.  
3 x 200 µl of every solution are pipetted into a 96-well plate, transferred to the VICTOR3V 
1420 plate reader (Multilabel counter, Perkin Elmer) and the absorption is determined 
photometrically at 595 nm.  
Reagents 
Bradford reagent 
100 mg Coomassie Brillant Blue G-250  Roth 
50 ml 96% v/v ethanol   Roth 
100 ml 85% v/v phosphoric acid   Sigma-Aldrich 
The solution is filled up to 1000 ml with bidest. water, stored in the dark for 4 weeks and 
filtered before use.   
Additional reagents 
• Bovine serum albumin (BSA) stock solution 2 mg/ml (GibcoTM, Invitrogen) 
• bidest. water 
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6.7. Materials 
Laboratory Equipment Company 
casette & firbre pads BioRad 
cover glass (24 x 24 mm) VWR 
cryo tube vials (1.8 µl) Nunc 
duran flasks (250, 500, 1000 ml) VWR/ Brand 
diverse Eppendorf pipettes  0.1-2.5  µl, 0.5-10  µl, 2-20 µl, 10-100  µl,  
 20-200 µl, 100-1000 µl 
diverse pipette tips: 2.5 µl, 10 µl, 100  µl, 200  µl, 1000 µl
 Sarstedt 
diverse pipette tips with filter  2.5  µl, 10  µl, 100  µl, 200  µl, 1000 µl
 Sarstedt 
diverse Eppendorf reaction tubes 0.2 ml, 1.5 ml, 2.0 ml 
glass plates (10 x 8 x 0.1 cm) BioRad 
haemocytometer ( 0.0025 mm2, depth 0.1 mm) Marienfeld, Germany 
micro test tube rack Brand 
needles (0.9 x 40 mm) Neolus, Terumo 
nitrocellulose membranes (pore size 0.2 µM) Schleicher & Schuell Whatman 
parafilm "M" Pechiney Plastic Packaging 
pasteur pipettes (length 230mm) Roth 
PCR-foil MicroAmp® 96-Well Optical Adhesive Film, 
 Applied Biosystems 
PCR-plates MicroAmp® Optical 96-well Reaction Plate, 
 Applied Biosystems 
syringe (1 ml) Thermo 
tissue culture flasks (25, 75, 175 cm2) Sarstedt 
tissue culture dishes (100 x 20 mm) Sarstedt 
tubes (15, 50 ml) Sarstedt 
Whatman-paper (GB005) Schleicher & Schuell Whatman 
10 well comb (1.0 mm) BioRad 
24-well tissue culture plate VWR 
96-well tissue culture plate Costar 
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Device Model Company 
analytical balance Atilon ATL-124-I Acculab 
autoclave Systec DX-150 Bartelt 
biofreezer MDF-U53V Sanyo 
centrifuge Mikro 220R V 1.02 Hettich 
 Rotina 420R Hettich 
 Mikro 200 V 1.29 Hettich 
electrophoresis power supply EV231 Peqlab 
electrophoresis unit  Mini-Protein Tetra Cell 552BR BioRad 
film sealing unit Folio Severin 
fridge Comfort Max Frost Liebherr 
incubator Hera cell 240i Thermo Scientific 
laminar Air Flow Hera Safe KS18 Thermo Scientific 
luminescence image analyser LAS-4000 Fujifilm 
magnetic stiffer IKAMAG RH64212 IKA-Labortechnik 
microscope Axiovert  40C Zeiss 
mini-centrifuge Kinetic Energy-Galaxy Mini Centrifuge VWR 
ph-meter Seven Easy Mettler Toledo 
pipetting aid  pipetus Hirschmann  
  Laborgeräte 
plate reader Victor3V 1420 Multilabel counter Perkin Elmer 
PCR Step One Plus Real-Time PCR System Applied Biosystems 
shaker Roto-Shake Genie Scientific Industries 
 Mini-Rocker MR-1 Peqlab 
spectrophotometer Nano Drop 2000c Peqlab 
suction system Vacusafe Compfort V04 & IBS Integro  
 Integra Vacuboy Biosciences 
thermo incubator Thriller Peqlab 
thermo shaker TS-100 Thermo 
thermocycler Dyad Disciple  BioRad 
transfer tank & unit Trans Blot Cell 49BR BioRad 
ultrasonic bath USC 300T VWR 
ultraviolet sterilizing PCR workstation  Peqlab  
vortex Vortex Genie 2 Scientific Industries 
 Bio Vortex V1 Peqlab 
water purification system Milli Q, Direct 8 Millipore 
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8.2. Abstract 
The Alternaria toxins alternariol (AOH) and alternariol monomethyl ether (AME) are, 
according to the EFSA, on the list of mycotoxins with an urgent need for further 
investigations of toxicity, permitting a better risk assessment for man and animal. The 
consumption of Alternaria spp. contaminated grain is associated with increased incidences of 
oesophageal cancer in Linxian, China (Liu et al., 1992). Fehr (2008) and Schreck et al. 
(2011) reported the induction of CYP1A1 by Alternaria toxins, leading to investigations 
addressing the role of the aryl hydrocarbon receptor (AhR) in AME- and AOH-mediated 
CYP1A1 induction in human oesophageal carcinoma cells (KYSE510). 
The question whether mycotoxin-induced CYP1A1 mRNA levels were AhR-dependent was 
investigated by two different approaches. Firstly, oesophageal AhR knockdown cells were 
generated by RNAi technology and were used for studying the impact of Alternaria toxins on 
CYP1A1. Secondly, the Ah-receptor of KYSE510 cells was inhibited in a pre-treatment with 
10 µM MNF prior the incubation with the Alternaria toxins.  
AOH and AME significantly induced CYP1A1 in a concentration dependent manner in AhR-
expressing cells (non-transfected and dsRNA-transfected (negative control) KYSE510) after 
24 h of incubation. Any changes in CYP1A1 transcript levels were observed at low mycotoxin 
concentrations (≤ 0.1 µM), whereas at higher concentrations (≥ 1 µM) CYP1A1 induction 
peaked by 2.5-fold for AME and 8-fold for AOH. Similar results for both cell types suggested, 
that the transfection procedure did not influence the response of KYSE510 cells towards 
AME and AOH. In AhR-suppressed (AhR-siRNA transfected) KYSE510 cells, CYP1A1 levels 
were significantly reduced after AME- as well as AOH-treatment in comparison to control 
cells, supporting the AhR-dependence of CYP1A1 induction by both mycotoxins. At high 
concentrations (10 µM AME, 50 µM AOH), CYP1A1 transcripts plummeted below the 
endogenous level, giving rise to consider the interference of a putative, yet unknown 
pathway. 
The results obtained with MNF-inhibited cells were generally in line with those of transiently 
siRNA-transfected KYSE510 cells, suggesting a crucial role of the Ah-receptor in AME-
mediated CYP1A1 induction.  
Glutathione-S-transferases (GST) are important phase II drug metabolising enzymes, 
bearing a considerable role in the detoxification of xenobiotics. After establishment and 
optimisation of the GST assay according to Habig et al. (1973), the impact of AME and AOH 
on GST activities in human colon carcinoma cells (HT29) was investigated. Only a marginal, 
yet significant increase in GST activity at high AOH concentrations (10 µM, 50 µM) was 
observed, suggesting a minor role of GST in the detoxification of both Alternaria toxins.  
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8.3. Zusammenfassung 
Die Alternaria Toxine Alternariol (AOH) und Alternariolmonomethylether (AME) wurden von 
der EFSA auf die Liste der Mykotoxine gesetzt, die noch einer weitgehenden toxikologische 
Untersuchungen bedürfen, um eine bessere Risikobewertung für Mensch und Tier zu 
ermöglichen. Der Konsum von Alternaria spp. kontaminierten Getreide wurde in Linxian, 
China in Verbindung mit Ösophaguskarzinom gebracht. In bereits veröffentlichten Daten von 
Fehr (2008) und Schreck et al. (2011) wurde die Induktion von CYP1A1 durch Alternaria 
Toxine beschrieben, was zu weiteren Untersuchungen über die Rolle des Arylhydrocarbon 
Rezeptors (AhR) in der AME- und AOH-vermittelten CYP1A1 Induktion in humanen 
Ösophagus Karzinomzellen (KYSE510) veranlasste. 
Die Frage, ob die Induktion von CYP1A1 mRNA durch Mykotoxine Ah-Rezeptor vermittelt 
abläuft, wurde in zwei verschiedene Ansätze geklärt. Zuerst wurden AhR-supprimierte 
Ösophagus Karzinomzellen mithilfe der RNAi Technologie generiert, die ein geeignetes 
Modell für die Untersuchung des Einfluss der Alternaria Toxine auf CYP1A1 Genexpression 
darstellten. Zweitens wurde der Ah-Rezeptor in KYSE510 Zellen durch eine Vorbehandlung 
mit 10 µM MNF inhibiert.  
Die signifikante Induktion von CYP1A1 in AhR-exprimierenden Zellen (nicht-transfizierte und 
dsRNA-transfizierte (Negativkontrolle) KYSE510) nach 24 h war abhängig von der 
applizierten AME- und AOH-Konzentration. Keine Änderungen der CYP1A1 Transkripte 
wurden bei geringen Mykotoxinkonzentrationen (≤ 0.1 µM) beobachtet, wobei höhere 
Konzentrationen (≥ 1 µM) eine maximale, 2.5-fache Induktion für AME und eine 8-fache 
Induktion für AOH hervor riefen. Vergleichbare Ergebnisse in beiden Zelltypen lassen auf 
keinerlei Veränderungen durch die Transfektion der KYSE510, in Hinblick auf ihre Reaktion 
auf AME und AOH, schließen. In AhR-supprimierten (AhR-siRNA transfizierten) KYSE510 
Zellen waren die CYP1A1 mRNA Level nach der Inkubation mit AME und AOH im Vergleich 
zu den Kontrollzellen signifikant erniedrigt, was für die AhR-Abhängigkeit der CYP1A1 
Induktion spricht. Das Absinken der CYP1A1 Transkripte unterhalb das endogene Level bei 
hohen Konzentrationen (10 µM AME, 50 µM AOH) lässt auf die Interferenz eines bisher 
unbekannten Signalweges vermuten.  
Die Ergebnisse die mithilfe MNF-inhibierter KYSE510 Zellen ermittelt wurden, sind generell 
in Einklang mit denen, die mit transient siRNA-transfizierten Zellen erzielt wurden und 
sprechen für eine entscheidende Rolle des Ah-Rezeptors in der AME-vermittelten CYP1A1 
Induktion. 
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Glutathion-S-Transferasen (GST) gehören zu den Phase II Enzymen und tragen einen 
beachtlichen Anteil zur Detoxifizierung von Xenobiotika bei. Nach der Etablierung und 
Optimierung des GST Assays nach Habig et al. (1973), wurde der Einfluss von AME und 
AOH auf die GST Aktivitäten in humanen Kolonkarzinomzellen (HT29) untersucht. Ein 
marginaler, aber doch signifikant erhöhter Anstieg der GST Aktivität bei hohen AOH 
Konzentrationen (10 µM, 50 µM) lässt auf einen minimalen Beitrag dieser Enzyme in der 
Detoxifizierung beider Alternaria Toxine schließen. 
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8.4. Data 
In the following all measurement values are listed, used for the representation of the graphs. 
The dates refer to the day the measurement was performed. The calculation of the 
cytotoxicity of AME determined in the SRB assay is described in chapter 6.2. 
“Sulforhodamine B (SRB) assay” in more detail. The measurement values are given in tables 
16 & 17 and represented in figure 18. Calculations of CYP1A1 & AhR relative quantities and 
the GST-activities are described in chapter 6.4.5. “Real Time PCR” and chapter 6.6. 
“Glutathione-S-Transferase (GST) Enzyme Activity”, respectively. CYP1A1 and AhR relative 
quantity (RQ)-values are given in table 18 – 34 (represented in figure 19 – 32) and GST-
activities are listed in table 35 – 52 (represented in figure 33 – 43). Outliers identified by the 
Nalimov outlier test are grey-shaded in the following tables. 
Table 16: Absorbance-values determined in the SRB assay at λ = 570 nm in KYSE510-cells, cultivated for 72 h 
and treated with AME for 24 h. 
P (passage) 12 
(2011/03/17) DMSO 0.1µM AME 1µM AME 10µM AME 
A1 1.026 1.000 0.833 0.941 
A2 1.121 0.861 0.959 1.024 
A3 0.945 0.907 0.952 0.944 
A4 1.054 0.676 0.809 0.717 
A5 1.077 0.729 0.772 0.786 
A6 1.141 0.998 0.896 1.019 
A7 0.905 0.973 0.865 0.750 
A8 0.954 0.768 0.867 0.778 
P14 (2011/03/24)  
A1 1.641 1.302 1.473 1.473 
A2 1.366 1.370 1.385 1.465 
A3 1.394 1.450 1.473 1.439 
A4 1.234 1.360 1.317 1.447 
A5 1.463 1.475 1.265 1.378 
A6 1.146 1.349 1.463 1.189 
A7 1.139 1.491 0.094 1.085 
A8 1.545 1.452 1.181 1.529 
P16 (2011/05/05)  A1 0.648 0.585 0.725 0.766 
A2 0.746 0.778 0.749 0.756 
A3 0.682 0.776 0.746 0.643 
A4 0.664 0.711 0.720 0.676 
A5 0.738 0.713 0.766 0.810 
A6 0.708 0.642 0.742 0.787 
A7 0.734 0.650 0.632 0.606 
A8 0.647 0.788 0.783 0.783 
P23 (2011/05/05) DMSO 0.1µM AME 1µM AME 10µM AME 
A1 1.148 1.176 1.036 0.859 
A2 1.034 0.953 1.096 1.156 
A3 1.063 1.148 1.127 0.568 
A4 1.022 0.903 0.824 0.888 
A5 1.064 1.138 1.080 0.957 
A6 1.151 0.794 1.144 1.185 
A7 1.093 0.886 1.044 0.968 
A8 0.991 0.941 0.844 0.454 
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P23 (2011/07/25) DMSO 0.1µM AME 1µM AME 10µM AME 
A1 0.706 0.701 0.676 0.692 
A2 0.773 0.711 0.741 0.683 
A3 0.844 0.790 0.732 0.661 
A4 0.848 0.750 0.787 0.655 
A5 0.707 0.794 0.696 0.663 
A6 0.812 0.869 0.754 0.711 
A7 0.763 0.855 0.734 0.760 
A8 0.726 0.747 0.645 0.621 
Table 17: Arithmetic mean and standard deviation (SD) of absorbance-values in KYSE510-cells. The absorbance 
values are given in table 16, whereas the grey shaded outliers are not used for the calculation of the 
arithmetic mean, depicted in figure 18 as T/C [%]. 
 DMSO 0.1µM AME 1µM AME 10µM AME T/C [%] 100 96.33 95.91 93.43 
SD 8.05 11.99 10.06 14.65 
Table 18: CYP1A1 and AhR relative quantities (RQ) in KYSE510-cells, cultivated for 24 h and treated with AME 
for 12 h. The RQ-values are depicted in figure 19 A. 
 β-Actin CYP1A1 
 CT CT Δ CT ΔΔ CT RQ P 12 (2011/07/07) 
DMSO 16.38 24.85 8.47 0.00 1.00 
0.1 µM AME 16.69 24.75 8.06 -0.41 1.33 
1 µM AME 16.71 24.55 7.84 -0.63 1.55 
10 µM AME 16.90 29.22 12.33 3.86 0.07 
5 µM BaP 16.50 20.40 3.90 -4.57 23.81 
 β-Actin AhR 
 CT CT Δ CT ΔΔ CT RQ P 12 (2011/07/07) 
DMSO 16.38 22.36 5.98 0.00 1.00 
0.1 µM AME 16.69 22.54 5.84 -0.13 1.10 
1 µM AME 16.71 22.61 5.90 -0.08 1.06 
10 µM AME 16.90 22.87 5.97 0.00 1.00 
5 µM BaP 16.50 22.48 5.98 0.00 1.00 
Table 19: CYP1A1 and AhR relative quantities in KYSE510-cells, cultivated for 24 h and treated with AME for 
6 h. The RQ-values are depicted in figure 19 B. 
 β-Actin CYP1A1 
 CT CT Δ CT ΔΔ CT RQ P 8 (2011/05/26) 
DMSO 17.64 26.74 9.10 0.00 1.00 
0.1 µM AME 18.78 27.68 8.90 -0.20 1.15 
1 µM AME 16.70 28.18 11.48 2.38 0.19 
10 µM AME 16.26 30.15 13.89 4.79 0.04 
5 µM BaP 16.88 21.17 4.29 -4.81 28.04 
 β-Actin AhR 
 CT CT Δ CT ΔΔ CT RQ P 8 (2011/05/26) 
DMSO 17.64 22.84 5.20 0.00 1.00 
0.1 µM AME 18.78 24.23 5.45 0.25 0.84 
1 µM AME 16.70 22.18 5.49 0.29 0.82 
10 µM AME 16.26 21.99 5.73 0.53 0.69 
5 µM BaP 16.88 22.38 5.50 0.30 0.81 
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Table 20: CYP1A1 and AhR relative quantities in KYSE510-cells, cultivated for 24 h and treated with AME for 
24 h. 
 β-Actin CYP1A1 
 CT CT Δ CT ΔΔ CT RQ P29_1 (2011/05/16) 
DMSO 19.84 28.07 8.22 0.00 1.00 
0.1 µM AME 19.13 27.44 8.31 0.09 0.94 
1 µM AME 18.76 27.02 8.27 0.04 0.97 
10 µM AME 18.55 29.41 10.87 2.64 0.16 
5 µM ARO 18.93 24.73 5.80 -2.42 5.37 
P29_2 (2011/05/16) 
DMSO 18.37 27.20 8.83 0.00 1.00 
0.1 µM AME 19.14 27.51 8.36 -0.47 1.38 
1 µM AME 19.42 27.82 8.40 -0.43 1.35 
10 µM AME 18.74 29.81 11.07 2.24 0.21 
5 µM ARO 20.44 26.40 5.96 -2.87 7.29 
P7 (2011/05/19) 
DMSO 16.55 24.98 8.44 0.00 1.00 
0.1 µM AME 16.46 24.78 8.31 -0.12 1.09 
1 µM AME 17.12 24.98 7.86 -0.57 1.48 
10 µM AME 16.65 28.93 12.28 3.84 0.07 
5 µM ARO 16.88 23.17 6.28 -2.15 4.45 
5 µM BaP 17.64 21.44 3.80 -4.63 24.82 
P8 (2011/05/26) 
DMSO 16.82 25.81 8.98 0.00 1.00 
0.1 µM AME 16.96 25.96 9.00 0.01 0.99 
1 µM AME 16.82 26.01 9.19 0.21 0.86 
10 µM AME 17.05 28.51 11.46 2.48 0.18 
5 µM BaP 16.95 19.54 2.59 -6.39 84.09 
P31_1 (2011/09/05) 
DMSO 16.11 25.48 9.37 0.00 1.00 
1 µM AME 15.97 24.87 8.90 -0.47 1.39 
5µM BaP 16.46 20.44 3.98 -5.40 42.18 
P31_2 (2011/09/05) 
DMSO 16.17 25.55 9.38 0.00 1.00 
1 µM AME 16.14 25.27 9.13 -0.25 1.19 
5µM BaP 16.01 19.91 3.90 -5.48 44.72 
 β-Actin AhR 
 CT CT Δ CT ΔΔ CT RQ P 29_1 (2011/05/16) 
DMSO 19,84 24,19 4,35 0,00 1,00 
0.1 µM AME 19,13 23,83 4,69 0,34 0,79 
1 µM AME 18,76 23,66 4,90 0,56 0,68 
10 µM AME 18,55 23,58 5,03 0,69 0,62 
5 µM ARO 18,93 23,96 5,02 0,67 0,63 
P29_2 (2011/05/16) 
DMSO 18,37 23,76 5,39 0,00 1,00 
0.1 µM AME 19,14 23,82 4,67 -0,72 1,64 
1 µM AME 19,42 24,32 4,89 -0,50 1,41 
10 µM AME 18,74 23,92 5,18 -0,21 1,16 
5 µM ARO 20,44 26,23 5,79 0,40 0,76 
P7 (2011/05/19) 
DMSO 16,55 22,47 5,92 0,00 1,00 
0.1 µM AME 16,46 22,63 6,16 0,24 0,84 
1 µM AME 17,12 22,74 5,62 -0,30 1,23 
10 µM AME 16,65 22,88 6,23 0,31 0,81 
5 µM ARO 16,88 22,78 5,89 -0,03 1,02 
5 µM BaP 17,64 22,84 5,20 -0,72 1,65 
P8 (2011/05/26) 
DMSO 16,82 21,97 5,14 0,00 1,00 
0.1 µM AME 16,96 22,13 5,17 0,02 0,98 
1 µM AME 16,82 22,04 5,23 0,08 0,94 
10 µM AME 17,05 22,60 5,56 0,41 0,75 
5 µM BaP 16,95 21,63 4,68 -0,46 1,38 
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 β-Actin AhR 
 CT CT Δ CT ΔΔ CT RQ P31_1 (2011/09/05) 
DMSO 16,11 22,52 6,41 0,00 1,00 
1 µM AME 15,97 22,42 6,45 0,04 0,97 
5µM BaP 16,46 22,99 6,52 0,11 0,93 
P31_2 (2011/09/05) 
DMSO 16,17 22,81 6,64 0,00 1,00 
1 µM AME 16,14 22,92 6,78 0,14 0,91 
5µM BaP 16,01 22,34 6,32 -0,32 1,25 
Table 21: Arithmetic mean and SD of CYP1A1 and AhR relative quantities in KYSE510-cells after 24 h AME-
treatment. The RQ-values are given in table 20, whereas the grey shaded outliers are not used for the 
calculation of the arithmetic mean RQ, depicted in figure 20. 
  CYP1A1 AhR 
  mean RQ SD mean RQ SD 
DMSO 1.00 0.00 1.00 0.00 
0.1µM AME 1.01 0.06 0.87 0.08 
1µM AME 1.21 0.22 1.02 0.24 
10µM AME 0.18 0.02 0.73 0.08 
5µM ARO 5.70 1.19 0.80 0.16 
5µM BaP 37.24 8.84 1.42 0.17 
Table 22: CYP1A1 and AhR relative quantities in KYSE510-cells, cultivated for 24 h and treated with AOH for 
24 h. The RQ-values are depicted in figure 21. 
 β-Actin CYP1A1 
 CT CT Δ CT ΔΔ CT RQ P29 (2011/05/10) 
DMSO 19.07 28.38 9.31 0.00 1.00 
0.1 µM AOH 17.92 25.48 7.56 -1.75 3.37 
1 µM AOH 18.84 25.80 6.95 -2.36 5.13 
10 µM AOH 18.70 29.08 10.38 1.07 0.48 
50 µM AOH 18.98 31.82 12.84 3.53 0.09 
5 µM ARO 18.46 23.79 5.33 -3.98 15.77 
 β-Actin AhR 
 CT CT Δ CT ΔΔ CT RQ P29 (2011/05/10) 
DMSO 19.07 24.75 5.69 0.00 1.00 
0.1 µM AOH 17.92 23.89 5.97 0.29 0.82 
1 µM AOH 18.84 24.21 5.37 -0.32 1.25 
10 µM AOH 18.70 24.52 5.82 0.13 0.91 
50 µM AOH 18.98 24.85 5.87 0.19 0.88 
5 µM ARO 18.46 24.05 5.59 -0.09 1.07 
Table 23: CYP1A1 and AhR RQ in KYSE510-cells, cultivated for 48 h and treated with AME for 24 h. 
 β-Actin CYP1A1 
 CT CT Δ CT ΔΔ CT RQ P 12 (2011/06/09) 
DMSO 19.46 30.41 10.94 0.00 1.00 
0.1 µM AME 19.96 30.96 11.00 0.06 0.96 
1 µM AME 19.54 29.15 9.61 -1.33 2.51 
10 µM AME 19.42 30.92 11.50 0.55 0.68 
5 µM BaP 19.55 20.63 1.09 -9.86 928.41 
P 14 (2011/06/24) 
DMSO 16.90 26.20 9.30 0.00 1.00 
0.1 µM AME 17.54 28.33 10.79 1.49 0.35 
1 µM AME 16.80 24.98 8.19 -1.11 2.16 
5 µM AME 17.00 27.22 10.22 0.92 0.53 
10 µM AME 16.96 27.67 10.71 1.42 0.37 
5 µM BaP 16.96 17.54 0.58 -8.72 420.52 
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 β-Actin CYP1A1 
 CT CT Δ CT ΔΔ CT RQ P 15 (2011/07/08) 
DMSO 16.81 26.16 9.35 0.00 1.00 
0.1 µM AME 16.92 26.68 9.76 0.41 0.75 
1 µM AME 16.89 25.19 8.30 -1.05 2.07 
5 µM AME 16.95 26.71 9.76 0.41 0.75 
10 µM AME 16.81 27.13 10.32 0.97 0.51 
5 µM BaP 17.10 18.33 1.23 -8.12 278.25 
P 20_1 (2011/07/25) 
DMSO 17.06 26.53 9.47 0.00 1.00 
0.1 µM AME 16.95 26.38 9.43 -0.05 1.03 
1 µM AME 16.94 25.14 8.20 -1.27 2.42 
5 µM AME 17.04 27.08 10.04 0.56 0.68 
10 µM AME 16.93 27.31 10.38 0.90 0.53 
5 µM BaP 17.16 18.71 1.54 -7.93 243.89 
P 20_2 (2011/08/02) 
DMSO 16.81 22.93 6.12 0.00 1.00 
0.1 µM AME 16.96 23.14 6.18 0.07 0.95 
1 µM AME 16.89 21.76 4.87 -1.25 2.38 
5 µM AME 16.83 23.27 6.44 0.33 0.80 
10 µM AME 16.61 23.24 6.63 0.52 0.70 
5 µM BaP 16.91 14.85 -2.05 -8.17 288.11 
 β-Actin AhR 
 CT CT Δ CT ΔΔ CT RQ P 12 (2011/06/20) 
DMSO 19.23 24.34 5.11 0.00 1.00 
0.1 µM AME 19.87 24.64 4.77 -0.34 1.27 
1 µM AME 19.32 24.40 5.08 -0.03 1.02 
10 µM AME 19.18 24.17 4.99 -0.12 1.09 
5 µM BaP 19.33 23.73 4.39 -0.72 1.65 
P 14 (2011/06/27) 
DMSO 16.87 21.81 4.94 0.00 1.00 
0.1 µM AME 17.52 22.49 4.98 0.04 0.97 
1 µM AME 16.72 21.87 5.15 0.21 0.86 
5 µM AME 16.87 21.95 5.07 0.14 0.91 
10 µM AME 16.98 21.89 4.91 -0.03 1.02 
5 µM BaP 17.00 21.04 4.03 -0.91 1.87 
P 15 (2011/07/08) 
DMSO 16.99 22.32 5.33 0.00 1.00 
0.1 µM AME 17.14 22.59 5.45 0.12 0.92 
1 µM AME 17.09 22.42 5.33 0.00 1.00 
5 µM AME 17.22 22.52 5.29 -0.04 1.03 
10 µM AME 16.99 22.35 5.35 0.02 0.98 
5 µM BaP 17.36 21.68 4.32 -1.01 2.01 
P 20_1 (2011/08/03) 
DMSO 16.97 22.35 5.38 0.00 1.00 
0.1 µM AME 16.85 22.42 5.57 0.19 0.88 
1 µM AME 16.92 22.30 5.38 0.00 1.00 
5 µM AME 17.01 22.39 5.37 -0.01 1.01 
10 µM AME 16.84 22.21 5.37 -0.01 1.01 
5 µM BaP 17.12 21.68 4.56 -0.82 1.76 
P 20_2 (2011/08/03) 
DMSO 16.69 21.72 5.04 0.00 1.00 
0.1 µM AME 16.91 21.71 4.80 -0.23 1.18 
1 µM AME 16.80 21.67 4.86 -0.17 1.13 
5 µM AME 16.85 21.64 4.79 -0.25 1.19 
10 µM AME 16.58 21.53 4.96 -0.08 1.06 
5 µM BaP 16.79 20.92 4.13 -0.91 1.88 
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Table 24: Arithmetic mean and SD of CYP1A1 and AhR relative quantities in KYSE510-cells after 24 h AME-
treatment. The RQ-values are given in table 23, whereas the grey shaded outliers are not used for the 
calculation of the arithmetic mean RQ, depicted in figure 23. 
 CYP1A1  AhR  
 mean RQ SD mean RQ SD DMSO 1.00 0.00 1.00 0.00 
0.1µM AME 0.98 0.04 1.04 0.15 
1µM AME 2.28 0.20 1.00 0.08 
10µM AME 0.74 0.05 1.03 0.10 
5µM ARO 0.61 0.08 1.03 0.04 
5µM BaP 270.08 18.96 1.83 0.12 
Table 25: CYP1A1 and AhR RQ in KYSE510-cells, cultivated for 48 h and treated with AOH for 24 h.  
 β-Actin CYP1A1 
 CT CT Δ CT ΔΔ CT RQ P20_1 (2011/08/08) 
DMSO 16.37 26.06 9.69 0.00 1.00 
0.1 µM AOH 16.50 24.95 8.45 -1.24 2.37 
1 µM AOH 16.59 23.29 6.70 -2.99 7.95 
10 µM AOH 16.89 24.15 7.26 -2.44 5.41 
50 µM AOH 17.25 27.52 10.27 0.58 0.67 
5 µM BaP 17.10 18.53 1.43 -8.26 306.38 
P20_2 (2011/08/08) 
DMSO 16.80 26.63 9.83 0.00 1.00 
0.1 µM AOH 16.79 25.26 8.47 -1.36 2.57 
1 µM AOH 16.82 23.71 6.89 -2.94 7.68 
10 µM AOH 17.06 24.78 7.72 -2.11 4.32 
50 µM AOH 16.98 27.19 10.21 0.38 0.77 
5 µM BaP 17.42 19.13 1.71 -8.13 279.19 
P23 (2011/08/22) 
DMSO 16.57 27.55 10.98 0.00 1.00 
0.1 µM AOH 16.52 27.51 10.99 0.01 0.99 
1 µM AOH 16.68 24.33 7.65 -3.33 10.06 
10 µM AOH 16.96 24.00 7.04 -3.94 15.37 
50 µM AOH 16.68 26.11 9.43 -1.55 2.92 
5 µM BaP 16.85 17.94 1.09 -9.89 947.27 
P24_1 (2011/08/09) 
DMSO 17.13 28.54 11.41 0.00 1.00 
0.1 µM AOH 17.68 28.34 10.66 -0.75 1.68 
1 µM AOH 17.20 24.30 7.10 -4.31 19.78 
10 µM AOH 17.22 25.13 7.91 -3.50 11.32 
50 µM AOH 16.66 28.04 11.37 -0.04 1.03 
5 µM BaP 17.25 18.41 1.16 -10.25 1214.41 
P24_2 (2011/08/17) 
DMSO 17.44 28.38 10.93 0.00 1.00 
0.1 µM AOH 17.36 27.74 10.38 -0.55 1.47 
1 µM AOH 17.14 23.63 6.50 -4.44 21.65 
5 µM AOH 17.31 23.75 6.45 -4.48 22.38 
10 µM AOH 17.55 25.32 7.78 -3.16 8.92 
5 µM BaP 17.57 18.37 0.80 -10.13 1119.61 
P27 (2011/08/17) 
DMSO 16.83 26.20 9.37 0.00 1.00 
0.1 µM AOH 16.88 25.05 8.18 -1.19 2.28 
1 µM AOH 16.95 23.26 6.31 -3.05 8.31 
10 µM AOH 16.72 23.65 6.93 -2.43 5.41 
50 µM AOH 16.43 27.18 10.75 1.38 0.38 
5 µM BaP 16.92 18.48 1.55 -7.82 225.34 
P32 (2011/08/31) 
DMSO 16.90 26.68 9.78 0.00 1.00 
0.1 µM AOH 16.93 25.06 8.13 -1.64 3.12 
1 µM AOH 16.92 23.82 6.90 -2.88 7.34 
10 µM AOH 17.03 27.33 10.31 0.53 0.69 
50 µM AOH 16.69 28.12 11.42 1.65 0.32 
5 µM BaP 17.03 18.52 1.49 -8.28 311.82 
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 β-Actin AhR 
 CT CT Δ CT ΔΔ CT RQ P31 (2011/09/02) 
DMSO 17.41 26.82 9.41 0.00 1.00 
0.1 µM AOH 17.34 25.64 8.31 -1.11 2.16 
1 µM AOH 17.48 24.90 7.43 -1.99 3.97 
10 µM AOH 17.08 28.04 10.96 1.55 0.34 
50 µM AOH 16.83 29.45 12.61 3.20 0.11 
5 µM BaP 17.54 18.92 1.38 -8.03 261.83 
P20_1 (2011/08/08) 
DMSO 16.37 21.95 5.58 0.00 1.00 
0.1 µM AOH 16.50 22.09 5.59 0.01 0.99 
1 µM AOH 16.59 22.12 5.53 -0.05 1.04 
10 µM AOH 16.89 22.49 5.60 0.01 0.99 
50 µM AOH 17.25 22.93 5.68 0.09 0.94 
5 µM BaP 17.10 21.82 4.72 -0.86 1.82 
P20_2 (2011/08/08) 
DMSO 16.80 22.45 5.65 0.00 1.00 
0.1 µM AOH 16.79 22.32 5.54 -0.12 1.09 
1 µM AOH 16.82 22.54 5.72 0.06 0.96 
10 µM AOH 17.06 22.95 5.88 0.23 0.85 
50 µM AOH 16.98 22.87 5.90 0.24 0.85 
5 µM BaP 17.42 22.47 5.05 -0.61 1.52 
P23 (2011/08/22) 
DMSO 16.57 22.37 5.80 0.00 1.00 
0.1 µM AOH 16.52 22.65 6.13 0.33 0.80 
1 µM AOH 16.68 22.92 6.24 0.44 0.74 
10 µM AOH 16.96 22.41 5.45 -0.35 1.28 
50 µM AOH 16.68 22.55 5.87 0.07 0.95 
5 µM BaP 16.85 21.67 4.83 -0.97 1.96 
P24_1 (2011/08/10) 
DMSO 17.01 21.91 4.90 0.00 1.00 
0.1 µM AOH 17.58 22.53 4.95 0.05 0.97 
1 µM AOH 17.11 21.94 4.83 -0.06 1.05 
10 µM AOH 17.12 22.08 4.96 0.06 0.96 
50 µM AOH 16.57 21.65 5.08 0.18 0.88 
5 µM BaP 17.24 21.43 4.19 -0.71 1.64 
P24_2 (2011/08/25) 
DMSO 17.54 22.73 5.20 0.00 1.00 
0.1 µM AOH 17.34 22.70 5.37 0.17 0.89 
1 µM AOH 17.25 22.53 5.28 0.08 0.95 
5 µM AOH 17.31 22.53 5.23 0.03 0.98 
10 µM AOH 17.61 22.80 5.19 -0.01 1.01 
5 µM BaP 17.57 21.85 4.29 -0.91 1.88 
P27 (2011/09/16) 
DMSO 16.79 21.84 5.05 0.00 1.00 
0.1 µM AOH 16.81 21.77 4.96 -0.09 1.06 
1 µM AOH 16.89 21.86 4.97 -0.08 1.06 
10 µM AOH 16.60 21.96 5.36 0.31 0.81 
50 µM AOH 16.29 21.67 5.38 0.33 0.79 
5 µM BaP 16.89 21.11 4.23 -0.82 1.77 
P32 (2011/09/13) 
DMSO 17.27 22.41 5.15 0.00 1.00 
0.1 µM AOH 16.94 22.22 5.28 0.13 0.91 
1 µM AOH 17.10 22.23 5.13 -0.02 1.02 
10 µM AOH 17.20 22.73 5.53 0.38 0.77 
50 µM AOH 16.79 22.06 5.27 0.12 0.92 
5 µM BaP 17.16 21.66 4.50 -0.65 1.57 
P31 (2011/09/06) 
DMSO 16.83 22.66 5.83 0.00 1.00 
0.1 µM AOH 16.80 22.71 5.91 0.08 0.94 
1 µM AOH 17.46 22.90 5.44 -0.38 1.30 
10 µM AOH 16.64 22.96 6.32 0.49 0.71 
50 µM AOH 16.35 22.45 6.10 0.27 0.83 
5 µM BaP 17.00 22.10 5.09 -0.73 1.66 
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Table 26: Arithmetic mean and SD of CYP1A1 and AhR relative quantities in KYSE510-cells after 24 h AOH-
treatment. The RQ-values are given in table 25, whereas the grey shaded outliers are not used for the 
calculation of the arithmetic mean RQ, depicted in figure 24. 
 CYP1A1 AhR 
 mean RQ SD mean RQ SD DMSO 1.00 0.00 1.00 0.00 
0.1 µM AOH 1.93 0.52 0.96 0.09 
1 µM AOH 7.82 0.35 1.02 0.04 
10 µM AOH 7.08 2.63 0.98 0.15 
50 µM AOH 0.55 0.31 0.86 0.05 
5 µM BaP 276.91 31.56 1.67 0.11 
Table 27: CYP1A1 and AhR relative quantities in KYSE510-cells, transfected with siRNA 1 and siRNA 2, 
respectively for 48 h.  
 β-Actin CYP1A1 
 CT CT Δ CT ΔΔ CT RQ P15 (2011/03/29) 
ds_RNA 19.74 30.40 10.66 0.00 1.00 
si_RNA 1 24.29 34.06 9.77 -0.89 1.85 
si_RNA 2 21.04 30.97 9.92 -0.74 1.67 
P17 (2011/04/04) 
ds_RNA 18.93 29.23 10.30 0.00 1.00 
si_RNA 1 19.15 28.97 9.82 -0.49 1.40 
si_RNA 2 18.69 28.93 10.25 -0.06 1.04 
P17_1 (2011/04/04) 
ds_RNA 18.65 29.32 10.67 0.00 1.00 
si_RNA 2 18.27 28.55 10.28 -0.39 1.31 
P17_2 (2011/04/04) 
ds_RNA 18.14 29.01 10.87 0.00 1.00 
si_RNA 2 19.90 29.94 10.04 -0.83 1.78 
 β-Actin AhR 
 CT CT Δ CT ΔΔ CT RQ P15 (2011/03/29) 
ds_RNA 19.74 24.93 5.19 0.00 1.00 
si_RNA 1 24.29 29.44 5.15 -0.04 1.03 
si_RNA 2 21.04 28.37 7.32 2.13 0.23 
P17 (2011/04/04) 
ds_RNA 18.93 24.42 5.49 0.00 1.00 
si_RNA 1 19.15 25.90 6.75 1.26 0.42 
si_RNA 2 18.69 26.62 7.93 2.45 0.18 
P17_1 (2011/04/04) 
ds_RNA 18.65 24.41 5.76 0.00 1.00 
si_RNA 2 18.27 26.78 8.51 2.75 0.15 
P17_2 (2011/04/04) 
ds_RNA 18.14 24.05 5.91 0.00 1.00 
si_RNA 2 19.90 27.64 7.74 1.83 0.28 
Table 28: Arithmetic mean and SD of CYP1A1 and AhR relative quantities in KYSE510-cells after 48 h of 
transfection with siRNA 1 and siRNA 2, respectively. The RQ-values are given in table 27 and the 
arithmetic mean RQ is depicted in figure 24. 
 CYP1A1 AhR 
 mean RQ SD mean RQ SD ds_RNA 1.00 0.00 1.00 0.00 
si_RNA1 1.63 0.23 0.72 0.31 
si_RNA2 1.45 0.29 0.21 0.05 
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Table 29: CYP1A1 and AhR relative quantities in KYSE510-cells, transfected for 48 h with siRNA_2 and 
ds_RNA, respectively and treated with AME for 24 h. The calculation of the RQ of the blue shaded 
measurement values is performed with another, also blue shaded reference point.  
 β-Actin CYP1A1 
 CT CT Δ CT ΔΔ CT RQ P22_1 (2011/05/02) 
ds_DMSO 19.82 31.10 11.28 0.00 1.00 
ds_10 µM AME 20.65 28.86 8.22 -3.06 8.34 
si_DMSO 18.19 28.12 9.93 0.00 1.00 
si_0.1 µM AME 19.65 28.86 9.22 -0.71 1.64 
si_1 µM AME 18.74 26.93 8.20 -1.73 3.32 
si_5 µM AME 20.87 30.03 9.16 -0.77 1.70 
si_10 µM AME 16.65 26.55 9.90 -0.03 1.02 
P22_2 (2011/05/02) 
ds_DMSO 18.58 29.61 11.03 0.00 1.00 
ds_10 µM AME 19.83 27.56 7.73 -3.31 9.89 
si_DMSO 21.36 30.86 9.50 0.00 1.00 
si_0.1 µM AME 20.94 29.91 8.97 -0.53 1.44 
si_1 µM AME 19.51 27.09 7.58 -1.92 3.78 
si_5 µM AME 21.58 30.12 8.53 -0.97 1.96 
si_10 µM AME 23.67 33.23 9.55 0.05 0.96 
P24_1 (2011/05/18) 
ds_DMSO 17.57 27.92 10.35 0.00 1.00 
ds_10 µM AME 17.09 25.89 8.80 -1.56 2.94 
si_DMSO 17.34 26.55 9.21 0.00 1.00 
si_0.1 µM AME 17.41 26.02 8.61 -0.60 1.52 
si_1 µM AME 16.84 25.24 8.40 -0.81 1.75 
si_5 µM AME 17.69 27.41 9.72 0.51 0.70 
si_10 µM AME 16.73 26.95 10.22 1.01 0.50 
P24_2 (2011/07/05) 
ds_DMSO 16.99 27.15 10.16 0.00 1.00 
ds_10 µM AME 16.83 25.72 8.89 -1.27 2.41 
si_DMSO 16.86 26.42 9.57 0.00 1.00 
si_0.1 µM AME 17.30 26.84 9.55 -0.02 1.01 
si_1 µM AME 16.75 25.64 8.89 -0.68 1.60 
si_5 µM AME 16.88 27.53 10.65 1.08 0.47 
si_10 µM AME 16.95 27.81 10.86 1.29 0.41 
P 12 (2011/06/09) 
DMSO 19.46 30.41 10.94 0.00 1.00 
0.1 µM AME 19.96 30.96 11.00 0.06 0.96 
1 µM AME 19.54 29.15 9.61 -1.33 2.51 
10 µM AME 19.42 30.92 11.50 0.55 0.68 
5 µM BaP 19.55 20.63 1.09 -9.86 928.41 
ds_DMSO 18.23 29.12 10.89 0.00 1.00 
ds_0.1 µM AME 18.65 29.83 11.19 0.30 0.81 
ds_1 µM AME 18.67 28.31 9.64 -1.25 2.37 
P 12 (2011/06/09) 
ds_10 µM AME 19.07 30.37 11.30 0.41 0.75 
ds_5 µM BaP 19.35 20.67 1.32 -9.57 757.95 
si_DMSO 18.41 28.27 9.87 0.00 1.00 
si_0.1 µM AME 18.50 27.98 9.48 -0.39 1.31 
si_1 µM AME 18.88 28.28 9.40 -0.47 1.38 
si_10 µM AME 18.34 32.90 14.56 4.69 0.04 
si_5 µM BaP 19.36 22.77 3.42 -6.45 87.20 
P 14 (2011/06/24) 
DMSO 16.90 26.20 9.30 0.00 1.00 
0.1 µM AME 17.54 28.33 10.79 1.49 0.35 
1 µM AME 16.80 24.98 8.19 -1.11 2.16 
5 µM AME 17.00 27.22 10.22 0.92 0.53 
10 µM AME 16.96 27.67 10.71 1.42 0.37 
5 µM BaP 16.96 17.54 0.58 -8.72 420.52 
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 β-Actin CYP1A1 P 14 (2011/06/24) CT CT Δ CT ΔΔ CT RQ 
ds_DMSO 16.96 26.37 9.40 0.00 1.00 
ds_0.1 µM AME 17.51 27.71 10.21 0.80 0.57 
ds_1 µM AME 17.06 25.15 8.09 -1.32 2.49 
ds_5 µM AME 16.94 26.53 9.59 0.19 0.88 
ds_10 µM AME 17.39 27.60 10.20 0.80 0.57 
ds_5 µM BaP 17.29 18.08 0.79 -8.61 392.04 
si_DMSO 16.31 25.46 9.15 0.00 1.00 
si_0.1 µM AME 17.42 26.35 8.93 -0.21 1.16 
si_1 µM AME 16.90 25.45 8.55 -0.60 1.51 
si_5 µM AME 16.80 27.83 11.03 1.88 0.27 
si_10 µM AME 16.85 29.75 12.90 3.75 0.07 
si_5 µM BaP 17.02 20.47 3.45 -5.70 52.06 
P12 (2011/06/30) 
ds_DMSO 17.26 28.22 10.95 0.00 1.00 
ds_0.05 µM AME 17.20 28.49 11.29 0.33 0.79 
ds_1 µM AME 17.55 26.31 8.75 -2.20 4.59 
ds_5 µM AME 16.82 26.45 9.63 -1.32 2.50 
ds_5 µM BaP 17.11 18.73 1.62 -9.33 643.02 
si_DMSO 16.20 26.12 9.92 0.00 1.00 
si_0.05 µM AME 16.37 26.03 9.66 -0.25 1.19 
si_1 µM AME 16.94 26.12 9.18 -0.74 1.67 
si_5 µM AME 17.01 27.93 10.92 1.00 0.50 
si_5 µM BaP 16.46 20.20 3.74 -6.17 72.17 
P13 (2011/06/30) 
ds_DMSO 16.75 26.95 10.20 0.00 1.00 
ds_0.05 µM AME 16.83 27.28 10.45 0.25 0.84 
ds_1 µM AME 17.41 25.95 8.54 -1.66 3.15 
ds_5 µM AME 16.92 26.59 9.67 -0.53 1.44 
P13 (2011/06/30) 
ds_5 µM BaP 16.98 18.41 1.44 -8.76 434.01 
si_DMSO 16.41 25.92 9.50 0.00 1.00 
si_0.05 µM AME 16.43 25.86 9.42 -0.08 1.06 
si_1 µM AME 17.33 26.48 9.15 -0.35 1.27 
si_5 µM AME 16.87 27.83 10.96 1.46 0.36 
si_5 µM BaP 16.84 20.45 3.60 -5.90 59.61 
P15 (2011/07/08) 
DMSO 16.81 26.16 9.35 0.00 1.00 
0.1 µM AME 16.92 26.68 9.76 0.41 0.75 
1 µM AME 16.89 25.19 8.30 -1.05 2.07 
5 µM AME 16.95 26.71 9.76 0.41 0.75 
10 µM AME 16.81 27.13 10.32 0.97 0.51 
5 µM BaP 17.10 18.33 1.23 -8.12 278.25 
ds_DMSO 16.71 26.13 9.43 0.00 1.00 
ds_0.1 µM AME 16.71 26.55 9.84 0.41 0.75 
ds_1 µM AME 16.94 25.12 8.17 -1.25 2.38 
ds_5 µM AME 16.87 26.12 9.25 -0.18 1.13 
ds_10 µM AME 16.95 26.98 10.04 0.61 0.66 
ds_5 µM BaP 17.55 18.95 1.40 -8.03 261.45 
si_DMSO 16.42 25.78 9.35 0.00 1.00 
si_0.1 µM AME 16.38 25.63 9.25 -0.10 1.07 
si_1 µM AME 16.31 25.35 9.04 -0.31 1.24 
si_5 µM AME 17.33 27.29 9.96 0.61 0.65 
si_10 µM AME 16.23 28.95 12.72 3.37 0.10 
si_5 µM BaP 16.83 20.50 3.67 -5.68 51.19 
P 20_1 (2011/07/25) 
DMSO 17.06 26.53 9.47 0.00 1.00 
0.1 µM AME 16.95 26.38 9.43 -0.05 1.03 
1 µM AME 16.94 25.14 8.20 -1.27 2.42 
5 µM AME 17.04 27.08 10.04 0.56 0.68 
10 µM AME 16.93 27.31 10.38 0.90 0.53 
5 µM BaP 17.16 18.71 1.54 -7.93 243.89 
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 β-Actin CYP1A1 
 CT CT Δ CT ΔΔ CT RQ ds_DMSO 16.94 26.51 9.57 0.00 1.00 
ds_0.1 µM AME 17.16 26.59 9.43 -0.14 1.10 
ds_1 µM AME 17.22 25.44 8.21 -1.36 2.56 
ds_5 µM AME 16.67 26.07 9.40 -0.17 1.12 
ds_10 µM AME 16.93 26.92 9.99 0.42 0.75 
ds_DMSO 16.92 26.64 9.72 0.00 1.00 
ds_5 µM BaP 17.00 18.87 1.87 -7.85 230.23 
si_DMSO 16.29 25.51 9.22 0.00 1.00 
si_0.1 µM AME 16.37 25.12 8.75 -0.47 1.39 
si_1 µM AME 16.37 25.67 9.30 0.08 0.94 
P 20_1 (2011/07/25) 
si_5 µM AME 16.62 27.94 11.32 2.10 0.23 
si_10 µM AME 16.56 30.15 13.59 4.37 0.05 
si_5 µM BaP 16.76 20.91 4.16 -5.06 33.40 
P 20_2 (2011/08/02) 
DMSO 16.81 22.93 6.12 0.00 1.00 
0.1 µM AME 16.96 23.14 6.18 0.07 0.95 
1 µM AME 16.89 21.76 4.87 -1.25 2.38 
5 µM AME 16.83 23.27 6.44 0.33 0.80 
10 µM AME 16.61 23.24 6.63 0.52 0.70 
5 µM BaP 16.91 14.85 -2.05 -8.17 288.11 
ds_DMSO 16.69 22.76 6.08 0.00 1.00 
ds_0.1 µM AME 16.74 22.78 6.04 -0.04 1.03 
ds_1 µM AME 16.77 21.34 4.57 -1.51 2.84 
ds_5 µM AME 16.88 23.15 6.27 0.19 0.87 
ds_10 µM AME 16.60 23.11 6.51 0.43 0.74 
ds_5 µM BaP 16.80 15.23 -1.58 -7.65 201.26 
si_DMSO 16.40 22.45 6.04 0.00 1.00 
si_0.1 µM AME 16.17 21.86 5.70 -0.35 1.27 
si_1 µM AME 16.23 21.84 5.61 -0.44 1.35 
si_5 µM AME 16.37 24.67 8.30 2.26 0.21 
si_10 µM AME 16.25 25.89 9.64 3.60 0.08 
si_5 µM BaP 16.93 17.54 0.61 -5.44 43.27 
 β-Actin AhR 
 CT CT Δ CT ΔΔ CT RQ P22_1 (2011/05/02) 
ds_DMSO 19.82 24.92 5.09 0.00 1.00 
ds_10 µM AME 20.65 25.85 5.20 0.11 0.93 
si_DMSO 18.19 25.71 7.52 0.00 1.00 
si_0.1 µM AME 19.65 27.38 7.74 0.22 0.86 
si_1 µM AME 18.74 26.62 7.89 0.37 0.77 
si_5 µM AME 20.87 28.39 7.52 0.00 1.00 
si_10 µM AME 16.65 24.86 8.21 0.69 0.62 
P22_2 (2011/05/02) 
ds_DMSO 18.58 23.31 4.74 0.00 1.00 
ds_10 µM AME 19.83 24.54 4.71 -0.03 1.02 
si_DMSO 21.36 28.07 6.71 0.00 1.00 
si_0.1 µM AME 20.94 28.04 7.10 0.39 0.76 
si_1 µM AME 19.51 25.94 6.43 -0.28 1.21 
si_5 µM AME 21.58 28.94 7.36 0.65 0.64 
si_10 µM AME 23.67 30.98 7.31 0.60 0.66 
P24_1 (2011/05/18)     
ds_DMSO 17.57 22.26 4.69 0.00 1.00 
ds_10 µM AME 17.09 22.12 5.03 0.34 0.79 
si_DMSO 17.34 24.41 7.07 0.00 1.00 
si_0.1 µM AME 17.41 24.40 6.99 -0.08 1.06 
si_1 µM AME 16.84 23.79 6.95 -0.12 1.09 
si_5 µM AME 17.69 24.62 6.93 -0.14 1.10 
si_10 µM AME 16.73 24.04 7.31 0.24 0.85 
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 β-Actin AhR 
 CT CT Δ CT ΔΔ CT RQ P24_2 (2011/07/05) 
ds_DMSO 16.99 22.57 5.58 0.00 1.00 
ds_10 µM AME 16.83 22.35 5.53 -0.05 1.04 
si_DMSO 16.86 24.62 7.77 0.00 1.00 
si_0.1 µM AME 17.30 24.81 7.52 -0.25 1.19 
si_1 µM AME 16.75 24.50 7.75 -0.01 1.01 
si_5 µM AME 16.88 24.81 7.93 0.16 0.89 
si_10 µM AME 16.95 24.71 7.76 0.00 1.00 
P 12 (2011/06/20) 
DMSO 19.23 24.34 5.11 0.00 1.00 
0.1 µM AME 19.87 24.64 4.77 -0.34 1.27 
1 µM AME 19.32 24.40 5.08 -0.03 1.02 
10 µM AME 19.18 24.17 4.99 -0.12 1.09 
5 µM BaP 19.33 23.73 4.39 -0.72 1.65 
ds_DMSO 18.02 23.27 5.25 0.00 1.00 
ds_0.1 µM AME 18.42 23.90 5.48 0.23 0.85 
ds_1 µM AME 18.56 23.92 5.36 0.11 0.93 
ds_10 µM AME 19.02 24.44 5.42 0.16 0.89 
ds_5 µM BaP 19.24 23.86 4.61 -0.64 1.56 
si_DMSO 18.29 26.41 8.11 0.00 1.00 
si_0.1 µM AME 18.41 26.69 8.28 0.17 0.89 
si_1 µM AME 18.70 26.81 8.11 0.00 1.00 
si_10 µM AME 18.15 26.85 8.71 0.59 0.66 
si_5 µM BaP 19.21 26.70 7.49 -0.63 1.54 
P 14 (2011/06/27) 
DMSO 16.87 21.81 4.94 0.00 1.00 
0.1 µM AME 17.52 22.49 4.98 0.04 0.97 
1 µM AME 16.72 21.87 5.15 0.21 0.86 
5 µM AME 16.87 21.95 5.07 0.14 0.91 
10 µM AME 16.98 21.89 4.91 -0.03 1.02 
5 µM BaP 17.00 21.04 4.03 -0.91 1.87 
ds_DMSO 16.94 22.14 5.19 0.00 1.00 
ds_0.1 µM AME 17.56 22.84 5.28 0.08 0.94 
ds_1 µM AME 17.04 22.24 5.20 0.00 1.00 
ds_5 µM AME 16.90 22.05 5.15 -0.04 1.03 
P 14 (2011/06/27) 
ds_10 µM AME 17.35 22.58 5.23 0.04 0.97 
ds_5 µM BaP 17.27 21.59 4.32 -0.88 1.83 
si_DMSO 16.31 24.20 7.89 0.00 1.00 
si_0.1 µM AME 17.34 25.42 8.08 0.20 0.87 
si_1 µM AME 16.79 24.72 7.93 0.04 0.97 
si_5 µM AME 16.70 24.73 8.03 0.14 0.91 
si_10 µM AME 16.70 24.89 8.19 0.31 0.81 
si_5 µM BaP 17.08 24.68 7.60 -0.28 1.22 
P12 (2011/06/30) 
ds_DMSO 17.26 22.09 4.83 0.00 1.00 
ds_0.05 µM AME 17.20 22.59 5.39 0.56 0.68 
ds_1 µM AME 17.55 22.71 5.16 0.33 0.80 
ds_5 µM AME 16.82 21.90 5.09 0.26 0.84 
ds_5 µM BaP 17.11 21.46 4.35 -0.48 1.39 
si_DMSO 16.20 24.48 8.28 0.00 1.00 
si_0.05 µM AME 16.37 24.31 7.95 -0.33 1.26 
si_1 µM AME 16.94 25.06 8.12 -0.16 1.11 
si_5 µM AME 17.01 24.49 7.48 -0.80 1.74 
si_5 µM BaP 16.46 23.81 7.36 -0.92 1.89 
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 β-Actin AhR 
 CT CT Δ CT ΔΔ CT RQ P13 (2011/06/30) 
ds_DMSO 16.75 22.24 5.49 0.00 1.00 
ds_0.05 µM AME 16.83 22.58 5.74 0.25 0.84 
ds_1 µM AME 17.41 22.75 5.34 -0.15 1.11 
ds_5 µM AME 16.92 22.27 5.35 -0.14 1.11 
ds_5 µM BaP 16.98 21.77 4.79 -0.70 1.62 
si_DMSO 16.41 24.60 8.19 0.00 1.00 
si_0.05 µM AME 16.43 24.01 7.58 -0.61 1.53 
si_1 µM AME 17.33 25.30 7.97 -0.22 1.17 
si_5 µM AME 16.87 24.61 7.74 -0.45 1.37 
si_5 µM BaP 16.84 24.07 7.23 -0.96 1.95 
P15 (2011/07/08) 
DMSO 16.99 22.32 5.33 0.00 1.00 
0.1 µM AME 17.14 22.59 5.45 0.12 0.92 
1 µM AME 17.09 22.42 5.33 0.00 1.00 
5 µM AME 17.22 22.52 5.29 -0.04 1.03 
10 µM AME 16.99 22.35 5.35 0.02 0.98 
5 µM BaP 17.36 21.68 4.32 -1.01 2.01 
ds_DMSO 16.90 22.43 5.53 0.00 1.00 
ds_0.1 µM AME 16.96 22.49 5.53 0.00 1.00 
ds_1 µM AME 17.13 22.56 5.43 -0.10 1.07 
ds_5 µM AME 17.08 22.48 5.40 -0.13 1.10 
ds_10 µM AME 17.17 22.62 5.45 -0.08 1.06 
P15 (2011/07/08) 
ds_5 µM BaP 17.75 22.30 4.55 -0.98 1.97 
si_DMSO 16.61 24.89 8.29 0.00 1.00 
si_0.1 µM AME 16.64 24.71 8.07 -0.22 1.17 
si_1 µM AME 16.53 24.62 8.10 -0.19 1.14 
si_5 µM AME 17.63 25.88 8.25 -0.04 1.03 
si_10 µM AME 16.53 24.90 8.37 0.08 0.95 
si_5 µM BaP 17.08 24.48 7.40 -0.89 1.85 
P 20_1 (2011/08/08) 
DMSO 16.97 22.35 5.38 0.00 1.00 
0.1 µM AME 16.85 22.42 5.57 0.19 0.88 
1 µM AME 16.92 22.30 5.38 0.00 1.00 
5 µM AME 17.01 22.39 5.37 -0.01 1.01 
10 µM AME 16.84 22.21 5.37 -0.01 1.01 
5 µM BaP 17.12 21.68 4.56 -0.82 1.76 
ds_DMSO 16.85 22.62 5.77 0.00 1.00 
ds_0.1 µM AME 17.05 22.77 5.72 -0.05 1.03 
ds_1 µM AME 16.13 22.88 6.75 0.98 0.51 
ds_5 µM AME 16.56 22.27 5.71 -0.06 1.04 
ds_10 µM AME 16.77 22.70 5.93 0.16 0.89 
ds_5 µM BaP 16.94 21.92 4.98 -0.79 1.72 
si_DMSO 16.21 24.24 8.03 0.00 1.00 
si_0.1 µM AME 16.22 24.22 8.00 -0.03 1.02 
si_1 µM AME 16.25 24.57 8.32 0.29 0.82 
si_5 µM AME 16.50 24.92 8.42 0.38 0.77 
si_5 µM BaP 16.63 24.66 8.03 -0.01 1.00 
si_DMSO 16.27 25.78 9.51 0.00 1.00 
si_10 µM AME 16.55 30.25 13.70 4.19 0.05 
P 20_2 (2011/08/03) 
DMSO 16.69 21.72 5.04 0.00 1.00 
0.1 µM AME 16.91 21.71 4.80 -0.23 1.18 
1 µM AME 16.80 21.67 4.86 -0.17 1.13 
5 µM AME 16.85 21.64 4.79 -0.25 1.19 
10 µM AME 16.58 21.53 4.96 -0.08 1.06 
5 µM BaP 16.79 20.92 4.13 -0.91 1.88 
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 β-Actin AhR 
 CT CT Δ CT ΔΔ CT RQ ds_DMSO 16.67 21.57 4.90 0.00 1.00 
ds_0.1 µM AME 16.69 21.75 5.07 0.17 0.89 
ds_1 µM AME 16.69 21.49 4.80 -0.10 1.07 
ds_5 µM AME 16.87 21.67 4.80 -0.11 1.08 
ds_10 µM AME 16.55 21.65 5.10 0.20 0.87 
ds_5 µM BaP 16.81 21.21 4.39 -0.51 1.42 
si_DMSO 16.42 23.91 7.49 0.00 1.00 
si_0.1 µM AME 16.21 23.81 7.60 0.11 0.93 
P 20_2 (2011/08/03) 
si_1 µM AME 16.11 23.82 7.70 0.21 0.86 
si_5 µM AME 16.39 24.16 7.77 0.28 0.82 
si_10 µM AME 16.17 23.98 7.81 0.32 0.80 
si_5 µM BaP 16.93 24.07 7.14 -0.35 1.27 
Table 30: Arithmetic mean and SD of CYP1A1 and AhR relative quantities in KYSE510-cells 48 h post-
transfection and after 24 h AME-treatment. The RQ-values are given in table 29, whereas the grey 
shaded outliers are not used for the calculation of the arithmetic mean RQ, depicted in figure 28 A, 
29 A and 30. 
 CYP1A1 
 non-transfected ds_RNA si_RNA 
 mean RQ SD mean RQ SD mean RQ SD DMSO 1.00 0.00 1.00 0.00 1.00 0.00 
0.1µM AME 0.98 0.04 0.71 0.10 1.25 0.16 
1µM AME 2.28 0.20 2.45 0.08 1.39 0.13 
5µM AME 0.74 0.05 1.00 0.13 0.42 0.19 
10µM AME 0.61 0.08 0.72 0.04 0.07 0.02 
5µM BaP 270.08 18.96 297.42 97.95 54.29 3.78 
 AhR 
 non-transfected ds_RNA si_RNA 
 mean RQ SD mean RQ SD mean RQ SD DMSO 1.00 0.00 1.00 0.00 1.00 0.00 
0.1µM AME 1.04 0.15 0.94 0.07 1.02 0.12 
1µM AME 1.00 0.08 1.04 0.21 1.01 0.13 
5µM AME 1.03 0.10 1.07 0.03 0.98 0.20 
10µM AME 1.03 0.04 0.93 0.07 0.83 0.12 
5µM BaP 1.83 0.12 1.69 0.18 1.47 0.34 
Table 31: CYP1A1 and AhR relative quantities in KYSE510-cells, transfected for 48 h with siRNA_2 and 
ds_RNA, respectively and treated with AOH for 24 h.  
 β-Actin CYP1A1 
 CT CT Δ CT ΔΔ CT RQ P20_1 (2011/08/08) 
DMSO 16.37 26.06 9.69 0.00 1.00 
0.1 µM AOH 16.50 24.95 8.45 -1.24 2.37 
1 µM AOH 16.59 23.29 6.70 -2.99 7.95 
10 µM AOH 16.89 24.15 7.26 -2.44 5.41 
50 µM AOH 17.25 27.52 10.27 0.58 0.67 
5 µM BaP 17.10 18.53 1.43 -8.26 306.38 
P20_2 (2011/08/08) 
DMSO 16.80 26.63 9.83 0.00 1.00 
0.1 µM AOH 16.79 25.26 8.47 -1.36 2.57 
1 µM AOH 16.82 23.71 6.89 -2.94 7.68 
10 µM AOH 17.06 24.78 7.72 -2.11 4.32 
50 µM AOH 16.98 27.19 10.21 0.38 0.77 
5 µM BaP 17.42 19.13 1.71 -8.13 279.19 
P23 (2011/08/22) 
DMSO 16.57 27.55 10.98 0.00 1.00 
0.1 µM AOH 16.52 27.51 10.99 0.01 0.99 
1 µM AOH 16.68 24.33 7.65 -3.33 10.06 
10 µM AOH 16.96 24.00 7.04 -3.94 15.37 
50 µM AOH 16.68 26.11 9.43 -1.55 2.92 
5 µM BaP 16.85 17.94 1.09 -9.89 947.27 
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 β-Actin CYP1A1 
 CT CT Δ CT ΔΔ CT RQ P24_1 (2011/08/09) 
DMSO 17.13 28.54 11.41 0.00 1.00 
0.1 µM AOH 17.68 28.34 10.66 -0.75 1.68 
1 µM AOH 17.20 24.30 7.10 -4.31 19.78 
10 µM AOH 17.22 25.13 7.91 -3.50 11.32 
50 µM AOH 16.66 28.04 11.37 -0.04 1.03 
5 µM BaP 17.25 18.41 1.16 -10.25 1214.41 
ds_DMSO 17.12 28.37 11.25 0.00 1.00 
ds_0.1 µM AOH 17.69 28.05 10.36 -0.89 1.86 
ds_1 µM AOH 17.30 24.21 6.90 -4.35 20.37 
ds_10 µM AOH 17.02 25.26 8.24 -3.01 8.07 
ds_50 µM AOH 16.40 28.42 12.02 0.77 0.59 
ds_5 µM BaP 17.26 18.54 1.28 -9.97 1001.58 
si_DMSO 16.89 26.79 9.90 0.00 1.00 
si_0.1 µM AOH 16.71 25.92 9.21 -0.69 1.61 
si_1 µM AOH 16.86 24.72 7.86 -2.04 4.11 
si_10 µM AOH 16.79 27.58 10.79 0.89 0.54 
si_50 µM AOH 16.57 31.07 14.50 4.60 0.04 
si_5 µM BaP 17.02 20.62 3.61 -6.29 78.43 
P24_2 (2011/08/17) 
DMSO 17.44 28.38 10.93 0.00 1.00 
0.1 µM AOH 17.36 27.74 10.38 -0.55 1.47 
1 µM AOH 17.14 23.63 6.50 -4.44 21.65 
5 µM AOH 17.31 23.75 6.45 -4.48 22.38 
10 µM AOH 17.55 25.32 7.78 -3.16 8.92 
5 µM BaP 17.57 18.37 0.80 -10.13 1119.61 
ds_DMSO 16.92 27.66 10.74 0.00 1.00 
ds_0.1 µM AOH 16.92 26.79 9.87 -0.87 1.83 
ds_1 µM AOH 16.98 23.24 6.26 -4.48 22.29 
ds_5 µM AOH 17.20 23.64 6.44 -4.30 19.69 
ds_10 µM AOH 16.87 24.67 7.81 -2.94 7.65 
ds_5 µM BaP 17.26 18.39 1.13 -9.61 782.27 
si_DMSO 16.61 26.28 9.67 0.00 1.00 
si_0.1 µM AOH 16.66 25.40 8.74 -0.94 1.91 
si_1 µM AOH 16.56 24.01 7.45 -2.22 4.66 
si_5 µM AOH 16.41 25.18 8.77 -0.90 1.87 
si_10 µM AOH 16.39 26.87 10.47 0.80 0.57 
si_5 µM BaP 17.26 20.93 3.68 -6.00 63.94 
P27 (2011/08/17) 
DMSO 16.83 26.20 9.37 0.00 1.00 
0.1 µM AOH 16.88 25.05 8.18 -1.19 2.28 
1 µM AOH 16.95 23.26 6.31 -3.05 8.31 
10 µM AOH 16.72 23.65 6.93 -2.43 5.41 
50 µM AOH 16.43 27.18 10.75 1.38 0.38 
5 µM BaP 16.92 18.48 1.55 -7.82 225.34 
ds_DMSO 16.70 26.05 9.35 0.00 1.00 
ds_0.1 µM AOH 16.60 24.63 8.03 -1.31 2.49 
ds_1 µM AOH 16.74 22.93 6.20 -3.15 8.88 
ds_10 µM AOH 16.65 23.75 7.10 -2.25 4.74 
ds_50 µM AOH 16.22 27.58 11.36 2.01 0.25 
ds_5 µM BaP 16.91 18.79 1.88 -7.47 177.13 
si_DMSO 16.44 25.81 9.36 0.00 1.00 
si_0.1 µM AOH 16.68 25.02 8.34 -1.02 2.03 
si_1 µM AOH 16.48 23.83 7.35 -2.02 4.05 
si_10 µM AOH 16.22 26.25 10.03 0.67 0.63 
si_50 µM AOH 16.50 29.22 12.72 3.36 0.10 
si_5 µM BaP 16.75 20.25 3.49 -5.87 58.51 
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 β-Actin CYP1A1 
 CT CT Δ CT ΔΔ CT RQ P32 (2011/08/31) 
DMSO 16.90 26.68 9.78 0.00 1.00 
0.1 µM AOH 16.93 25.06 8.13 -1.64 3.12 
1 µM AOH 16.92 23.82 6.90 -2.88 7.34 
10 µM AOH 17.03 27.33 10.31 0.53 0.69 
50 µM AOH 16.69 28.12 11.42 1.65 0.32 
5 µM BaP 17.03 18.52 1.49 -8.28 311.82 
ds_DMSO 16.85 26.30 9.45 0.00 1.00 
ds_0.1 µM AOH 16.85 25.16 8.32 -1.13 2.20 
ds_1 µM AOH 16.85 23.39 6.54 -2.91 7.51 
ds_10 µM AOH 16.62 26.25 9.63 0.18 0.88 
ds_50 µM AOH 16.49 28.72 12.23 2.78 0.15 
ds_5 µM BaP 16.90 18.51 1.61 -7.84 229.26 
si_DMSO 16.62 27.06 10.45 0.00 1.00 
si_0.1 µM AOH 16.54 25.97 9.43 -1.02 2.02 
si_1 µM AOH 16.76 25.19 8.43 -2.02 4.05 
si_10 µM AOH 16.38 28.89 12.51 2.06 0.24 
si_50 µM AOH 16.65 30.21 13.56 3.11 0.12 
si_5 µM BaP 16.90 19.95 3.04 -7.41 169.57 
P31 (2011/09/02) 
DMSO 17.41 26.82 9.41 0.00 1.00 
0.1 µM AOH 17.34 25.64 8.31 -1.11 2.16 
1 µM AOH 17.48 24.90 7.43 -1.99 3.97 
10 µM AOH 17.08 28.04 10.96 1.55 0.34 
50 µM AOH 16.83 29.45 12.61 3.20 0.11 
5 µM BaP 17.54 18.92 1.38 -8.03 261.83 
ds_DMSO 17.16 26.89 9.73 0.00 1.00 
ds_0.1 µM AOH 17.02 25.48 8.46 -1.27 2.41 
ds_1 µM AOH 16.98 24.14 7.15 -2.57 5.95 
ds_10 µM AOH 16.80 27.36 10.56 0.83 0.56 
ds_50 µM AOH 16.79 29.88 13.09 3.37 0.10 
ds_5 µM BaP 17.39 18.89 1.49 -8.23 300.84 
si_DMSO 17.02 27.39 10.37 0.00 1.00 
si_0.1 µM AOH 17.07 26.43 9.36 -1.01 2.01 
si_1 µM AOH 16.94 25.60 8.66 -1.71 3.27 
si_10 µM AOH 16.64 29.84 13.19 2.83 0.14 
si_50 µM AOH 17.17 31.84 14.67 4.30 0.05 
si_5 µM BaP 17.21 20.61 3.41 -6.96 124.57 
 β-Actin AhR 
 CT CT Δ CT ΔΔ CT RQ P20_1 (2011/08/08) 
DMSO 16.37 21.95 5.58 0.00 1.00 
0.1 µM AOH 16.50 22.09 5.59 0.01 0.99 
1 µM AOH 16.59 22.12 5.53 -0.05 1.04 
10 µM AOH 16.89 22.49 5.60 0.01 0.99 
50 µM AOH 17.25 22.93 5.68 0.09 0.94 
5 µM BaP 17.10 21.82 4.72 -0.86 1.82 
P20_2 (2011/08/08) 
DMSO 16.80 22.45 5.65 0.00 1.00 
0.1 µM AOH 16.79 22.32 5.54 -0.12 1.09 
1 µM AOH 16.82 22.54 5.72 0.06 0.96 
10 µM AOH 17.06 22.95 5.88 0.23 0.85 
50 µM AOH 16.98 22.87 5.90 0.24 0.85 
5 µM BaP 17.42 22.47 5.05 -0.61 1.52 
P23 (2011/08/22) 
DMSO 16.57 22.37 5.80 0.00 1.00 
0.1 µM AOH 16.52 22.65 6.13 0.33 0.80 
1 µM AOH 16.68 22.92 6.24 0.44 0.74 
10 µM AOH 16.96 22.41 5.45 -0.35 1.28 
50 µM AOH 16.68 22.55 5.87 0.07 0.95 
5 µM BaP 16.85 21.67 4.83 -0.97 1.96 
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 β-Actin AhR 
 CT CT Δ CT ΔΔ CT RQ P24_1(2011(08/10) 
DMSO 17.01 21.91 4.90 0.00 1.00 
0.1 µM AOH 17.58 22.53 4.95 0.05 0.97 
1 µM AOH 17.11 21.94 4.83 -0.06 1.05 
10 µM AOH 17.12 22.08 4.96 0.06 0.96 
50 µM AOH 16.57 21.65 5.08 0.18 0.88 
5 µM BaP 17.24 21.43 4.19 -0.71 1.64 
ds_DMSO 16.99 22.17 5.17 0.00 1.00 
ds_0.1 µM AOH 17.60 22.45 4.85 -0.32 1.25 
ds_1 µM AOH 17.23 22.21 4.98 -0.19 1.14 
ds_10 µM AOH 17.01 22.38 5.37 0.20 0.87 
ds_50 µM AOH 15.97 21.80 5.83 0.65 0.64 
ds_5 µM BaP 17.23 21.64 4.41 -0.76 1.69 
si_DMSO 16.83 24.30 7.47 0.00 1.00 
si_0.1 µM AOH 16.68 24.18 7.50 0.03 0.98 
si_1 µM AOH 16.73 24.14 7.41 -0.06 1.04 
si_10 µM AOH 16.71 24.78 8.07 0.60 0.66 
si_50 µM AOH 16.39 24.81 8.42 0.95 0.52 
si_5 µM BaP 16.92 24.21 7.28 -0.19 1.14 
P24_2 (2011/08/25) 
DMSO 17.54 22.73 5.20 0.00 1.00 
0.1 µM AOH 17.34 22.70 5.37 0.17 0.89 
1 µM AOH 17.25 22.53 5.28 0.08 0.95 
5 µM AOH 17.31 22.53 5.23 0.03 0.98 
10 µM AOH 17.61 22.80 5.19 -0.01 1.01 
5 µM BaP 17.57 21.85 4.29 -0.91 1.88 
ds_DMSO 17.05 22.55 5.50 0.00 1.00 
ds_0.1 µM AOH 17.04 22.53 5.49 -0.01 1.01 
ds_1 µM AOH 17.01 22.47 5.45 -0.05 1.03 
ds_5 µM AOH 17.23 22.69 5.46 -0.04 1.03 
ds_10 µM AOH 16.96 22.59 5.63 0.13 0.91 
ds_DMSO 16.94 22.56 5.62 0.00 1.00 
ds_5 µM BaP 17.15 21.92 4.77 -0.86 1.81 
si_DMSO 16.67 24.53 7.87 0.00 1.00 
si_0.1 µM AOH 16.70 24.51 7.81 -0.06 1.04 
si_1 µM AOH 16.66 24.54 7.88 0.01 0.99 
P24_2 (2011/08/25) 
si_5 µM AOH 16.48 24.74 8.26 0.39 0.76 
si_10 µM AOH 16.56 24.94 8.38 0.51 0.70 
si_5 µM BaP 17.35 25.16 7.81 -0.06 1.04 
P27 (2011/09/16) 
DMSO 16.79 21.84 5.05 0.00 1.00 
0.1 µM AOH 16.81 21.77 4.96 -0.09 1.06 
1 µM AOH 16.89 21.86 4.97 -0.08 1.06 
10 µM AOH 16.60 21.96 5.36 0.31 0.81 
50 µM AOH 16.29 21.67 5.38 0.33 0.79 
5 µM BaP 16.89 21.11 4.23 -0.82 1.77 
ds_DMSO 16.62 22.02 5.40 0.00 1.00 
ds_0.1 µM AOH 16.63 21.96 5.33 -0.07 1.05 
ds_1 µM AOH 16.69 21.86 5.17 -0.23 1.17 
ds_10 µM AOH 16.55 22.06 5.51 0.12 0.92 
ds_50 µM AOH 16.15 21.80 5.66 0.26 0.84 
ds_5 µM BaP 16.80 21.42 4.62 -0.78 1.71 
si_DMSO 16.32 23.63 7.30 0.00 1.00 
si_0.1 µM AOH 16.87 23.97 7.10 -0.20 1.15 
si_1 µM AOH 16.36 23.60 7.24 -0.06 1.04 
si_10 µM AOH 16.17 24.73 8.56 1.25 0.42 
si_50 µM AOH 16.39 24.24 7.85 0.54 0.69 
si_5 µM BaP 16.60 23.82 7.22 -0.08 1.06 
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 β-Actin AhR 
 CT CT Δ CT ΔΔ CT RQ P32 (2011/09/13) 
DMSO 17.27 22.41 5.15 0.00 1.00 
0.1 µM AOH 16.94 22.22 5.28 0.13 0.91 
1 µM AOH 17.10 22.23 5.13 -0.02 1.02 
10 µM AOH 17.20 22.73 5.53 0.38 0.77 
50 µM AOH 16.79 22.06 5.27 0.12 0.92 
5 µM BaP 17.16 21.66 4.50 -0.65 1.57 
ds_DMSO 16.95 22.38 5.43 0.00 1.00 
ds_0.1 µM AOH 16.96 22.37 5.41 -0.02 1.02 
ds_1 µM AOH 16.95 22.35 5.40 -0.03 1.02 
ds_10 µM AOH 16.76 22.36 5.60 0.17 0.89 
ds_50 µM AOH 16.55 21.99 5.43 0.00 1.00 
ds_5 µM BaP 17.00 21.90 4.90 -0.53 1.44 
si_DMSO 16.76 24.04 7.28 0.00 1.00 
si_0.1 µM AOH 16.59 24.34 7.75 0.47 0.72 
si_1 µM AOH 16.75 24.57 7.81 0.53 0.69 
si_10 µM AOH 16.46 24.70 8.24 0.95 0.52 
si_50 µM AOH 16.78 24.76 7.98 0.70 0.62 
si_5 µM BaP 17.05 23.90 6.85 -0.43 1.35 
P31 (2011/09/06) 
DMSO 16.83 22.66 5.83 0.00 1.00 
0.1 µM AOH 16.80 22.71 5.91 0.08 0.94 
1 µM AOH 17.46 22.90 5.44 -0.38 1.30 
10 µM AOH 16.64 22.96 6.32 0.49 0.71 
50 µM AOH 16.35 22.45 6.10 0.27 0.83 
5 µM BaP 17.00 22.10 5.09 -0.73 1.66 
ds_DMSO 16.63 22.77 6.14 0.00 1.00 
ds_0.1 µM AOH 16.57 22.72 6.15 0.01 0.99 
ds_1 µM AOH 16.47 22.60 6.13 -0.01 1.01 
ds_10 µM AOH 16.18 22.62 6.44 0.30 0.81 
ds_50 µM AOH 16.01 22.34 6.33 0.18 0.88 
ds_5 µM BaP 16.84 22.13 5.29 -0.86 1.81 
si_DMSO 16.48 24.82 8.34 0.00 1.00 
si_0.1 µM AOH 16.64 24.96 8.31 -0.03 1.02 
si_1 µM AOH 16.43 24.10 7.68 -0.67 1.59 
si_10 µM AOH 16.06 25.05 8.99 0.65 0.64 
si_50 µM AOH 16.62 25.50 8.88 0.54 0.69 
si_5 µM BaP 16.74 24.43 7.69 -0.65 1.57 
Table 32: Arithmetic mean and SD of CYP1A1 and AhR relative quantities in KYSE510-cells 48 h post-
transfection and after 24 h AOH-treatment. The RQ-values are given in table 31, whereas the grey 
shaded outliers are not used for the calculation of the arithmetic mean RQ, depicted in figure 28 B, 
29 B and 31. 
 CYP1A1 
 non-transfected ds_RNA si_RNA 
 mean RQ SD mean RQ SD mean RQ SD DMSO 1.00 0.00 1.00 0.00 1.00 0.00 
0.1µM AOH 1.93 0.52 2.16 0.27 1.92 0.16 
1µM AOH 7.82 0.35 7.45 1.20 4.07 0.03 
10µM AOH 7.08 2.63 6.82 1.48 0.58 0.04 
50µM AOH 0.55 0.31 0.16 0.06 0.08 0.03 
5µM BaP 276.91 31.56 235.74 50.71 66.96 8.41 
 AhR 
 non-transfected ds_RNA si_RNA 
 mean RQ SD mean RQ SD mean RQ SD DMSO 1.00 0.00 1.00 0.00 1.00 0.00 
0.1µM AOH 0.96 0.09 1.07 0.07 0.93 0.16 
1µM AOH 1.02 0.04 1.03 0.00 0.76 0.00 
10µM AOH 0.92 0.08 0.90 0.02 0.68 0.02 
50µM AOH 0.86 0.05 0.91 0.07 0.63 0.07 
5µM BaP 1.67 0.11 1.66 0.16 1.08 0.04 
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Table 33: CYP1A1 and AhR relative quantities in KYSE510-cells, 15 min pre-treated with 10 µM MNF and 
subsequent AME-treatment for 24 h. 
 β-Actin CYP1A1 AhR 
 CT CT Δ CT ΔΔ CT RQ CT Δ CT ΔΔ CT RQ P17_1 (2011/04/01) 
DMSO 21.30 25.04 3.74 0.00 1.00 24.81 3.52 0.00 1.00 
1µM AME 20.24 25.25 5.00 1.26 0.42 25.84 5.60 2.08 0.24 
10µM AME 20.44 27.02 6.58 2.84 0.14 26.17 5.73 2.21 0.22 
P17_2 (2011/04/01) 
DMSO 17.52 23.72 6.21 0.00 1.00 23.23 5.71 0.00 1.00 
0.1µM AME 19.28 25.11 5.82 -0.38 1.30 25.27 5.99 0.27 0.83 
1µM AME 18.00 23.63 5.63 -0.58 1.49 23.90 5.90 0.18 0.88 
10µM AME 20.89 28.30 7.41 1.20 0.44 26.68 5.79 0.08 0.95 
P19_1 (2011/04/18) 
DMSO 18.78 23.95 5.18 0.00 1.00 24.79 6.01 0.00 1.00 
0.1µM AME 18.69 24.10 5.41 0.24 0.85 24.48 5.79 -0.22 1.16 
1µM AME 18.95 26.50 7.56 2.38 0.19 24.97 6.03 0.02 0.99 
5µM AME 19.13 27.95 8.82 3.65 0.08 24.94 5.81 -0.20 1.15 
10µM AME 19.50 28.79 9.29 4.12 0.06 25.87 6.36 0.35 0.78 
10µM AME-MNF 18.96 29.67 10.72 5.54 0.02 25.05 6.10 0.08 0.94 
P19_2 (2011/04/18) 
DMSO 19.48 24.28 4.81 0.00 1.00 25.06 5.58 0.00 1.00 
0.1µM AME 19.87 24.80 4.93 0.12 0.92 25.42 5.55 -0.03 1.02 
1µM AME 19.18 25.31 6.13 1.32 0.40 24.69 5.50 -0.08 1.06 
5µM AME 18.72 27.88 9.16 4.36 0.05 24.50 5.78 0.20 0.87 
10µM AME 19.31 27.42 8.11 3.30 0.10 24.94 5.63 0.05 0.96 
10µM AME-MNF 22.65 32.27 9.62 4.82 0.04 28.14 5.49 -0.09 1.07 
P21_1 (2011/04/21) 
DMSO 19.19 24.04 4.85 0.00 1.00 25.98 6.79 0.00 1.00 
0.1µM AME 28.88 36.92 8.04 3.19 0.11 36.01 7.13 0.34 0.79 
1µM AME 18.85 25.00 6.15 1.30 0.41 25.08 6.23 -0.55 1.47 
5µM AME 19.10 26.64 7.54 2.69 0.15 25.78 6.68 -0.10 1.07 
10µM AME 19.37 28.05 8.68 3.83 0.07 26.16 6.79 0.01 1.00 
10µM AME-MNF 19.95 28.85 8.90 4.05 0.06 26.93 6.99 0.20 0.87 
P21_2 (2011/04/21) 
DMSO 29.65 35.53 5.89 0.00 1.00 35.05 5.40 0.00 1.00 
0.1µM AME 21.82 26.39 4.57 -1.32 2.49 27.03 5.21 -0.20 1.15 
1µM AME 19.76 25.64 5.88 -0.01 1.00 26.11 6.35 0.95 0.52 
5µM AME 19.47 26.90 7.43 1.54 0.34 25.92 6.45 1.05 0.48 
10µM AME 18.92 27.50 8.58 2.70 0.15 25.80 6.87 1.47 0.36 
10µM AME-MNF 19.18 27.97 8.79 2.90 0.13 26.15 6.97 1.57 0.34 
P28_2 (2011/05/12) 
DMSO-Med 19.77 29.61 9.84 0.00 1.00 23.94 4.16 0.00 1.00 
MNF-Med 21.05 25.06 4.01 -5.83 56.83 25.03 3.98 -0.18 1.14 
P28_2 (2011/05/12) 
DMSO-Med 20.55 30.78 10.23 0.00 1.00 24.94 4.39 0.00 1.00 
MNF-Med 20.12 24.93 4.81 -5.41 42.65 24.45 4.34 -0.05 1.04 
P29_1 (2011/05/13) 
DMSO-Med 18.41 27.69 9.28 0.00 1.00 23.31 4.90 0.00 1.00 
MNF-Med 20.61 25.88 5.27 -4.00 16.04 25.78 5.17 0.28 0.83 
P29_2 (2011/05/13) 
DMSO-Med 17.57 27.18 9.61 0.00 1.00 23.81 6.23 0.00 1.00 
MNF-Med 17.26 24.13 6.87 -2.74 6.68 23.43 6.17 -0.06 1.05 
P30_1 (2011/08/26) 
DMSO 16.29 23.01 6.72 0.00 1.00 22.37 6.07 0.00 1.00 
0.1µM AME 18.95 24.70 5.75 -0.97 1.95 23.91 4.96 -1.11 2.17 
10µM AME 16.35 26.46 10.11 3.39 0.10 22.51 6.16 0.09 0.94 
DMSO-Med 16.14 25.42 9.28 0.00 1.00 22.58 6.45 0.00 1.00 
MNF-Med 16.32 23.94 7.62 -1.66 3.16 22.68 6.36 -0.09 1.06 
MNF-DMSO 16.29 23.01 6.72 -2.57 5.92 22.37 6.07 -0.37 1.29 
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 β-Actin CYP1A1 AhR 
 CT CT Δ CT ΔΔ CT RQ CT Δ CT ΔΔ CT RQ P30_2 (2011/08/26) 
DMSO 16.27 22.95 6.68 0.00 1.00 22.26 5.98 0.00 1.00 
0.1µM AME 16.38 23.45 7.07 0.40 0.76 22.32 5.93 -0.05 1.03 
10µM AME 16.37 25.84 9.47 2.79 0.14 22.55 6.18 0.20 0.87 
DMSO-Med 16.19 25.30 9.11 0.00 1.00 22.53 6.34 0.00 1.00 
MNF-Med 16.23 22.62 6.39 -2.73 6.61 22.50 6.27 -0.07 1.05 
MNF-DMSO 16.27 22.95 6.68 -2.44 5.42 22.26 5.98 -0.36 1.28 
P30_1 (2011/08/29) 
DMSO-Med 18.38 27.86 9.49 0.00 1.00 23.81 5.43 0.00 1.00 
MNF-Med 16.44 22.25 5.81 -3.67 12.76 23.05 6.61 1.17 0.44 
P30_2 (2011/08/29) 
DMSO-Med 17.59 26.93 9.34 0.00 1.00 23.75 6.16 0.00 1.00 
MNF-Med 16.55 22.00 5.44 -3.90 14.90 22.95 6.40 0.24 0.85 
P31_1 (2011/09/05) 
DMSO 15.85 24.26 8.41 0.00 1.00 22.39 6.53 0.00 1.00 
1µM AME 16.40 26.07 9.67 1.26 0.42 22.89 6.49 -0.04 1.03 
DMSO-Med 15.90 25.54 9.64 0.00 1.00 22.62 6.73 0.00 1.00 
MNF-Med 15.75 23.14 7.39 -2.26 4.77 22.66 6.91 0.18 0.88 
MNF-DMSO 15.85 24.26 8.41 -1.23 2.35 22.39 6.53 -0.19 1.14 
P31_2 (2011/09/05) 
DMSO 15.84 23.15 7.31 0.00 1.00 22.35 6.51 0.00 1.00 
1µM AME 15.85 24.32 8.46 1.15 0.45 22.68 6.83 0.32 0.80 
DMSO-Med 15.99 25.97 9.98 0.00 1.00 22.77 6.78 0.00 1.00 
MNF-Med 16.00 22.60 6.60 -3.38 10.41 23.09 7.09 0.31 0.81 
MNF-DMSO 15.84 23.15 7.31 -2.67 6.36 22.35 6.51 -0.27 1.21 
Table 34: Arithmetic mean and SD of CYP1A1 relative quantities in KYSE510-cells 15 min pre-treated with 
10 µM MNF and subsequently AME-treatment for 24 h. The RQ-values are given in table 33, whereas 
the grey shaded outliers are not used for the calculation of the arithmetic mean RQ, depicted in 
figure 32. 
 mean RQ SD DMSO-Med 1.00 0.00 
MNF-Med 11.23 1.90 
DMSO 5.90 0.38 
0.1 µM AME 5.65 1.22 
1 µM AME 2.46 0.10 
5 µM AME 0.56 0.26 
10 µM AME 0.60 0.19 
Table 35: GST activity determined in the GST assay according to Habig et al. in HT29-cells, cultivated for 48 h 
and treated with AME for 24 h.  
 slope/ k 
GST activity 
[µmol/ml*min] 
β (protein) 
[mg/ml] 
GST activity 
[nmol/min*mg] 
mean GST act. 
[nmol/min*mg] 
mean GST 
activity [%] 
2011/06/03 dilution factor (df) = 20 
DMSO 0.0531 0.2457 0.850 289.23 290.42 107.15 0.0535 0.2477 0.850 291.60 
DMSO 
(AOH) 
0.0509 0.2356 0.850 277.36 285.31 105.26 0.0538 0.2491 0.850 293.26 
0.01 µM 
AME 
0.0549 0.2539 0.928 273.72 282.38 104.18 0.0583 0.2700 0.928 291.04 
0.1 µM 
AME 
0.0542 0.2508 0.857 292.48 293.78 108.39 0.0546 0.2530 0.857 295.08 
1 µM AME 0.0593 0.2745 1.514 181.26 179.30  66.15  0.0580 0.2685 1.514 177.33 
10 µM 
AME 
0.0604 0.2796 0.993 281.57 293.05 108.12 0.0653 0.3024 0.993 304.53 
50 µM 
AME 
0.0498 0.2305 0.975 236.35 233.23 86.05 0.0485 0.2245 0.975 230.11 
2011/06/08 df = 20 
DMSO 0.0566 0.2622 1.017 257.81 251.47 92.78 0.0539 0.2493 1.017 245.13 
DMSO 
(AOH) 
0.0662 0.3066 1.127 272.14 273.15 100.77 0.0667 0.3089 1.127 274.16 
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 slope/ k 
GST activity 
[µmol/ml*min] 
β (protein) 
[mg/ml] 
GST activity 
[nmol/min*mg] 
mean GST act. 
[nmol/min*mg] 
mean GST 
activity [%] 
0.01 µM 
AME 
0.0568 0.2630 1.026 256.33 248.43 91.65 0.0533 0.2468 1.026 240.53 
0.1 µM 
AME 
0.0529 0.2451 0.981 249.82 259.35 95.68 0.0570 0.2638 0.981 268.88 
1 µM AME 0.0621 0.2874 1.141 251.89 249.39 92.01 0.0608 0.2817 1.141 246.89 
10 µM 
AME 
0.0597 0.2764 0.985 280.74 238.21 87.88 0.0416 0.1927 0.985 195.67 
50 µM 
AME 
0.0626 0.2896 0.994 291.45 281.69 103.93 0.0584 0.2702 0.994 271.94 
2011/06/17 df = 10 
DMSO 0.0691 0.1599 0.770 207.68 213.23  78.67  0.0728 0.1684 0.770 218.78 
DMSO 
(AOH) 
0.0723 0.3345 1.307 255.95 259.56 95.76 0.0743 0.3440 1.307 263.17 
0.01 µM 
AME 
0.0743 0.1720 0.768 223.88 235.12 86.74 0.0818 0.1893 0.768 246.36 
0.1 µM 
AME 
0.0756 0.1749 0.736 237.50 248.93 91.84 0.0828 0.1917 0.736 260.36 
1 µM AME 0.0841 0.1947 0.773 251.96 248.38 91.64 0.0817 0.1892 0.773 244.81 
10 µM 
AME 
0.0791 0.1832 0.778 235.58 235.58 86.91 0.0806 0.1866 0.816 228.73 
50 µM 
AME 0.0691 0.1599 0.770 207.68 228.73 84.39 
2011/06/22 df = 20 
DMSO 0.0612 0.2833 0.916 309.12 306.48 113.07 0.0601 0.2785 0.916 303.83 
0.01 µM 
AME 
0.0686 0.3176 0.816 388.93 372.00 137.24 0.0626 0.2899 0.816 355.07 
0.1 µM 
AME 
0.0704 0.3257 0.915 356.00 355.81 131.27 0.0703 0.3254 0.915 355.63 
1 µM AME 0.0638 0.2952 1.001 294.95 298.39 110.09 0.0653 0.3021 1.001 301.82 
10 µM 
AME 
0.0684 0.3165 1.073 294.80 294.64 108.70 0.0683 0.3161 1.073 294.49 
50 µM 
AME 
0.0703 0.3256 1.054 308.79 307.14 113.32 0.0696 0.3221 1.054 305.49 
2011/06/28 df = 20 
DMSO 0.0607 0.2810 1.042 269.78 265.81 98.07 0.0589 0.2727 1.042 261.84 
0.1 µM 
AME 
0.0640 0.2965 0.812 364.88 351.62 129.72 0.0594 0.2749 0.812 338.35 
1 µM AME 0.0575 0.2664 0.853 312.28 318.56 117.53 0.0598 0.2771 0.853 324.83 
10 µM 
AME 
0.0641 0.2966 1.107 267.82 274.43 101.25 0.0672 0.3112 1.107 281.04 
2011/07/01 df = 20 
DMSO 0.0708 0.3280 1.191 275.41 271.64 100.22 0.0689 0.3190 1.191 267.87 
0.01 µM 
AME 
0.0652 0.3018 1.108 272.32 274.48 101.27 0.0662 0.3066 1.108 276.65 
0.1 µM 
AME 
0.0742 0.3437 1.334 257.66 261.40 96.44 0.0764 0.3537 1.334 265.15 
1 µM AME 0.0782 0.3622 1.265 286.37 277.35 102.32 0.0733 0.3394 1.265 268.33 
10 µM 
AME 
0.0628 0.2907 1.146 253.57 264.83 97.70 0.0684 0.3165 1.146 276.09 
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Table 36: Arithmetic mean and SD of GST-activities in HT29-cells. The GST-activities are given in table 35, 
whereas the grey-shaded outliers are not used for the calculation of the arithmetic mean. In figure 33A 
the mean GST-activities of all experiments are depicted as T/C[%]. 
 
mean GST activity 
[nmol/min*mg] 
mean GST activity 
[%] SD [%] 
DMSO 271.05 100.00 4.68 
0.01 µM AME 260.10 95.96 7.06 
0.1 µM AME 295.15 108.89 16.10 
1 µM AME 278.41 102.72 10.11 
10 µM AME 266.79 98.43 8.68 
50 µM AME 262.70 96.92 12.18 
Table 37: GST activity determined in the GST assay according to Habig et al. in HT29-cells, cultivated for 48 h 
and treated with AOH for 24 h. 
 slope/ k 
GST activity 
[µmol/ml*min] 
β (protein) 
[mg/ml] 
GST activity 
[nmol/min*mg] 
mean GST act. 
[nmol/min*mg] 
mean GST 
activity [%] 
2011/06/03 df = 20 
DMSO 
(AOH) 
0.0509 0.2356 0.850 277.36 285.31 104.90 0.0538 0.2491 0.850 293.26 
DMSO 
(AME) 
0.0531 0.2457 0.850 289.23 290.42 106.78 0.0535 0.2477 0.850 291.60 
0.01 µM 
AOH 
0.0498 0.2305 0.928 248.50 243.83 89.65 0.0479 0.2219 0.928 239.17 
0.1 µM 
AOH 
0.0525 0.2430 0.857 283.43 290.88 106.95 0.0553 0.2558 0.857 298.33 
1 µM AOH 0.0600 0.2777 1.146 242.22 242.22 89.06 
10 µM 
AOH 
0.0646 0.2990 0.993 301.09 300.26 110.40 0.0642 0.2974 0.993 299.43 
50 µM 
AOH 
0.0609 0.2819 0.975 288.96 309.98 113.97 0.0697 0.3229 0.975 331.00 
2011/06/08 df = 20 
DMSO 
(AOH) 
0.0662 0.3066 1.127 272.14 273.15 100.43 0.0667 0.3089 1.127 274.16 
DMSO 
(AME) 
0.0566 0.2622 1.017 257.81 251.47 92.46 0.0539 0.2493 1.017 245.13 
0.01 µM 
AOH 
0.0643 0.2975 0.901 330.37 319.87 117.61 0.0602 0.2786 0.901 309.37 
0.1 µM 
AOH 
0.0733 0.3394 1.032 328.73 323.61 118.98 0.0710 0.3288 1.032 318.49 
1 µM AOH 0.0752 0.3480 1.069 325.58 331.82 122.00 0.0780 0.3613 1.069 338.06 
10 µM 
AOH 
0.0623 0.2884 1.029 280.20 305.75 112.42 0.0737 0.3411 1.029 331.31 
50 µM 
AOH 
0.0762 0.3529 1.123 314.22 308.41 113.39 0.0734 0.3399 1.123 302.59 
2011/06/17 df = 20 
DMSO 0.0723 0.3345 1.307 255.95 259.56 95.43 0.0743 0.3440 1.307 263.17 
0.01 µM 
AOH 
0.0723 0.3349 1.300 257.60 259.24 95.31 0.0733 0.3392 1.300 260.87 
0.1 µM 
AOH 
0.0552 0.2556 1.112 229.89 260.67 95.84 0.0700 0.3240 1.112 291.45 
1 µM AOH 0.0694 0.3214 1.068 301.01 307.81 113.17 0.0726 0.3360 1.068 314.62 
10 µM 
AOH 
0.0629 0.2914 1.134 257.07 268.08 98.57 0.0683 0.3164 1.134 279.09 
50 µM 
AOH 
0.0701 0.3245 1.049 309.46 307.16 112.93 0.0690 0.3197 1.049 304.86 
 
153 
Table 38: Arithmetic mean and SD of GST-activities in HT29-cells. The GST-activities are given in table 37, 
whereas the grey-shaded outliers are not used for the calculation of the arithmetic mean. In figure 33 B 
the mean GST-activities of all experiments are depicted as T/C [%]. 
 
mean GST activity 
[nmol/min*mg] 
mean GST activity 
[%] SD [%] 
DMSO 271.98 100.00 5.44 
0.01 µM AOH 274.31 100.86 12.07 
0.1 µM AOH 291.72 107.26 9.45 
1 µM AOH 293.95 108.08 13.92 
10 µM AOH 291.36 107.13 6.11 
50 µM AOH 308.52 113.43 0.42 
Table 39: GST activity determined in the GST assay according to Habig et al. in HT29-cells, cultivated for 48 h 
and treated with MEN, BaP, tBHP, BSO, CGA, CGA+Tri and CGA+Tri+Kat for 24 h. 
 slope/ k 
GST activity 
[µmol/ml*min] 
β (protein) 
[mg/ml] 
GST activity 
[nmol/min*mg] 
mean GST act. 
[nmol/min*mg] 
mean GST 
activity [%] 
2011/06/03 df = 20 
1% DMSO 0.0531 0.2457 0.850 289.23 290.42  128.72  0.0535 0.2477 0.850 291.60 
20 µM MEN 
(AME) 
0.0514 0.2380 1.142 208.29 207.96 92.17 0.0512 0.2372 1.142 207.62 
20 µM MEN 
(AOH) 
0.0594 0.2750 1.142 240.68 247.27 109.60 0.0626 0.2900 1.142 253.87 
2011/06/08 df = 20 
1% DMSO 0.0566 0.2622 1.017 257.81 251.47 111.46 0.0539 0.2493 1.017 245.13 
20 µM MEN 0.0662 0.3066 0.990 309.54 307.24  136.17  0.0652 0.3020 0.990 304.93 
5 µM BaP 0.0691 0.3200 1.050 304.65 298.65 132.37 0.0664 0.3074 1.050 292.66 
2011/06/17 df = 10 
1% DMSO 0.0691 0.1599 0.770 207.68 213.23 94.51 0.0728 0.1684 0.770 218.78 
2.5 µM BaP 0.0851 0.1970 0.909 216.71 216.71 96.05 
2011/07/13 df = 10 
1% DMSO 0.0433 0.1001 0.484 206.80 212.17 94.04 0.0455 0.1053 0.484 217.54 
20 µM MEN 0.0504 0.1167 0.507 230.42 230.14 102.00 0.0503 0.1164 0.507 229.87 
0.1% 
DMSO 
0.0279 0.0645 0.327 197.07 198.18 120.46 0.0282 0.0652 0.327 199.29 
20 µM MEN 0.0364 0.0842 0.363 232.23 232.23 141.16 0.0364 0.0842 0.363 232.23 
CGA+Tri_1 0.0275 0.0636 0.310 205.15 202.17 122.89 0.0267 0.0618 0.310 199.20 
CGA+Tri_2 0.0543 0.1258 0.705 178.47 178.84  108.71  0.0546 0.1263 0.705 179.20 
CGA+Tri+ 
Kat_1 
0.0377 0.0872 0.447 195.19 200.79 122.05 0.0398 0.0922 0.447 206.38 
CGA+Tri+ 
Kat_2 
0.0343 0.0793 0.449 176.60 184.63  112.23  0.0374 0.0866 0.449 192.65 
1% H2O 
0.0459 0.1063 0.488 218.00 219.48 121.20 0.0465 0.1077 0.488 220.96 
0.5mM BSO 0.0377 0.0872 0.477 182.84 195.47 107.94 0.0429 0.0993 0.477 208.10 
1mM BSO 0.0525 0.1215 0.566 214.68 218.82 120.83 0.0545 0.1261 0.566 222.96 
2011/08/05 df = 10 
1% H2O 
0.0999 0.2313 1.356 170.59 
172.67 95.35 0.0994 0.2300 1.356 169.65 
0.1041 0.2410 1.356 177.77 
50µM tBHP 
0.0964 0.2231 1.378 161.89 
168.38 92.98 0.1000 0.2316 1.378 168.04 
0.1043 0.2415 1.378 175.22 
 
154 
 slope/ k 
GST activity 
[µmol/ml*min] 
β (protein) 
[mg/ml] 
GST activity 
[nmol/min*mg] 
mean GST act. 
[nmol/min*mg] 
mean GST 
activity [%] 
2011/08/20 df = 20 
1% H2O 
0.0610 0.2822 1.024 275.58 274.58  151.62  0.0605 0.2802 1.024 273.57 
50µM 
tBHP_1 
0.0658 0.3047 1.076 283.23 289.96 160.12 0.0689 0.3192 1.076 296.69 
50µM 
tBHP_2 
0.0596 0.2758 1.048 263.06 
252.74 139.56  0.0551 0.2552 1.048 243.38 
0.0570 0.2640 1.048 251.77 
2011/09/09 df = 10 
0.1% 
DMSO 
0.1414 0.3274 2.472 132.41 130.85 79.54 0.1381 0.3197 2.472 129.29 
10µM CGA 
0.1383 0.3201 2.301 139.10 
140.48 85.39 0.1373 0.3179 2.301 138.17 0.1439 0.3331 2.338 142.46 
0.1436 0.3325 2.338 142.19 
CGA+Tiri 
0.1563 0.3617 2.501 144.62 
136.86 83.19 0.1389 0.3215 2.501 128.53 0.1359 0.3146 2.267 138.77 
0.1327 0.3072 2.267 135.49 
1% H2O 
0.1487 0.3442 2.289 150.39 151.13 83.46 0.1502 0.3476 2.289 151.88 
50µM tBHP 
0.1493 0.3455 2.304 149.99 
137.82 76.10 0.1405 0.3252 2.304 141.16 0.1393 0.3224 2.548 126.53 
0.1470 0.3404 2.548 133.60 
Table 40: Arithmetic mean and SD of GST-activities in HT29-cells. The GST-activities are given in table 39, 
whereas the grey-shaded outliers are not used for the calculation of the arithmetic mean. In figure 34 
A, B and C the mean GST-activities of all experiments are depicted as T/C [%]. 
 
mean GST activity 
[nmol/min*mg] 
mean GST activity 
[%] SD [%] 
1%DMSO 225.62 100.00 14.28 
20µM MEN(1%) 228.46 101.26 18.86 
5µM BaP 298.65 132.37 - 
2.5µM BaP 216.71 96.05 - 
0.1%DMSO 164.51 100.00 20.46 
20µM MEN(0.1%) 232.23 141.16 - 
10µM CGA 140.48 85.39 - 
CGA+Tiri 169.52 103.04 19.85 
CGA+Tri+Kat 200.79 122.05 - 
1% H2O 181.10 112.90 15.75 
0.5mM BSO 195.47 107.94 - 
1mM BSO 218.82 120.83 - 
50µM tBHP 198.72 109.73 36.29 
Table 41: GST activity determined in the GST assay according to Habig et al. in HT29-cells, cultivated for 48 h 
and treated with MEN, BaP, tBHP and tBHQ for 1 h. 
 slope/ k 
GST activity 
[µmol/ml*min] 
β (protein) 
[mg/ml] 
GST activity 
[nmol/min*mg] 
mean GST act. 
[nmol/min*mg] 
mean GST 
activity [%] 
2011/06/17 df = 10 
DMSO 0.0691 0.1599 0.770 207.68 213.23 80.26 0.0728 0.1684 0.770 218.78 
10 µM MEN 0.0792 0.1833 0.824 222.51 222.51 83.76 
20 µM MEN 0.0653 0.1511 0.802 188.44 198.91 74.87 0.0725 0.1679 0.802 209.37 
 df = 20 
DMSO 0.0723 0.3345 1.307 255.95 259.56 97.70 0.0743 0.3440 1.307 263.17 
10 µM MEN 0.0698 0.3234 1.358 238.18 242.17 91.16 0.0722 0.3342 1.358 246.17 
20 µM MEN 0.0736 0.3410 1.313 259.62 259.33 97.62 0.0735 0.3402 1.313 259.04 
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 slope/ k 
GST activity 
[µmol/ml*min] 
β (protein) 
[mg/ml] 
GST activity 
[nmol/min*mg] 
mean GST act. 
[nmol/min*mg] 
mean GST 
activity [%] 
2011/06/22 df = 20 
DMSO 0.0612 0.2833 0.916 309.12 306.48 115.36 0.0601 0.2785 0.916 303.83 
10 µM MEN 0.0732 0.3391 1.321 256.71 247.29 93.08 0.0679 0.3142 1.321 237.87 
20 µM MEN 0.0680 0.3148 0.924 340.54 329.16 123.90 0.0635 0.2938 0.924 317.79 
5 µM BaP 0.0728 0.3372 0.996 338.35 335.19 126.17 0.0715 0.3309 0.996 332.02 
2011/06/28 df = 20 
DMSO 0.0607 0.2810 1.042 269.78 265.81 100.05 0.0589 0.2727 1.042 261.84 
10 µM MEN 0.0630 0.2918 1.148 254.22 252.25 94.95 0.0620 0.2872 1.148 250.28 
20 µM MEN 0.0679 0.3144 1.081 290.75 286.23 107.74 0.0658 0.3046 1.081 281.71 
10 µM tBHQ 0.0546 0.2529 0.968 261.23 281.27 105.87 0.0630 0.2917 0.968 301.31 
20 µM tBHQ 0.0686 0.3178 1.189 267.26 269.59 101.47 0.0698 0.3233 1.189 271.91 
2011/07/01 df = 20 
DMSO 0.0708 0.3280 1.191 275.41 271.64 102.25 0.0689 0.3190 1.191 267.87 
5 µM BaP 0.0741 0.3428 1.198 286.06 262.27 98.72 0.0617 0.2858 1.198 238.48 
5 µM BaP 0.0603 0.2790 1.096 254.66 256.23 96.44 0.0610 0.2825 1.096 257.79 
200 µM 
tBHQ 
0.0694 0.3211 1.350 237.83 
231.50 87.14 0.0676 0.3129 1.350 231.81 
0.0656 0.3036 1.350 224.88 
200 µM 
tBHQ 
0.0663 0.3069 1.166 263.26 
276.85 104.21 0.0705 0.3264 1.166 279.91 
0.0690 0.3192 1.166 273.80 
2011/08/19 df = 10 
1% H2O 
0.0722 0.1672 0.839 199.27 
289.53 100.00 0.1041 0.2410 0.839 287.30 
0.1010 0.2338 0.839 278.68 
50 µM tBHP 0.1027 0.2378 0.791 300.38 294.16 101.60 0.0985 0.2279 0.791 287.94 
50 µM tBHP 0.1077 0.2494 0.842 296.22 284.00 98.09 0.0988 0.2288 0.842 271.78 
Table 42: Arithmetic mean and SD of GST-activities in HT29-cells. The GST-activities are given in table 41, 
whereas the grey-shaded outliers are not used for the calculation of the arithmetic mean. In figure 35 A 
and B the mean GST-activities of all experiments are depicted as T/C [%]. 
 
mean GST activity 
[nmol/min*mg] 
mean GST activity 
[%] SD [%] 
1%DMSO 265.67 100.00 1.86 
10µM MEN 247.24 93.06 1.55 
20µM MEN 291.58 109.75 10.82 
5µM BaP 284.56 107.11 13.51 
10µM tBHQ 281.27 105.87 - 
20µM tBHQ 269.59 101.47 - 
200µM tBHQ 276.85 104.21 - 
1% H2O 289.53 100.00 - 
50µM tBHP 294.16 99.85 1.75 
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Table 43: GST activity determined in the GST assay according to Habig et al. in HT29-cells, cultivated for 48 h 
and treated with AME for 6 h. In figure 36 the mean GST activity is depicted as T/C [%]. 
Table 44: GST activity determined in the GST assay according to Habig et al. in HT29-cells, cultivated for 48 h 
and treated with SFN and MEN for 9 h. In figure 37 A the mean GST activity is depicted as T/C [%]. 
 slope/ k 
GST activity 
[µmol/ml*min] 
β (protein) 
[mg/ml] 
GST activity 
[nmol/min*mg] 
mean GST act. 
[nmol/min*mg] 
mean GST 
activity [%] 
2011/08/04 df = 10 
1%DMSO 
0.0696 0.1610 0.709 227.08 
228.76 100.00 0.0682 0.1579 0.709 222.78 
0.0724 0.1676 0.709 236.43 
10µM SFN 
0.0726 0.1681 0.771 217.94 
221.50 96.82 0.0708 0.1639 0.771 212.49 
0.0780 0.1805 0.771 234.06 
20µM SFN 
0.0711 0.1647 0.755 218.12 
226.95 99.21 0.0759 0.1758 0.755 232.86 
0.0750 0.1736 0.755 229.88 
20 µM MEN 
0.0635 0.1470 0.615 238.90 
267.53 116.94 0.0777 0.1798 0.615 292.26 
0.0721 0.1670 0.615 271.42 
Table 45: GST activity determined in the GST assay according to Habig et al. in HT29-cells, cultivated for 48 h 
and treated with BaP, tBHQ, MEN and SFN for 16 h. In figure 37 B the mean GST activity is depicted 
as T/C [%]. 
 slope/ k 
GST activity 
[µmol/ml*min] 
β (protein) 
[mg/ml] 
GST activity 
[nmol/min*mg] 
mean GST act. 
[nmol/min*mg] 
mean GST 
activity [%] 
2011/08/13 df = 20 
1% DMSO 0.07665 0.35485 1.066 332.90 336.01 100.00 0.07808 0.36148 1.066 339.12 
5 µM BaP 0.08240 0.38146 1.010 377.77 386.60 115.06 0.08625 0.39931 1.010 395.44 
200 µM tBHQ 0.08430 0.39028 1.095 356.53 346.79 103.21 0.07969 0.36895 1.095 337.04 
20 µM MEN 0.07554 0.34972 0.989 353.55 353.55 105.22 
15 µM SFN 0.07864 0.36406 1.022 356.33 356.33 106.05 
 slope/ k 
GST activity 
[µmol/ml*min] 
β 
(protein) 
[mg/ml] 
GST activity 
[nmol/min*mg] 
mean GST 
activity 
[nmol/min*mg] 
GST 
activity 
[%] 
mean 
GST act. 
[%] 
2011/07/05 df = 10 
 
DMSO 0.0635 0.1469 0.751 195.48 196.02 100.00 0.0638 0.1477 0.751 196.55 
0.01 µM 
AME 
0.0350 0.0811 0.367 220.69 216.11 110.25 0.0336 0.0777 0.367 211.53 
0.1 µM AME 0.0276 0.0639 0.373 171.59 190.27 97.07 0.0336 0.0778 0.373 208.95 
1 µM AME 0.0518 0.1200 0.578 207.54 218.82 111.63 0.0575 0.1330 0.578 230.11 
10 µM AME 0.0511 0.1182 0.541 218.51 216.31 110.35 0.0500 0.1158 0.541 214.12 
50 µM AME 0.0369 0.0854 0.383 223.31 220.50 112.49 0.0360 0.0833 0.383 217.69 
5 µM BaP_1 0.0287 0.0665 0.381 174.20 190.69 97.28 103.50 
(±6.22) 
0.0341 0.0790 0.381 207.18 
5 µM BaP_2 0.0291 0.0674 0.304 221.52 215.08 109.72 0.0274 0.0635 0.304 208.64 
200 µM 
tBHQ_1 
0.0328 0.0760 0.362 210.03 209.56 106.91 102.99 
(±3.92) 
0.0327 0.0756 0.362 209.10 
200 µM 
tBHQ_2 
0.0255 0.0590 0.297 198.83 194.21 99.08 0.0243 0.0563 0.297 189.60 
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Table 46: GST-A1, -A2, -P1, and –T1 relative quantities in HT29-cells, cultivated for 24 h and treated with 50 µM 
tBHP for 1 h and 24 h, respectively. The RQ-values are depicted in figure 38. 
 β-Actin GST-A1 GST-A2 
 CT CT Δ CT ΔΔ CT RQ CT Δ CT ΔΔ CT RQ 2011/08/22    H2O _1h 15.83 34.63 18.80 0.00 1.00 34.00 18.16 0.00 1.00 
50 µM tBHP_1h 15.65 34.66 19.01 0.21 0.86 33.94 18.30 0.13 0.91 
 β-Actin GST-P1 GST-T1 H2O _1h 15.83 16.77 0.94 0.00 1.00 25.00 9.17 0.00 1.00 
50 µM tBHP_1h 15.65 16.40 0.76 -0.18 1.13 24.49 8.84 -0.33 1.25 
 β-Actin GST-A1 GST-A2 H2O _24h 15.92 34.80 18.88 0.00 1.00 33.38 17.46 0.00 1.00 
50 µM tBHP_24h 15.97 33.78 17.81 -1.07 2.10 33.17 17.20 -0.26 1.20 
 β-Actin GST-P1 GST-T1 H2O _24h 15.92 16.49 0.57 0.00 1.00 24.30 8.38 0.00 1.00 
50 µM tBHP_24h 15.97 16.60 0.63 0.06 0.96 24.01 8.04 -0.34 1.27 
Table 47: GST-A1 and -A2 relative quantities in HT29-cells, cultivated for 24 h and treated with SFN, MEN, tBHQ 
and BaP for 1 h. The RQ-values are depicted in figure 39. 
 β-Actin GST-A1 GST-A2 
 CT CT Δ CT ΔΔ CT RQ CT Δ CT ΔΔ CT RQ 2011/08/12          DMSO 15.88 34.51 18.63 0.00 1.00 33.76 17.88 0.00 1.00 
15 µM SFN 16.10 34.75 18.64 0.01 0.99 33.74 17.63 -0.25 1.19 
20 µM MEN 16.18 34.26 18.09 -0.55 1.46 33.89 17.71 -0.17 1.13 
200 µM tBHQ 15.89 34.27 18.38 -0.25 1.19 33.83 17.93 0.05 0.97 
5 µM BaP 16.01 34.53 18.52 -0.11 1.08 33.55 17.54 -0.35 1.27 
Table 48: GST activity determined in the GST assay according to Habig et al. in HepG2-cells, cultivated for 48 h 
and treated with Que and SFN for 2 h and 24 h, respectively. In figure 40 A the GST activity is depicted 
as T/C [%]. 
 slope/ k 
GST activity 
[µmol/ml*min] 
β (protein) 
[mg/ml] 
 GST activity 
[nmol/min*mg] 
GST-  
activity [%] 
 df = 2.88 
DMSO 0.03714 0.02476 1.235 20.05 100.00 
40 µM Que (2h) 0.01680 0.01120 1.13 9.91 49.44 
 df = 4 DMSO 0.02878 0.02664 1.795 14.84 100.00 
15 µM SFN (24 h) 0.03260 0.03018 2.035 14.83 99.91 
Table 49: GST activity determined in the GST assay according to Habig et al. in HepG2-cells, cultivated for 72 h 
and treated with BaP and Que for 2 h. In figure 40 B the GST activity is depicted as T/C [%]. 
 slope/ k 
GST activity 
[µmol/ml*min] 
β (protein) 
[mg/ml] 
 GST activity 
[nmol/min*mg] 
GST-  
activity [%] 
 df = 4 DMSO 0.03644 0.03375 2.020 16.71 100.00 
5 µM BaP 0.02840 0.02630 2.220 11.85 70.91 
40 µM Que 0.01973 0.01827 2.160 8.46 50.63 
Table 50: GST-A1, -A2, -P1, and –T1 relative quantities in HepG2-cells, cultivated for 72 h and treated with Que 
and BaP for 2 h. The RQ-values are depicted in figure 41. 
 β-Actin GST-A1 GST-A2 
 CT CT Δ CT ΔΔ CT RQ CT Δ CT ΔΔ CT RQ 2011/08/22    DMSO 16.19 30.85 14.65 0.00 1.00 31.92 15.73 0.00 1.00 
40 µM Que 16.59 30.81 14.23 -0.43 1.34 32.14 15.56 -0.17 1.12 
5 µM BaP 16.27 31.20 14.92 0.27 0.83 32.54 16.27 0.54 0.69 
 β-Actin GST-P1 GST-T1 DMSO 16.19 31.59 15.39 0.00 1.00 23.03 6.84 0.00 1.00 
40 µM Que 16.59 30.36 13.78 -1.62 3.06 23.19 6.61 -0.23 1.17 
5 µM BaP 16.27 28.54 12.27 -3.13 8.73 22.98 6.71 -0.13 1.09 
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Table 51: GST activity determined in the GST assay according to Habig et al. in HT29-cells, cultivated for 72 h 
and treated with AME, AOH, MEN, CGA and CGA+Tri for 24 h. 
 slope/ k 
GST activity 
[µmol/ml*min] 
β (protein) 
[mg/ml] 
GST activity 
[nmol/min*mg] 
mean GST act. 
[nmol/min*mg] 
mean GST 
activity [%] 
2011/09/07 df = 10 
0.1%DMSO 0.1269 0.2938 2.105 139.56 139.56 62.04 
10µM CGA 1 0.1428 0.3306 2.511 131.68 131.68 58.53 
10µM CGA 2 0.1399 0.3238 2.416 134.00 134.00 59.57 
CGA+Tri 1 0.1402 0.3246 2.442 132.92 132.92 59.09 
CGA+Tri 2 0.1515 0.3508 2.191 160.08 160.08 71.16 
2011/09/14 df = 40 
1%DMSO 1  0.1145 1.0600 3.630 292.02 300.11  110.46  0.1208 1.1187 3.630 308.21 
1 µM AME 0.0921 0.8526 3.479 245.06 247.83 91.22 0.0942 0.8719 3.479 250.60 
10 µM AME 0.0977 0.9044 3.882 232.96 230.62 84.89 0.0957 0.8863 3.882 228.29 
50 µM AME 0.0926 0.8571 3.548 241.59 242.37 89.21 0.0932 0.8626 3.548 243.15 
0.1 µM AOH 0.0885 0.8195 3.149 260.26 264.79 97.46 0.0916 0.8480 3.149 269.31 
1 µM AOH 0.1039 0.9619 3.100 310.32 337.01 124.05 0.1218 1.1274 3.100 363.71 
10 µM AOH 0.0921 0.8528 3.140 271.61 300.49 110.60 0.1117 1.0341 3.140 329.37 
20 µM MEN 1 0.0862 0.7979 3.684 216.57 224.70  82.71  0.0926 0.8579 3.684 232.83 
20 µM MEN 
1_2 
0.1081 1.0012 3.684 271.73 267.34 98.40 0.1046 0.9688 3.684 262.95 
20 µM MEN 2 0.0783 0.7248 3.132 231.39 238.87  87.92  0.0833 0.7717 3.132 246.35 
0.1% DMSO 
0.0761 0.7046 3.120 225.80 
259.65 115.42 0.0891 0.8250 3.120 264.38 0.0871 0.8061 3.172 254.08 
0.1008 0.9337 3.172 294.33 
10 µM CGA 1 0.0860 0.7960 3.191 249.46 270.36 120.18 0.1004 0.9294 3.191 291.27 
10 µM CGA 
1a 
0.0901 0.8346 3.112 268.18 283.70 126.11 0.1006 0.9311 3.112 299.21 
10 µM CGA 2 0.0775 0.7176 3.544 202.50 219.01 97.36 0.0901 0.8347 3.544 235.53 
10 µM CGA 
2a 
0.0963 0.8918 3.303 270.02 259.02 115.14 0.0885 0.8192 3.303 248.03 
2011/09/14 df = 40 
1% DMSO 1 0.1019 0.9436 3.728 253.08 266.12 97.95 0.1124 1.0408 3.728 279.15 
1 µM AME 0.0967 0.8957 3.991 224.41 224.39 82.59 0.0967 0.8955 3.991 224.37 
10 µM AME 0.0980 0.9073 3.317 273.50 275.01 101.22 0.0991 0.9173 3.317 276.51 
50 µM AME 0.0983 0.9099 3.544 256.70 257.27 94.69 0.0987 0.9139 3.544 257.83 
0.1 µM AOH 0.0960 0.8888 3.167 280.59 293.97 108.20 0.1051 0.9735 3.167 307.34 
1 µM AOH 0.0961 0.8900 3.191 278.89 304.81 112.19 0.1140 1.0555 3.191 330.74 
10 µM AOH 0.1021 0.9449 3.261 289.75 308.34 113.49 0.1151 1.0662 3.261 326.93 
20 µM MEN 
1a 
0.0902 0.8356 3.185 262.36 273.10 100.52 0.0976 0.9041 3.185 283.84 
20 µM MEN 
2a 
0.0940 0.8703 3.341 260.45 275.28 101.32 0.1047 0.9694 3.341 290.12 
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 slope/ k 
GST activity 
[µmol/ml*min] 
β (protein) 
[mg/ml] 
GST activity 
[nmol/min*mg] 
mean GST act. 
[nmol/min*mg] 
mean GST 
activity [%] 
2011/09/17 df = 40 
DSMO 1  0.1133 1.0494 3.876 270.76 297.68  109.57  0.1359 1.2581 3.876 324.60 
DMSO 2 0.1175 1.0881 3.871 281.08 269.82 99.32 0.1081 1.0010 3.871 258.57 
DMSO 2 
(neu) 
0.1173 1.0866 3.871 280.67 279.11 102.73 0.1160 1.0745 3.871 277.54 
1 µM AME 0.1058 0.9799 3.740 262.01 273.97 100.84 0.1155 1.0694 3.740 285.94 
10 µM AME 0.1091 1.0104 3.704 272.79 281.05 103.45 0.1157 1.0716 3.704 289.31 
50 µM AME 0.1079 0.9994 3.805 262.67 274.95 101.20 0.1180 1.0929 3.805 287.24 
0.1 µM AOH 0.1238 1.1467 3.700 309.91 302.05 111.18 0.1176 1.0885 3.700 294.19 
1 µM AOH 0.1122 1.0393 3.789 274.29 285.05 104.92 0.1210 1.1208 3.789 295.80 
10 µM AOH  -0.0530 -0.4905 4.331 -113.26 -113.26  -41.69  -0.0530 -0.4905 4.331 -113.26 
20 µM MEN 1 0.1131 1.0469 3.990 262.36 264.27 97.27 0.1147 1.0621 3.990 266.18 
20 µM MEN 
1a 
0.1068 0.9892 4.052 244.13 252.81  93.05  0.1144 1.0596 4.052 261.49 
20 µM MEN 2 0.1011 0.9364 3.959 236.53 228.59  84.14  0.0943 0.8736 3.959 220.66 
20 µM MEN 
2a 
0.1045 0.9678 3.490 277.30 281.07 103.46 0.1074 0.9941 3.490 284.84 
0.1% DMSO 0.1018 0.9428 3.557 265.03 275.66 122.54 0.1100 1.0185 3.557 286.30 
10 µM 
CGA_1  
0.0976 0.9033 3.767 239.80 242.43  107.77  0.0997 0.9232 3.767 245.07 
10 µM 
CGA_2 
0.1068 0.9889 3.671 269.36 270.46 120.23 0.1077 0.9969 3.671 271.55 
Table 52:  Arithmetic mean and SD of GST-activities in HT29-cells. The GST-activities are given in table 51, 
whereas the grey-shaded outliers are not used for the calculation of the arithmetic mean. In figure 43 
A, B and C the mean GST-activities of all experiments are depicted as T/C [%]. 
 
mean GST activity 
[nmol/min*mg] 
mean GST activity 
[%] SD [%] 
1%DMSO 271.68 100.00 2.01 
1µM AME 248.73 91.55 7.45 
10µM AME 262.23 96.52 8.27 
50µM AME 258.20 95.04 4.90 
0.1µM AOH 286.94 105.61 5.89 
1µM AOH 308.96 113.72 7.88 
10µM AOH 304.42 112.05 1.45 
20µM MEN 272.21 100.19 2.18 
0.1%DMSO 224.96 100.00 27.00 
10µM CGA 226.33 100.61 25.36 
CGA+Tri 146.50 65.12 6.04 
 
